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   I
Abstract 
Background and aims: The beneficial effects of omega-3 polyunsaturated fatty acids (n-3 PUFAs) 
and their oxidized metabolites, especially for the prevention of cardiovascular disease and 
dyslipidemia, are widely described in the literature, but the underlying molecular mechanisms in 
humans are largely unknown. However, it is believed that n-3 PUFAs exert many effects via direct or 
indirect regulation of gene expression. A double-blind and placebo-controlled intervention trial was 
undertaken to analyze gene expression changes of normo- and dyslipidemic male subjects after fish 
oil (FO) supplementation and to find possible indications for a molecular mechanism of action. 
Dyslipidemic male subjects were included in the study population to consider the higher risk profile of 
developing cardiovascular disease in these subjects, as well as to focus on the gene regulatory effects 
of n-3 PUFAs on lipid metabolism-related genes in regard to the triacylglycerol (TG) lowering effect of 
n-3 PUFAs.  
Methods: Twenty normo- and twenty dyslipidemic men were supplemented for twelve weeks with six 
FO capsules per day (2.7 g n-3 PUFAs, 1.14 g docosahexaenoic acid and 1.56 g eicosapentaenoic 
acid) or six corn oil capsules (3 g linoleic acid). The gene expression levels were determined by whole 
genome microarray analysis at baseline, after four hours, one week, and twelve weeks of 
supplementation and pathway analyses of differential regulated genes were performed. In addition, 
selected transcripts were quantified by quantitative real-time polymerase chain reactions at baseline 
and after twelve weeks of supplementation. 
Results and conclusions: This proof of concept study revealed significant differences in gene 
expression profiles between normo- and dyslipidemic male subjects after FO supplementation. 
Dyslipidemic male subjects presented substantially more regulated genes and pathways, of which 
several were related to the immune system, inflammation, lipid metabolism, and cardiovascular 
disease. Additionally, the study showed that n-3 PUFAs activate and repress several transcription 
factors resulting in the regulation of numerous target genes. In this case, lipid metabolism-related 
transcription factors, such as the hepatic nuclear factor (HNF) 6 and HNF1ß, which could affect 
HNF4α, an additional important regulator of the lipid metabolism, were repressed by n-3 PUFA 
supplementation. Otherwise, peroxisome proliferator-activated receptor (PPAR) α was activated by n-
3 PUFA supplementation. The regulation of named transcription factors may induce expression 
changes of target genes resulting in TG lowering, which could be observed in normo- and dyslipidemic 
male subjects. Moreover, the activation of PPARα appears to play a significant role in various other 
cardioprotective effects of n-3 PUFAs. In this case, antioxidative genes were up-regulated and pro-
inflammatory genes were down-regulated after n-3 PUFA supplementation, suggesting that n-3 PUFA 
may induce anti-inflammatory and antioxidative effects via PPARα activation. 
Although this study revealed several indications of possible molecular mechanisms of action in what 
extent n-3 PUFAs mediate their cardioprotective effects, further studies analyzing a combination of 
gene expression, metabolic markers and clinical end-points are needed to clarify the mechanisms by 
which n-3 PUFAs trigger gene regulation and affect various regulatory networks.  
Trial registration: ClinicalTrials.gov (ID: NCT01089231) 
Keywords: omega-3 fatty acids, dyslipidemia, gene regulation 
Zusammenfassung   
II 
Zusammenfassung 
Hintergrund und Ziele der Arbeit: Omega-3 Fettsäuren (n-3 FS) und ihren oxidierten Metaboliten werden 
zahlreiche gesundheitsfördernde Effekte in der Prävention von kardiovaskulären Erkrankungen und 
Dyslipidämien nachgesagt. Die zu Grunde liegenden molekularen Mechanismen, besonders innerhalb des 
menschlichen Organsimuses, sind jedoch unzureichend geklärt. Allerdings wird vermutet, dass n-3 FS eine 
Vielzahl ihrer Effekte direkt oder indirekt über die Regulation der Genexpression ausüben. Daher wurde eine 
doppel-blinde und placebo-kontrollierte Interventionsstudie mit dem Ziel durchgeführt, 
Genexpressionsveränderungen nach einer Fischölsupplementierung in gesunden Probanden sowie in Probanden 
mit erhöhten Blutfettwerten zu analysieren, um Ansatzpunkte möglicher molekularer Wirkmechanismen 
identifizieren zu können. Der Einschluss von Probanden mit erhöhten Blutfettwerten sollte zum einen das höhere 
Risikoprofil dieser Probanden für die Entstehung kardiovaskulärer Erkrankungen berücksichtigen und zum 
anderen die gezielte Untersuchung der Triacylglycerol (TG)-senkenden Eigenschaften von n-3 FS ermöglichen.  
Methodik: Zwanzig gesunde männliche Probanden, sowie zwanzig männliche Probanden mit erhöhten 
Blutfettwerten wurden über zwölf Wochen mit sechs Fischölkapseln pro Tag (2.7 g n-3 FS, 1.14 g 
Docosahexaesäure und 1.56 g Eicosapentaensäure) oder sechs Maiskeimölkapseln (3 g Linolsäure) 
supplementiert. Mittels whole genome Microarrays wurden die Genexpression zum Startzeitpunkt (t0) der Studie 
sowie nach vier Stunden (t4h), einer Woche (t1) und zwölf Wochen (t12) Supplementierung gemessen. Die auf 
diese Weise identifizierten regulierten Gene wurden Pathway Analysen unterzogen. Zusätzlich wurden einige 
Transkripte mittels quantitativer Echtzeit-Polymerase-Kettenreaktion zu t0 und t12 quantifiziert. 
Ergebnisse und Schlussfolgerungen: Im Rahmen dieser Proof of concept Studie konnten signifikante 
Unterschiede im Genexpressionsprofil nach Fischölsupplementierung von gesunden Probanden und Probanden 
mit erhöhten Bluttfettwerten festgestellt werden. Die Probanden mit erhöhten Bluttfettwerten zeigten wesentlich 
mehr regulierte Gene und Pathways, von denen viele mit dem Immunsystem, Entzündungen, dem 
Fettstoffwechsel und kardiovaskulären Erkrankungen in Verbindung stehen. Des Weiteren zeigte die Studie, dass 
n-3 FS die Expression verschiedener Transkriptionsfaktoren sowie dessen Zielgene induzieren und unterdrücken 
können. Eine reduzierte Expression ist beispielsweise bei zwei Transkriptionsfaktoren des Fettstoffwechsels, dem 
hepatic nuclear factor (HNF) 6 und dem HNF1ß zu beobachten, die wiederum Einfluss auf HNF4α – ein ebenfalls 
wichtiger Schlüsselregulator des Fettstoffwechsels, nehmen können. Die Expression des Transkriptionsfaktors 
peroxisome proliferator-activated receptor (PPAR) α hingegen wurde durch die n-3 FS Supplementierung 
verstärkt. Die Regulation dieser genannten Transkriptionsfaktoren könnte für die Veränderung der 
Expressionsraten von Zielgenen verantwortlich sein, die wiederum eine TG Senkung induzieren, was sowohl in 
gesunden als auch in Probanden mit erhöhten Blutfettwerten beobachtet wurde. Des Weiteren scheint die 
Aktivierung von PPARα zur Umsetzung weiterer zahlreicher gesundheitsfördernder Effekte eine große Rolle zu 
spielen. So führt eine n-3 FS Supplementierung beispielsweise neben der PPARα Aktivierung gleichzeitig zu 
einer verstärkten Expression von antioxidativen Genen und einer Reduktion der Expression pro-inflammatorischer 
Gene. Dies lässt vermuten, dass anti-inflammatorische- sowie antioxidative Effekte von n-3 FS über eine PPARα 
Aktivierung vermittelt werden.  
Obwohl diese Studie zahlreiche Hinweise auf mögliche Wirkmechanismen zur Ausübung kardioprotektiver Effekte 
liefert, sind weitere Studien, die die Messung der Genexpression, metabolischer Marker und klinischer Endpunkte 
vereinen, nötig, um die Mechanismen zu klären, wie n-3 FS Genexpresionsveränderungen induzieren und 
verschiedene regulative Netzwerke beeinflussen.  
Trial Registrierung: ClinicalTrials.gov (ID: NCT01089231) 
Schlagwörter: omega-3 Fettsäuren, Dyslipidämie, Genregulation 
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Chapter 1  General Introduction 
   1
1. General introduction 
1.1 Cardiovascular disease and atherosclerosis  
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide 
(Roger et al. 2012), and frequently appears as a result of complications of atherosclerosis. 
Atherosclerosis is a chronic inflammatory disease of the artery system and is characterized 
by progressive degeneration of the large- and medium-sized arteries and alterations of the 
vascular wall. Blood lipids, especially free and esterified cholesterol, chalk, collagen and 
proteoglycans accumulate within the vascular wall, leading to the formation of arterial 
plaques, resulting in thickening, stiffness and decreased elasticity. These alterations are 
often followed by several cardiovascular events, such as sudden cardiac death, cardiac 
infarction and stroke, which are generally the result of plaque rupture and thrombosis. After 
plaque rupture, lipids and tissue factors are exposed to blood components, initializing the 
coagulation cascade, platelet adherence and thrombosis (Glass and Witztum 2001). The 
pathogenesis of atherosclerosis is very complex and several epidemiological and clinical 
studies evaluate factors which increase the risk of developing this disease. These known risk 
factors include influenceable factors, such as arterial hypertension, obesity, metabolic 
syndrome, diabetes, insulin resistance, dyslipidemia, and lifestyle factors (smoking, stress, 
high-fat diet), but also non-influenceable factors, such as male gender, age, family history, 
genetic disorders, and infectious agents.  
1.1.1 Pathogenesis of atherosclerosis 
Two main hypotheses were formulated in the past concerning the initial causes of the 
development of atherosclerosis: The “response-to-injury hypothesis” and the “lipoprotein-
induced atherosclerosis hypothesis” (Ross and Glomset 1973; Ross 1993). The response-to-
injury hypothesis generally implies that an endothelial injury induces the initiation of 
atherosclerosis, and that this injury could be produced by mechanical (trauma, hypertension), 
chemical (toxins, viral attacks, antigen-antibody reactions) or physical events (damage on a 
molecular level). A more specified approach, the “lipoprotein-induced atherosclerosis 
hypothesis”, assumes that endothelial injury is caused by oxidized low-density lipoprotein 
(oxLDL) (Brown and Goldstein 1983). In agreement with both hypotheses, the pathogenesis 
of atherosclerosis begins with an alteration of the endothelium, called endothelial activation, 
which could be induced by the factors named above. In addition, within these factors oxLDL 
is probably unique in initiating atherosclerosis without any other factors. Endothelial 
activation leads to an inflammatory response, resulting in recruitment and increased 
adhesion of leucocytes and monocytes which, in turn, lead to a release of cytokines, 
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chemokines, cell adhesion molecules (CAMs), and growth factors by endothelial cells, 
leucocytes and smooth muscle cells. These inflammatory proteins are involved in facilitating 
the migration of monocytes, which become macrophages after migration. Macrophages 
accumulate lipids in response to inflammatory proteins and transmute to foam cells, which 
compose, together with leucocytes, the so-called fatty streak (Mangge et al. 2004). In 
addition, the formation of foam cells increases the inflammatory response, resulting in 
additional migration and proliferation of smooth muscle cells, which secrete extracellular 
matrix (ECM) proteins that initiate tissue reorganization, resulting in plaque formation. 
Atherosclerosis-promoting risk factors and the various steps during the progression of 
atherosclerosis are displayed in Figure 1.1. The role of dyslipidemia, chronic inflammation 
and oxidative stress in the pathogenesis of atherosclerosis will be described in detail within 
the next section.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Simplified schematic representation of the pathogenesis of atherosclerosis. The 
figure was designed in accordance with Da Luz and Favarato 1999, and two figures found at 
http://journals.prous.com/journals/dot/19993508/html/dt350641/images/Marimon1.gif  
and http://ocw.tufts.edu/data/51/673632/673700_xlarge.jpg.  
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1.1.2 Role of dyslipidemia 
An unbalanced lipid profile, i.e. hypercholesterolemia, hypertriglyceridemia (HTG) or 
combined hyperlipidemia, has a considerable atherogenic potential and increases the 
cardiovascular risk (Yusuf et al. 2004). Hypercholesterolemia, in particular, which is 
characterized by an elevated level of cholesterol-transporting lipoproteins, plays a key role in 
the development and progression of atherosclerosis (Tóth 2009). In this context, an elevated 
low-density lipoprotein cholesterol (LDL-C) level is associated with a high risk of CVD (Klag 
et al. 1993), as well as with the extent of atherosclerosis in the aorta and coronary circulation 
(McGill et al. 1997). It is believed that high amounts of cholesterol-transporting lipoproteins 
could undergo oxidative modifications (see section 1.1.3), leading to the injury of vascular 
endothelial cells, which subsequently promotes the development of atherosclerosis. In 
addition, the risk of coronary disease is markedly increased if both levels of LDL-C and 
lipoprotein(a) (Lp(a)) are elevated (Armstrong et al. 1986). The positive correlation between 
the Lp(a) level and coronary heart disease (CHD) (Craig et al. 1998; Luc et al. 2002) may be 
caused by the reduced activity of plasminogen (Eaton et al. 1987) and altered LDL-C 
mediated delivery of cholesterol to the vessel wall (Armstrong et al. 1986).  
Similarly, HTG, which is characterized by an elevated triacylglycerol (TG) level, is also known 
as an independent risk factor of CHD (Assmann et al. 1998; Austin et al. 1998; Davingnon 
and Chon 1996; Hokanson and Austin 1996; Sarwar et al. 2010). TG in the blood circulation 
is carried inside chylomicrons, very low-density lipoprotein (VLDL), intermediate-density 
lipoproteins (IDL), LDL-C, and high-density lipoprotein cholesterol (HDL-C), of which 
chylomicrons and VLDL are the primary TG-rich lipoproteins (Dunbar and Rader 2005). 
Subsequently, associations between TG-rich lipoproteins and coronary events could be 
observed (Sacks et al. 2000).  
In addition to the hyperlipidemias described, low levels of HDL-C are associated with 
increased risk of CVD. Furthermore, the progression of atherosclerosis is inversely 
correlated with the level of HDL-C (McGill et al. 1997). This correlation and atheroprotective 
function of HDL-C could be partly caused by facilitating reverse cholesterol transport and 
transporting antioxidant enzymes, which can break down oxidized lipids and neutralize their 
pro-inflammatory effects (Libby et al. 2002). 
Because of the important role of the lipid profile for cardiovascular health, general guidelines 
for optimal total cholesterol (TC), LDL-C, HDL-C, and TG levels, as well as guidelines for the 
LDL-C level based on a person’s global risk of CHD, have been published. In general, the 
following levels for named lipids are recommended: LDL-C < 160 mg/dl (4.14 mmol/L), HDL-
C > 40 mg/dl (1.03 mmol/L), TC < 250 mg/dl (6.47 mmol/L), and TG < 150 mg/dl (3.88 
Chapter 1  General Introduction 
4 
mmol/L). In addition, high-risk individuals with CHD or CHD-risk equivalents should not 
feature a LDL-C level above 100 mg/dL (5.55 mmol/L), while an LDL-C goal of < 130 mg/dL 
(3.36 mmol/L) was recommended for those at moderate-risk who had ≥ 2 risk factors but no 
CHD or CHD-risk equivalents (Grundy et al. 2004).  
1.1.3 Role of chronic inflammation  
Inflammation is part of the body’s defense system in response to injury or infection with the 
goal of eliminating pathogens or toxins and to repair damaged tissue. The typical major 
symptoms, redness, swelling, heat, and pain, are the results of an increased transmigration 
of leucocytes (granulocytes, monocytes, macrophages, and lymphocytes) and the production 
of inflammatory mediators, such as cytokines, CAMs, chemokines, acute phase proteins, 
eicosanoids, nitric oxide (NO), matrix metalloproteinases (MMPs), and reactive oxygen 
species (ROS), which lead to local tissue damage, systemic effects on the central nervous 
system (fever, loss of appetite), skeletal muscle (proteolysis), adipose tissue (lipolysis) and 
liver (synthesis of acute phase proteins), as well as to pathogen destruction (Galli and Calder 
2009). Afterwards, the inflammatory process undergoes resolution and recovery, which is 
characterized by the repair of lesions and down-regulation of inflammatory mediators.  
Pathological chronic inflammation is characterized by an increased number of leucocytes in 
circulation and by an increased expression of inflammatory mediators, especially cytokines 
and CAMs, which are known and partly above-mentioned contributors to the development of 
atherosclerosis. Prospective epidemiological studies evaluated a positive correlation 
between vascular risk and the levels of cytokines, such as interleukin (IL) 6 and tumor 
necrosis factor (TNF) α; CAMs, such as intracellular (I) CAM-1, vascular (V) CAM-1, P-
selectin, and E-selectin; and downstream acute-phase reactants, such as C reactive protein 
(CRP), fibrinogen and serum amyloid A (Calder 2003; Libby et al. 2002). In addition, chronic 
inflammatory diseases, such as rheumatoid arthritis, psoriasis and inflammatory bowel 
disease (Crohn’s disease, ulcerative colitis), have been shown to be associated with a risk of 
CVD and atherosclerosis (Avina-Zubieta et al. 2012; Siegel et al. 2012; Yarur et al. 2011). 
Taken as a whole, chronic inflammation is able to promote the initiation and progression of 
atherosclerosis, which is visualized in Figure 1.2.  
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Figure 1.2: Role of chronic inflammation for the progression of atherosclerosis. This figure 
was designed in accordance with Libby et al. 2010. 
1.1.4 Role of oxidative stress 
Oxidative stress is defined as a state in which the level of ROS exists in excess, which could 
result from overproduction, a decreased antioxidative defense system, or a combination of 
both. An imbalance of the redox status in the vasculature could lead to pathophysiological 
consequences mainly caused by ROS-mediated oxidative modification of lipids and proteins 
(Leopold and Loscalzo 2009; Yung et al. 2006). In this context, several studies have shown 
an association between oxidative stress and the pathogenesis of atherosclerosis, endothelial 
dysfunction and CVD (Heinecke 2003; Jung et al. 2004; Knight 1995; Landmesser et al. 
2000; Madamanchi et al. 2005; Sydow et al 2003; Tyagi et al. 2005; Wang et al. 1998). ROS-
mediated oxidative modification of lipids and especially an increased level of oxLDL (Navab 
et al. 2004) plays a key role in the initiation and progression of arteriosclerotic vascular 
diseases (El-Melegy et al. 2008; Huang et al. 2008; Navab et al. 2002) due to several 
reasons. Firstly, elevated absorption of oxLDL into vascular cells enhances the formation of 
foam cells and atherogenic plaque (Lankin et al. 2007), and promotes inflammatory 
processes (Ehara et al. 2002) by the induction of gene expression of CAMs, chemokines and 
pro-inflammatory cytokines (Libby et al. 2002). In general, inflammatory processes are 
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promoted by the apoprotein moieties of all lipoprotein particles, which can undergo 
modification in the artery wall, resulting in inciting T-cell responses (Stemme et al. 1995). 
However, an increased oxLDL level elevates the concentration of asymmetric 
dimethylarginine (ADMA) (Böger and Bode-Böger 2000), an inhibitor of the nitrit oxide 
synthase (NOS), resulting in reduced vasodilation (Zhang et al. 2008) and increased risk of 
thrombosis (Anayeva et al. 1997; Mehta and Li 1998). Besides the ROS-mediated increase 
of oxLDL, ROS also increase the concentration of homocystein and decrease the 
concentration of fetuin A. An elevated homocystein level inhibits dimethylarginine 
dimethylaminohydrolase, an enzyme which catabolizes ADMA, resulting in an increased 
ADMA level and, in turn, decreased vasodilation by decreased NO production (Jia et al. 
2006; Jin et al. 2001; Stühlinger et al. 2001; Tyagi et al. 2005). Last but not least, a 
decreased level of fetuin A (Moe and Chen 2005), an inhibitor of vascular calcification, 
results in increased stiffness of arteries and is correlated with increased mortality of CVD 
patients (Ford et al. 2010; Jenkins et al. 2011). 
1.2 Omega-3 polyunsaturated fatty acids 
1.2.1 Structure and elongase/desaturase pathway 
Fatty acids (FAs) are composed of a carbon chain and vary in the chain length and number 
of double bonds. Depending on the number of double bonds, saturated fatty acids (SFAs) 
with no double bond, monounsaturated fatty acids (MUFAs) with one double bond and 
polyunsaturated fatty acids (PUFAs) with at least two double bonds are distinguished. 
PUFAs are subdivided into short-, medium- and long-chain PUFAs depending on the number 
of carbon atoms and thus, the chain length. The name “omega” indicates the position of the 
first double bond from the methyl terminal. Therefore, omega-3 polyunsaturated fatty acids 
(n-3 PUFAs) show the first double bond at the third carbon atom from the methyl terminal. 
The position of the first double bond is an important factor which influences the properties of 
FAs. The simplest n-3 PUFA is α-linolenic acid (ALA; 18:3), which can be converted to longer 
and most bioactive n-3 PUFAs, eicosapentaenoic acid (EPA, 20:5) and docosahexaenoic 
acid (DHA, 22:6) (Flachs et al. 2009). The most bioactive n-6 PUFA, which shows the first 
double bond at the sixth carbon atom from the methyl terminal, is arachidonic acid (AA; 
20:4). The chemical structures of these named FAs are shown in Figure 1.3. In general, FAs 
present the most energetic substrates of the diet and can be stored in the form of TGs or 
incorporated into phospholipids (PLs) of cellular membranes. The transport of FAs into the 
cell is achieved by FA transporters, and intracellular FAs are rapidly converted to fatty acyl-
CoA thioesters by acyl-CoA synthetases, which serve as substrates for the synthesis of 
neutral (triglycerides, cholesterol esters) and polar lipids (PLs, sphingolipids and 
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plasmalogens), as well as for elongation, desaturation, ß-oxidation, and protein acylation 
reactions (Jump 2002). The conversion of the essential FA ALA to EPA and DHA mentioned 
above is characterized by several elongations and desaturations catalyzed by rate-limiting 
∆6 and ∆5 desaturases. The different steps of conversion of n-3 PUFAs and n-6 PUFAs are 
displayed in Figure 1.4.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3: Chemical structure of α-linolenic acid, eicosapentaenoic acid, docosahexaenoic 
acid, and arachidonic acid 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Conversion of n-3 PUFAs and n-6 PUFAs in vivo. The figure was designed in 
accordance with Jump 2002.  
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Although the conversion from ALA to EPA and DHA is possible, exogenous sources of EPA 
and DHA are needed, because the conversion rate is low. Studies using isotope-labeled ALA 
showed conversion rates ranging between 0.2 and 8% for EPA and between 0 and 4% for 
DHA in males (Burdge 2004). Additionally, genetic, epigenetic and dietary co-factors, 
including magnesium, zinc and vitamin B6, could additionally modulate the conversion (Das 
2005; Devlin et al. 2007). Therefore, an adequate accommodation of body tissues is almost 
achieved by dietary intake of exogenous sources of EPA and DHA.  
1.2.2 Dietary intake recommendations and supply situation 
Dietary sources of ALA are mainly nuts, soy and rapeseed oils, whereas fatty fish especially 
is the primary food source of EPA and DHA. Nowadays, guidelines for the daily intake of n-3 
PUFAs and, in particular, EPA and DHA are recommended by different health organizations 
(i.e. Food and Agriculture Organization/World Health Organisation, American Dietetic 
Association, American Heart Association, International Society for the Study of Fatty Acids 
and Lipids (ISSFAL), German Association for Nutrition). Recommendations for EPA and 
DHA were established firstly to prevent an n-3 FA deficiency, while more recent 
recommendations are typically based on the prevention of CHD mortality. Therefore, ISSFAL 
approved the intake of 500 mg n-3 PUFAs per day for the primary prevention of subjects 
without CHD (ISSFAL 2004). Individuals with diagnosed CHD should consume 1 g EPA and 
DHA per day (Kris-Etherton et al. 2002), and subjects with HTG should obtain 2 – 4 g EPA 
and DHA per day for the secondary prevention of CHD (Kris-Etherton et al. 2003). Dietary 
guidelines for n-3 PUFA consumption are assessed by CHD disease status, but several 
other influencing factors, such as interindividual variability (gender, ethnicity, genetic 
disorders, epigenetic modifications, does not like fish), availability of fish products, food 
contaminants (heavy metals, polychlorinated biphenyls, dioxins), and particularly the dietary 
composition, are mostly not under consideration. The last named factor addresses the high 
intake of n-6 PUFAs in the typical western diet. As a result of this diet, the n-6 to n-3 ratio 
increased from 1:1 in ancestral nutrition to 20:1 (Sanders 2000; Simopoulus 2002). Thus, an 
aspired n-6 to n-3 ratio should be 4:1.  
A large percentage of the population cannot consume sufficient amounts of EPA and DHA 
only by eating fish (Meyer et al. 2003, Roger et al. 2012). High-concentrated or enriched 
products such as fish oil (FO) capsules are alternative sources to cover the daily demand. 
Beside this traditional supplement, other enriched dairy products, such as algal oil or powder, 
krill oil, plant oils (Tur et al. 2012), and also newly engineered oils yielded from transgenic 
plants, are a possibility to supplement n-3 PUFAs (Napier et al. 2004; Ruiz-López et al. 
2009). 
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1.2.3 Role in cardiovascular health 
Many epidemiologic studies have shown that n-3 PUFA intake influences the risk of 
developing CVD. First indications for the cardioprotective effects of n-3 PUFAs were found 
within the Greenland Eskimo population, who consumed diets very rich in n-3 PUFAs and 
showed a low rate of CHD events (Bang et al. 1971; Bang et al. 1980; Dyerberg et al. 1978). 
Furthermore, several observational studies revealed a decreased risk for CHD by a higher 
intake of fish or fish FA, while a few reported no association between high fish intake and 
decreased risk of CHD (for a study overview, see Wang et al. 2006). Numerous randomized 
intervention studies with CHD patients were conducted to analyze the effect of n-3 PUFAs for 
secondary prevention, resulting in reduced mortality (Burr et al. 1989; GISSI 1999; Schacky 
von et al. 1999). A meta-analysis suggested reduced rates of all-cause mortality, cardiac and 
sudden death, and possibly stroke after increased consumption of n-3 PUFAs from fish or 
fish-oil supplements, whereas the benefits of FO are stronger in secondary than in primary 
prevention settings (Wang et al. 2006). 
The physiological effects of n-3 PUFAs, which are linked to the prevention of CHD, are well-
documented. Besides anti-hypertensive (Cicero et al. 2009, 2010) and anti-thrombotic effects 
(Adkins and Kelley 2010), arrhythmias and atrial fibrillation are reduced (Leaf et al. 2003; 
Mozaffarian et al. 2005), vascular function and the lipid profile are improved (Nestel et al. 
2002), and inflammation is diminished. In the following sections, the effects of n-3 PUFAs on 
the lipid metabolism, as well as on inflammation and oxidative stress, are described in more 
detail. 
1.2.3.1 Effects on lipid metabolism 
The main clinical effect of an n-3 PUFA supplementation on the lipid profile is to reduce both 
elevated fasting and non-fasting TG levels (Seo et al. 2005). The TG-lowering effect of n-3 
PUFAs appears to be in a dose-dependent manner (Harris 1996; Musa-Veloso et al. 2010). 
Concerning this reduction, initial TG value is crucial for the extent of the reduction and the 
decrease is more pronounced at higher baseline TG levels (Musa-Veloso et al. 2010). 
Therefore, subjects with HTG benefit particular well from n-3 PUFA supplementation (Balk et 
al. 2006; Skulas-Ray et al. 2008; Tremoli et al. 1994). It is believed that TG reduction by n-3 
PUFAs is achieved by reduced VLDL-TG synthesis and secretion from the liver caused by 
several interrelated processes. An increased ß-oxidation of FAs as well as a decreased de 
novo lipogenesis (process of converting carbohydrates into fat) reduces FA availability for TG 
synthesis in the liver. Furthermore, the activity of hepatic enzymes for TG synthesis is 
reduced and hepatic synthesis of PLs rather than TGs is increased. In addition, with the 
decreased VLDL-TG synthesis and secretion from the liver, the TG clearance of circulating 
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VLDL and chylomicron particles is enhanced (Mozzaffarian and Wu 2011; Shearer et al. 
2012).  
Whereas total cholesterol levels are mostly not affected by n-3 PUFA supplementation 
(Harris 1989), cholesterol lipoproteins showed changes in many studies. Although existing 
results are inconsistent, two meta-analyses revealed that n-3 PUFAs could lead to a slight 
increase of HDL-C levels by 1 to 10% (Harris 1996; Balk et al. 2006). It is suspected that this 
increase is induced by a shift of the HDL-C particle composition from the TG-rich HDL3 
subtype to the cholesterol-rich HDL2 subtype (Mori et al. 1999, 2000). Studies investigating 
the effects of n-3 PUFAs on LDL-C levels also contributed heterogeneous results. However, 
most studies have shown that an n-3 PUFA supplementation results in increased LDL-C 
levels (Balk et al. 2006; Kelley et al. 2007). In this case, it is assumed that the LDL-C rise is 
caused by an enhanced conversion of VLDL to LDL-C (Lu et al. 1999) or an increased LDL 
particle size after modification of the LDL particle composition (Calabresi et al. 2000; 
Minihane et al. 2000). 
1.2.3.2 Effects on inflammation 
As mentioned in section 1.1.2, inflammation is a part of the body’s defense system and is 
characterized by the production of several inflammatory mediators. It is believed that PUFAs 
affect inflammation mainly via so-called oxylipins, which are oxidized metabolites of PUFAs 
produced by specific oxygenases, such as cyclooxygenases (COX) and lipoxygenases 
(LOX), as well as by cytochrome P450 enzymes (CYPs) (Figure 1.5). The family of oxylipins, 
which can be generated by n-3 PUFAs, comprise specific eicosanoids, lipoxins, resolvins, 
protectins, and maresin 1 (Figure 1.5).  
The effects of n-3 PUFAs on the eicosanoid synthesis and the accompanied impact on 
inflammation have been investigated in many studies so far. In this context, it was shown that 
the FA membrane composition is an important factor for the eicosanoid synthesis, because 
eicosanoids are produced by PUFAs released from membrane PLs. While, inflammatory 
cells contain a higher content of n-6 PUFAs, especially AA than n-3 PUFAs (EPA) (Calder 
2003), an increased n-3 PUFA intake results in a dose-dependent decrease of AA and 
increase of n-3 PUFAs in inflammatory cells. Eicosanoids derived from n-3 PUFAs are 
related to more favorable effects (anti-thrombotic, vasodilative and anti-inflammatory) than 
eicosanoids derived from n-6 PUFAs (pro-thrombotic, vasocontrictive and inflammatory) 
(Calder 2003; Molendi-Coste et al. 2011; Mozzaffarian and Wu 2011). Supplementation of 
humans with n-3 PUFAs results in a decreased production of prostaglandine (PG) E2, 
thromboxane (TX) B2, leukotriene (LT) B4, 5-hydroxyeicosatetraenoic acid, and LTE4, as well 
as in an increased production of LTB5, LTE5 and 5-hydroxyeicosapentaenoic acid. More 
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favorable effects of the n-3 PUFA-derived eicosanoids occur, because these eicosanoids are 
believed to be less potent than those formed from AA (Calder 2008). Furthermore, some 
eicosanoids, such as prostacyclin (PGI) 3, may serve as an endogenous inhibitor of the 
angiotensin converting enzyme and 3-hydroxy-3-methylglutaryl-coenzyme A reductase, as 
well as a NO enhancer to produce anti-hypertensive, anti-inflammatory and anti-
atherosclerotic effects by acting on vascular cells, leukocytes and platelets (Lagarde et al. 
2010). Accordingly, an increased amount of n-3 PUFAs in membranes is related to anti-
inflammatory effects.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5: Synthesis and actions of lipid mediators produced from arachidonic acid, 
eicosapentaenoic acid and docosahexaenoic acid. The Figure was designed in accordance 
with Calder 2009 and Molendi-Coste et al. 2011.  
Besides a changed eicosanoid production, other oxylipins have been identified as 
specialized mediators which stimulate host defense, attenuate inflammation, prevent platelet 
aggregation, lower blood pressure, have anti-arrhythmic action, reduce LDL-C, activate 
telomerase, and have cyto-protective properties (Molendi-Coste et al. 2011). These include 
epoxides, diols, triols, alcohols, CYP epoxygenase products, ketones, lipoxines, resolvines, 
and protectines (Shearer et al. 2010; Stables and Gilroy 2011). Because of the complexity of 
these metabolites produced, little is known about the individual effects of each metabolite, 
and studies focusing on the effects of these different metabolites are still under investigation. 
Nevertheless, some metabolites, such as resolvines and protectines, could be discovered 
which are responsible for reducing the duration of inflammation (Serhan 2010). In this case, it 
was shown that resolvin E1, resolvin D1 and protectin D1 inhibit transendothelial migration of 
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neutrophils and thus prevent neutrophilic infiltration at sites of inflammation. In addition, both 
resolvin D1 and protectin D1 inhibit IL-1ß production, which is an important mediator of 
inflammatory signaling processes (Serhan et al. 2008). 
1.2.3.3 Effects on oxidative stress 
N-3 PUFAs are very susceptible to oxidation, which was observed to increase lipid 
peroxidation of n-3 PUFAs in membranes in vivo (Palozza et al. 1996). However, some in 
vitro and also in vivo studies have shown that n-3 PUFAs appear to increase antioxidative 
capacity and thus reduce oxidative stress (Bouzidi et al. 2010; Richard et al. 2008), while the 
effectiveness of n-3 PUFAs in reducing the production of ROS is probably dependent on 
given doses and existing ROS-producing stimuli (Calder 2006). Investigations in patients with 
chronic renal failure showed reduced oxidative stress after n-3 PUFA supplementation 
(Bouzidi et al. 2010). Furthermore, an in vitro study with human aortic endothelial cells also 
determined reduced oxidative stress after n-3 PUFA treatment (Richard et al. 2008). It is 
believed that n-3 PUFAs may reduce oxidative stress by elevating the expression and activity 
of antioxidative genes, such as glutathione (Joulain et al. 1994; Komatsu et al. 2003; 
Lemaitre et al. 1997; Leonardi et al. 2007) and α- and γ-tocopherol content (Véricel et al. 
1999). 
In addition, a pro-oxidative state is associated with inflammation, which is partly caused by 
ROS-mediated activating of the transcription factor nuclear factor kappa b (NFκB), which 
regulates the expression of several pro-inflammatory proteins and thus inflammatory 
processes. In this context, it is hypothesized that some anti-inflammatory effects of n-3 
PUFAs are partly caused by local high inflammation. In centers of inflammation, the 
expression of oxidative enzymes, such as nicotinamid-adenin-dinukleotid-phosphat oxidase, 
myeloperoxidase, COX, and LOX, is elevated, leading to high ROS production which, in turn, 
results in the generation of a secondary oxidation product of n-3 PUFAs (Chaudhary et al. 
2004, Mishra et al. 2004). Because of the fact that experiments with EPA and oxidized EPA 
(oxEPA) have shown an inhibition of leucocyte-endothel interactions (Chaudhary et al. 2004; 
Mishra et al. 2004) only by oxEPA, it is speculated that oxidized n-3 PUFA products 
especially are responsible for local anti-inflammatory effects. This connection might be one 
aspect why the anti-inflammatory effects of n-3 PUFAs could be observed in vitro (Calder 
2003), but rarely in vivo (Calder 2006).  
1.2.4 Molecular mechanisms of action 
N-3 PUFAs excite several protective effects, but the molecular mechanisms are only 
rudimentarily understood. It is assumed that n-3 PUFAs act through several mechanisms, 
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including modifications in cell membrane composition and function, distinct eicosanoid 
production and gene expression modulation (Figure 1.6). The known mechanisms are 
described in detail in the following sections.  
 
Figure 1.6: Molecular pathways affected by n-3 PUFAs (Mozzafarian and Wu 2011) 
1.2.4.1 Modification of the cell membrane composition and consequences 
It is believed that several effects are partly caused by the fact that n-3 PUFAs are integral 
parts of cell membrane PLs and cell surfaces (Drevon 1992; Simopoulus 1999). Basically, 
biological membranes consist of PLs and cholesterol, which are ordered into a lipid bilayer. 
In addition, several different proteins with important membrane functions, such as enzymes, 
receptors and transporters, are enclosed in the lipid bilayer. An increased intake of n-3 
PUFAs results in a dose-dependent incorporation into membrane PLs (Blonk et al. 1990; 
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Harris et al. 1991), which is accompanied by displacement of n-6 PUFAs (such as AA). This 
change of the membrane composition is an initial trigger which could induce several further 
reactions, including not only changed membrane properties (fluidity and lipid raft structure), 
but also subsequently changed intracellular signaling and an altered pattern for the 
production of lipid mediators (Calder 2009).  
An increased incorporation of n-3 PUFAs modifies the lipid protein composition of membrane 
microdomains. In this connection, lipid rafts play a key role within signaling transduction 
processes. Lipid rafts are cell membrane subdomains which are rich in sphingolipids, 
cholesterol, SFA-carrying PLs, and large amount of proteins, which are involved in signaling 
transduction (Pike 2003). Although n-3 PUFAs are preferably incorporated into non-raft 
structures, probably due to their low affinity to cholesterol, it is believed that n-3 PUFAs 
influence raft formation and function from outside of rafts (Calder 2012). Interestingly, n-3 
PUFA incorporation into membranes reduces lipid rafts in T-cells by approximately 45% 
(Chapkin et al. 2008). Furthermore, it is believed that n-3 PUFAs could selectively displace 
acylated signaling proteins (Chapkin et al. 2008). A summary of experiments indicates that n-
3 PUFAs modify the membrane lipid/protein compositions resulting in changed signaling 
transduction of a variety of signaling pathways, such as T-cell signaling (Fan et al. 2004; Kim 
et al. 2008a; Zeyda et al. 2003).  
Besides changed signaling, receptors, transporters, ion channels, enzymes, and signaling 
molecules of receptors and proteins within the membrane are also modified by n-3 PUFA 
incorporation (Calder 2003). An example of the effects on receptors is the fact that the toll-
like receptor 4 can be suppressed by n-3 PUFAs via dimer-disruption, which is associated 
with downstream signaling, resulting in repression of the transcription factor NFκB and thus 
reduced COX-2 expression and PGE2 production (Lee et al. 2003). Among affected 
transporters within membranes, FA transport protein is induced by n-3 PUFAs via the 
activation of transcription factor peroxisome proliferator-activated receptors (PPARs) (Martin 
et al. 1997; Melton et al. 2011). Known ion channels which could be modified by n-3 PUFAs 
include, for example, the sodium channel, L-type calcium channel and potassium channel, 
and also ion pumps, such as the sodium–calcium exchanger (Richardson et al. 2011). The 
modulation of ion channels and ion pumps might be associated with the anti-arrhythmic 
effects of n-3 PUFAs in animals (McLennan 2001) and humans (Kumar et al. 2011). 
Membrane-bound enzymes such as phospholipase A2, which is responsible for the release 
of PUFAs from the membrane to generate substrates for the lipid mediator production, can 
be up-regulated by n-3 PUFAs (Grynberg et al. 1992). These released PUFAs can serve as 
precursors for the biosynthesis of lipid mediators (Calder 2010), which was described above 
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(see 1.2.3.2), and also as signaling molecules and ligands for transcription factors, modifying 
gene expression, which is explained in the next section.  
1.2.4.2 Effects on gene expression 
The regulation of gene expression is also discussed as a major part by which n-3 PUFAs 
excite their effects. In the last few decades, it was shown in in vitro studies that n-3 PUFAs 
could interact with several transcription factors, such as sterol regulatory element-binding 
protein (SREBP) 1 (Caputo et al. 2011), hepatic nuclear factor (HNF) 4α (López-Soldado et 
al. 2009), liver X receptors (LXRs) (Howell et al. 2009), retinoid X receptor (RXR) (Urquiza et 
al. 2000), farnesoid X receptor (FXR) (Zhao et al. 2004), carbohydrate response element 
binding proteins (ChREBP) (Nakamura et al. 2004), and PPARs (Oyekan 2011), resulting in 
expression changes of corresponding target genes (Clarke et al. 2002; Davidson 2006; Jump 
et al. 1999; Price et al. 2000; Vanden Heuvel 2009). In addition, several other transcription 
factors, such as NFκB, could be influenced indirectly, resulting in the regulation of a variety of 
pro-inflammatory and pro-atherogenic genes, including those encoding for IL-1, IL-6, IL-8, 
TNFα, E-selectin, VCAM-1, and COX-2 (Kang and Weylandt 2008; Massaro et al. 2008). As 
an example, the molecular mechanism of n-3 PUFAs on PPARs, SREBP-1 and NFκB are 
described in more detail.  
PPARs can be activated by the binding of n-3 PUFAs and eicosanoids (Forman et al. 1997), 
and this activation controls the expression of genes which are involved in lipid/glucose 
metabolism and adipogenesis (Jump 2002). In more detail, PPARα activation results in an 
up-regulation of enzymes involved in the ß-oxidation, i.e. acyl-CoA oxidase, CYP4A2, 
mitochondrial carnitine palmitoyltransferase 1, and peroxisomal FA oxidase in FO fed 
rodents (Halvorsen et al. 2001; Ren et al. 1997). An increased ß-oxidation thus reduces the 
availability of FA for TG synthesis and reduces the TG level in the circulation (Lombardo and 
Chicco 2006). In addition, PPARα activation results in a regulation of genes of the lipoprotein 
metabolism. More precisely, PPARα activation induces a repression of apolipoprotein (Apo) 
CIII and Apo B which, in turn, results in an enhanced lipoprotein lipase (LPL)-mediated 
catabolism of VLDL and reduced VLDL production (Staels et al. 1998). Besides PPARα, 
activation of PPARγ results in hepatic down-regulation of lipogenic enzymes, such as acetyl-
CoA carboxylase (ACC), FA synthase (FAS), S14 protein, stearyl-CoA desaturase-1 (SCD1), 
malic enzyme, ATP citrate lyase, and glycolytic enzymes (L-pyrovate kinase, Apo A1, ∆5 
desaturase, ∆6 desaturase), which lead to a reduced hepatic de novo lipogenesis (Lombardo 
and Chicco 2006). This reduced lipogenesis results in decreased TG synthesis and VLDL 
secretion from the liver.  
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SREBPs are membrane-bound transcription factors and are found to modulate the 
transcription of genes encoding enzymes of synthesis and uptake, including ACC, FAS, 
SCD1, and LPL (Brown and Goldstein 1997). Experiments with FO fed mice showed that n-3 
PUFA could repress SREBP-1, resulting in the down-regulation of cholesterogenic and 
lipogenic genes, such as LDL receptor (LDLR), 3-hydroxy-methyl glutaryl-CoA synthase, 3-
hydroxy-methyl glutaryl-CoA reductase, ACC, and SCD1 (Kim et al. 1999). 
NFκB is the key transcription factor in the regulation of inflammation and controls the 
expression of several pro-inflammatory genes, such as cytokines, CAMs, inducible NO 
synthase (iNOS), and COX-2. Animal studies have shown that FO supplementation 
decreases the activation of NFκB and the production of inflammatory cytokines, which could 
be also observed in human studies (Lombardo and Chicco 2006). It is believed that the 
inhibitory effect of n-3 PUFAs on NFκB activation is facilitated by two mechanisms. Firstly, 
activated PPARγ interacts with the p65 subunit of NFκB, preventing its translocation to the 
nucleus, or increases the synthesis of the inhibitor of κB (IκB) (Li et al. 2005; Storlien et al. 
1996). The second possibility to diminish NFκB activation is via modified signaling pathways, 
where two pathways are currently described. Firstly, NFκB could be repressed by the down-
regulation of protein kinase C within the mitogen-activated protein kinase (MAPK) pathway 
(Denys et al. 2005; Gorjao et al. 2007). Furthermore, DHA and probably EPA enhance the 
anti-inflammatory signaling of G-protein coupled surface receptor (GPR) 120, resulting in the 
maintenance of IκB and prevention of NFκB translocation to the nucleus (Calder 2012).  
1.3 Study objectives 
Although several approaches for explaining the molecular mechanism of n-3 PUFAs exist 
from in vitro studies, observations in humans could be evaluated by only a very few studies. 
Therefore, the aim of this study was to analyze gene expression changes after FO or CO 
supplementation of normo- and dyslipidemic male subjects and to find possible indications 
for the molecular mechanism of action described. The division of volunteers into normo- and 
dyslipidemic male subjects was performed for two reasons: Firstly, we wanted to consider 
the higher risk profile for developing CVD in dyslipidemic subjects; and secondly, to focus on 
the gene regulatory effects of n-3 PUFAs on lipid metabolism-related genes in regard to the 
TG-lowering effect of n-3 PUFAs, which was observed by many studies to be greater in 
these subjects (Hjerkinn et al. 2005; Marckmann and Gronbaek 1999).  
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Subjects of this study ingested either corn oil (CO) or FO capsules over twelve weeks and 
gene expression changes in whole blood samples were determined by microarray 
experiments and quantitative real-time polymerase chain reaction (qRT-PCR). The 
fundamental questions resulting from this study approach are as follows: 
1. Is it possible to identify gene expression changes after n-3 PUFA supplementation by 
microarray experiments and/or qRT-PCR? 
1.1. If this is the case, one aim was to display gene expression patterns of normo- and 
dyslipidemic male subjects after supplementation.  
2. Is human whole blood a suitable analysis material for gene expression changes after 
supplementation?  
2.1. Is it possible to present effects of the supplementation on inflammatory and lipid-
related genes? 
3. Is it possible to deduce some of the possible molecular mechanisms of n-3 PUFAs? 
These questions are attended to within the following three chapters. In chapter 2, total data 
of microarray experiments of all groups were presented and greater influence of FO 
supplementation on pathways of the lipid metabolism, inflammation and CVD in comparison 
with CO supplementation was discovered. Furthermore, anti-inflammatory gene expression 
after FO supplementation was observed, particularly in dyslipidemic male subjects. Because 
of the fact that dyslipidemic male subjects may have increased oxidative stress as a result of 
elevated lipid parameters (Ohara et al. 1993; Rocha-Pereira et al. 2001), the effects of FO 
supplementation on oxidative processes were analyzed (chapter 3). In addition, the effects 
of FO supplementation on the lipid metabolism are well known. Therefore, analysis of lipid-
related genes after FO supplementation was performed to investigate if n-3 PUFA effects on 
the lipid metabolism could be observed by gene expression changes in human blood 
(chapter 4). 
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2. Different gene expression profiles in normo- and dyslipidemic men after 
fish oil supplementation: Results from a randomized controlled trial 
2.1 Introduction 
Numerous epidemiologic and intervention studies have shown the beneficial effects of FO 
and its principal n-3 PUFAs, EPA and DHA, in the prevention of atherosclerosis and CVD 
(Amano et al. 2011; Sekikawa et al. 2008; Sudheendran et al. 2010). EPA and DHA are 
known to affect the lipid profile by reducing the elevated TG level and increasing the HDL-C 
level (Harris 1989; Musa-Veloso et al. 2010). Due to the effects on lipid levels, subjects with 
dyslipidemia, especially HTG, benefit from FO supplementation to reduce the cardiovascular 
risk (Balk et al. 2006; Skulas-Ray et al. 2008; Tremoli et al. 1994). 
Beyond the positive effects on lipid levels, other cardioprotective effects of EPA and DHA are 
known involving anti-inflammation, modulation of cardiac ion channels, influence on 
membrane microdomains and downstream cell signalling pathways, anti-thrombotic and anti-
arrhythmic effects, induction of haemodynamic changes, and improvement of endothelial 
function (Adkins and Kelley 2010; Cottin et al. 2011). The underlying molecular mechanisms 
by which EPA and DHA exert these beneficial effects on cardiovascular health are not 
completely understood. It is believed that many effects of n-3 PUFAs are mediated by 
interferences with signalling transduction pathways (Massaro et al. 2008). 
N-3 PUFAs are known to affect a myriad of molecular pathways, including the regulation of 
gene expression (Mozaffarian and Wu 2011). This regulation can be driven by n-3 PUFAs 
directly, or by their secondary metabolites, for example, eicosanoids. It is known that n-3 
PUFAs induce changes in the expression of several genes related to lipid and carbohydrate 
metabolism, cell differentiation and growth, cytokine, adhesion, and eicosanoid production, 
as well as oxidative and immune system processes (Jump 2008; Nakamura et al. 2004; 
Siddiqui et al. 2009). The inhibition of inflammatory signalling, observed in in vitro and animal 
studies, is viewed as one of the major mechanisms on how n-3 PUFAs may improve 
cardiovascular health (Massaro et al. 2011). However, the anti-inflammatory effect of n-3 
PUFAs has not been completely confirmed in human subjects (Cottin et al. 2011). 
Only a few human studies have investigated genome-wide expression changes after FO 
supplementation to identify specific metabolic pathways. Bouwens and co-workers analysed 
the effects of FO supplementation on whole genome expression changes and performed 
several pathway analyses which mainly showed a down-regulation of genes involved in 
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inflammatory and stress-related pathways (Bouwens et al. 2009). Another study monitored 
the expression changes of 588 genes after FO supplementation and discovered a regulative 
effect in several lymphocyte functions such as signalling, cell cycle, cytokine production, and 
apoptotic and stress response (Gorjão et al. 2006). To our knowledge, gene expression 
profiles in response to FO supplementation have not been investigated in dyslipidemic 
subjects so far. Connections between dyslipidemia, especially HTG and HDL-
hypocholesterolemia, and chronic inflammation have already been uncovered (Esteve et al. 
2005). The discovery of specific FO metabolic pathways which are influenced by FO in 
dyslipidemic states may provide insights into the anti-inflammatory and lipid-lowering effects 
of n-3 PUFAs. In addition, it is not known if normo- and dyslipidemic subjects display different 
gene expression profiles in response to FO supplementation. Accordingly, we conducted a 
nutrition study to identify the differences in gene expression profiles after FO 
supplementation between normo- and dyslipidemic subjects. 
2.2 Material and Methods 
A randomized, double-blind, controlled, parallel intervention study of three months duration 
was undertaken. This investigator-initiated study was designed and conducted according to 
the principles of the Good Clinical Practice (GCP) Guidelines laid down in the Declaration of 
Helsinki. The study was registered at ClinicalTrials.gov (ID: NCT01089231). 
2.2.1 Subjects 
The recruitment of subjects was performed by several advertisements and study placards in 
Hannover. One hundred and six subjects were pre-selected via telephone interviews 
according to the following exclusion criteria: Female; body-mass-index (BMI) > 35; smoker; 
intake of any corticosteroid, lipid-lowering or anti-inflammatory drugs; diagnosed chronic - 
cardiovascular or liver diseases; gastrointestinal disorders; blood coagulation disorders and 
intake of coagulation-inhibiting drugs (i.e. Marcumar); renal failure; periodic intake of 
laxatives; ingestion of supplements enriched with n-3 PUFAs, phytosterols, 
polyglucosamines, other lipid-binding ingredients, or daily eating of fatty fish; allergy to fish or 
FO; or participation in another clinical study < 30 days before the start of the study or at the 
same time. The pre-selected subjects were invited for a screening examination to collect 
fasting blood and determine serum lipid levels. Among these subjects, 20 normolipidemic 
men (TC < 200 mg/dl; LDL-C < 130 mg/dl; TG < 150 mg/dl) and 20 dyslipidemic men 
(TC > 200 mg/dl; LDL-C > 130 mg/dl; TG > 150 mg/ml), aged between 29 and 51 years, 
were enrolled in the study population (Figure 2.1). All subjects included gave their written 
informed consent to take part in the study, which was approved by the Freiburger ethics 
committee. 
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Figure 2.1: Flow chart of subject recruitment and sample selection for microarray analysis.  
2.2.2 Study design 
The 20 normolipidemic and the 20 dyslipidemic subjects were subdivided into two groups. 
Thus, a total of four groups with ten men per group passed through the study. The formation 
of groups was performed by stratified allocation according to each subject’s age to realise a 
comparable mean age between the groups. The four study groups were randomly assigned 
to different study products by an uninvolved collaborator. Subjects ingested either six FO or 
six CO capsules per day for a period of twelve weeks. The daily n-3 PUFA intake via FO 
capsules was 2.7 g (1.14 g DHA and 1.56 g EPA). The predominant FA of the CO capsules 
was the n-6-PUFA linoleic acid (LA, 18:2n-6). Thus, the daily LA intake via CO capsules was 
3.05 g LA. The subjects were instructed to ingest the capsules together with food, three in 
the morning and three in the evening, and to maintain their usual exercise and dietary habits 
throughout the intervention time. As an exception, on the first intervention day, all six 
capsules were ingested at the same time in the morning after a standardised breakfast. 
Fasting blood samples were collected by venepuncture during each visit. Additionally, 
participants completed a questionnaire to obtain information about changes in medication, 
diet (i.e. changes in weekly fish intake, preferred fish dishes or species, respectively) and 
lifestyle habits (i.e. physical activity), as well as the tolerability of the capsules. 
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2.2.3 Determination of fasting serum lipids and red blood cell membrane fatty 
acid composition 
Fasting venous blood samples were collected in BD Vacutainer® Blood Collection Tubes 
(Becton Dickinson, Heidelberg, Germany). The plasma lipid levels were determined by an 
external contract laboratory (LADR, Hannover; Germany) at baseline (t0), after one week (t1) 
and after twelve weeks (t12) of supplementation. Red blood cell (RBC) membrane FA 
composition including the omega-3 index, given as EPA and DHA, was analysed at t0 and t12 
according to the omega-3 index methodology (Harris and von Schacky 2004). Results are 
presented as a percentage of the total FAs identified after response factor correction. The 
coefficient of variation for EPA and DHA was 5%. Quality was assured according to DIN ISO 
15189. 
2.2.4 Statistical analysis of blood levels 
Statistical analysis of clinical parameters was processed with SPSS software version 17 
(SPSS Inc., Chicago, IL, USA). The results are based on per protocol population, defined as 
subjects completing all visits not infringing the study protocol, and are presented as 
mean ± SD (Table 2.1). Differences between t0 and t12 were tested within the groups by t-test 
for dependent samples. Group differences were examined with a two-factor variance 
analysis (ANOVA) combined with a post hoc test of contrast (Scheffé). Additionally, 
differences between groups were analysed by covariance analysis (ANCOVA) using the 
corresponding baseline values as covariates to detect possible effects caused by diverse 
baseline values. Statistical significance was generally accepted at p < 0.05.  
2.2.5 Microarray analyses 
2.2.5.1 Sample collection 
Fasting venous blood samples were collected in PAXgene Blood RNA Tubes (PreAnalytiX, 
Hombrechtikon, Switzerland) at baseline (t0), after one week (t1), and after twelve weeks (t12) 
of supplementation to analyse medium- and long-term effects of the FO and CO 
supplementation on gene expression regulation. For short-term effects, venous blood 
samples were collected four hours (t4h) after the first intake of the capsules. The time point of 
four hours was selected in accordance with results achieved in a previous study where the 
strongest postprandial gene expression changes in peripheral blood mononuclear cells 
(PBMCs) of healthy men were observed after four and six hours (Bouwens et al. 2010). The 
whole blood samples collected were incubated for 24 hours in the PAXgene Blood RNA 
Tubes at room temperature. 
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2.2.5.2 Total RNA isolation from human whole blood and RNA purification 
The total ribonucleic acid (RNA) was isolated with the PAXgene Blood RNA Kit (PreAnalytiX, 
Hombrechtikon, Switzerland), according to the manufacturer’s recommended procedures. 
RNA yield was quantified by Nanodrop ND-1000 spectrophotometer (peQLab Biotechnologie 
GmbH, Erlangen, Germany) measurement. Total RNA was purified with the Globin Clear Kit 
(Ambion, Applied Biosystems, Darmstadt, Germany), according to the manufacturer’s 
instructions. The reduction of highly abundant globin mRNA transcripts in whole blood 
samples is necessary to enable the detection of low-abundance transcripts (Debey et al. 
2006). The purified RNA was quantified again, and the quality was measured with an Agilent 
2100 Bioanalyzer using RNA 6000 Nano Chips and a RNA 6000 Nano Kit (Agilent 
Technologies, Böblingen, Germany).  
2.2.5.3 Sample pooling 
Equal amounts of purified RNA samples from each member of the respective group were 
pooled together. This was done for all different time points (t0, t4h, t1, and t12). Therefore, four 
pool-samples were generated by this process for each group, which results in a total of 
sixteen pool-samples for the microarray experiments. This approach was chosen to reduce 
biological inter-individual variability, which is frequent due to variations in relative proportions 
of specific blood cell subsets, gender, age, and disease state (Whitney et al. 2003). 
2.2.5.4 cDNA synthesis and hybridisation 
First-strand complementary desoxyribonucleic acid (cDNA) synthesis and tyramide signal 
amplification (TSA) were performed using MicromaxTM TSATM Labeling and Detection Kit 
(Perkin Elmer Life Sciences, Rodgau, Germany) with several protocol modifications. A total 
amount of 6 µg from every RNA pool, as well as random hexamer primer (Fermentas, St. 
Leon-Rot, Germany) and oligo dT primer (Roth, Karlsruhe, Germany), were used for the 
cDNA synthesis, which was facilitated by using Superskript III reverse transcriptase 
(Invitrogen, Karlsruhe, Germany). The incubation time of two hours was split into two one 
hour incubations and additional Superskript III was added after first hour. Each RNA pool 
was synthesized into two different labelled cDNAs, fluorescein-labelled and biotin-labelled 
cDNA.  
After labelling, the cDNA samples were purified with the QIAquick PCR Purification Kit 
(Qiagen, Hilden, Germany), according to the manufacturer’s instructions. Furthermore, the 
cDNA samples were first vacuum-dried and then resolved in hybridization buffer (4 x SSPE; 
2.5 x Denhardt’s reagent; 30% formamid). After a final degradation step (3 minutes, 95°C), 
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one-tenth of top-block (Sigma-Aldrich, Steinheim, Germany) was added. Equal amounts of 
biotin-labelled cDNA and fluorescein-labelled cDNA were hybridized simultaneously in one 
experiment to human whole genome OneArray™ Microarrays (Phalanx Biotech Group; 
Belmont, CA, USA). Hybridizations were carried out overnight at 42°C in hybridization 
chambers (Eppendorf AG, Hamburg, Germany). 
After hybridization, unbound and non-specifically fixed cDNA was removed by stringent 
washing from the array. Specifically bound fluorescein- and biotin-labelled cDNA were 
sequentially detected with a series of conjugate reporter molecules according to the TSA 
process, ultimately with tyramide-Cy3 and tyramide-Cy5. Microarray experiments were 
performed for each study group in a loop design (Figure 2.2) to save microarrays and 
prevent dye-dependent variety effects (Kerr and Churchill 2001).  
 
Figure 2.2: Loop-Design of microarray experiments.  
2.2.5.5 Microarray data analysis 
Microarrays were scanned several times with a 4000 B scanner (Axon Instruments, Inc., 
Union City, CA, USA) and images were quantified using GenePixPro 6.0 Software. The 
average pixel intensity within each spot was determined and a local background was 
computed for each spot. Net signal was determined by subtracting local background from the 
average intensity. Signals not consistently detectable (background corrected signal lower 
than two times background standard deviation) were excluded from further analysis. 
Following the primary analysis, data from different scans had to be summarized. The scans 
first had to be normalized by the sum of all corresponding spot-intensities due to different 
laser power and photomultiplier-tube settings. Afterwards, data from different scans for each 
individual spot could be averaged by the mean. The mean of the data for differently labelled 
targets for each gene on two microarrays was taken. It was assumed that the distribution of 
the pre-processed data was normal and hence, a standard two-state pooled-variance t-test 
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(1% and 5% probability of error) was applied in order to detect differentially expressed 
genes. Array data were submitted to Gene Expression Omnibus (GEO) which supports 
minimum information about a microarray experiment (MIAME) (Barrett et al. 2007). The 
accession number of the submitted dataset is GSE34898. Genes that were detected as 
differentially expressed between baseline and measurement time point (t4h, t1 or t12) were 
subjected to pathway analysis by the Kyoto Encyclopaedia of Genes and Genomes (KEGG) 
database (http://www.genome.jp/kegg/pathway.html).  
2.3 Results 
2.3.1 Subject characteristics 
At baseline, no significant differences of the mean age, mean weight and the content of EPA 
and DHA in RBC membranes, as well as in the omega-3 index, were observed between all 
groups. However, comparison of both FO groups showed that the dyslipidemic FO group had 
a 4.8 kg/m² higher BMI, higher TC and TG level, lower HDL-C level, a higher LDL-C/HDL-C 
ratio, and a lower AA content in RBC membranes than the normolipidemic FO group (Table 
2.1). Comparisons of both CO groups showed higher LDL-C and TC levels, as well as a 
higher LDL-C/HDL-C ratio, in the dyslipidemic CO group than in the normolipidemic CO 
group. 
All 40 subjects (20 normolipidemic and 20 dyslipidemic men) completed the study. However, 
it was necessary to exclude the RNA samples of ten subjects from the microarray 
experiments and data analysis due to several reasons: Low RNA yield (four subjects), 
consumption of alcohol with effects on serum TG levels (two subjects), consumption of 
medication that lead to exclusion (three subjects), and highly elevated TG level (> 1000 
mg/dl in one subject). Therefore, RNA pools were generated and data were analysed from 
nine (FO-N), six (CO-N), eight (CO-D), and seven (FO-D) subjects for each investigation time 
point (Figure 2.1). 
2.3.2 Changes of blood lipids, fatty acid composition of red blood cell 
membranes and omega-3 index 
The effects of the supplementation with either FO or CO in normo- and dyslipidemic subjects 
on serum lipids and FA composition of RBC membranes are shown in Table 2.1. Blood lipids 
showed only slight differences between t0 and t12. A significant increase in HDL-C levels was 
observed in the FO-D group, whereas a tendency for increased HDL-C levels was seen in 
the FO-N group. Furthermore, trends for an increased LDL-C and decreased TG level were 
observed in the FO-D group. Comparison of the t12 values between the FO and CO groups 
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with by ANCOVA using t0 values as covariates, showed lower TG levels in the FO-N group 
than in the CO-N group and higher HDL-C levels, as well as a trend of lower LDL-C levels, in 
the FO-D group than in the CO-D group.  
Several significant differences could be observed in the FA composition of RBC membranes 
and the omega-3 index between the groups. Within both FO groups, the percentage of EPA 
and DHA, as well as the omega-3 index in RBC membranes, significantly increased after 
twelve weeks of supplementation (p < 0.001). Additionally, the FO-N group showed a 
significant decrease of the percentage of AA and LA in RBC membranes. Within both CO 
groups, no statistical differences between t0 and t12 values could be detected, except the 
increase of the percentage of EPA in RBC membranes in the CO-D group. Group 
comparisons of the t12 values between the FO and CO groups showed significantly higher 
percentages of EPA, DHA and omega-3 index, as well as lower percentages of AA in RBC 
membranes in both the FO-N and FO-D group in comparison to the respective CO groups.  
2.3.3 Microarray analyses 
2.3.3.1 Number of regulated genes 
The total number of regulated genes of each study group was determined and compared 
between groups. Both dyslipidemic study groups showed a higher number of regulated 
genes than normolipidemic study groups, independent of the type of supplemented oil 
(Figure 2.3).  
The differences in the total number of regulated genes between the two CO groups are 
small, whereas both FO groups showed substantial differences. A further determination of 
the direction of regulated genes in total within each group discovered a higher number of 
down-regulated genes in both dyslipidemic groups (CO-D and FO-D). In contrast, a higher 
number of up-regulated genes were observed in both normolipidemic groups (CO-N and FO-
N). Another observation was made concerning the pattern of up- and down-regulated genes 
within each group depending on the time point of investigation. Whereas the pattern of up- 
and down-regulated genes was similar at the first two early time points (t4h and t1), the 
pattern changed into the opposite direction after twelve weeks of supplementation (t12). This 
observation was made in all groups, except the FO-D group. 
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Figure 2.3: Number of regulated genes. Number of genes that were regulated in the normo-
lipidemic fish oil group (FO-N), normolipidemic corn oil group (CO-N), dyslipidemic corn oil 
group (CO-D), and dyslipidemic fish oil group (FO-D) after four hours (t4h), one week (t1) and 
twelve weeks (t12) of supple-mentation. Total regulated genes summarize all genes regulated 
during the different time points, without doubles, respectively. 
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Table 2.1: Anthropometric data, serum lipid levels and red blood cell membrane fatty acid composition of the four treatment groups (FO-N, 
CO-N, FO-D, CO-D) at baseline (t0) and after supplementation with fish oil or corn oil over twelve weeks (t12).  
FO-N (n = 10) CO-N (n = 7) CO-D (n = 8) FO-D (n = 9) 
Parameters 
t0 t12 t0 t12 t0 t12 t0 t12 
Age [years] 37.50± 8.11  37.40± 8.30  41.80± 8.94  40.20± 8.64  
Body height [cm] 180.30± 6.29  181.60± 7.54  182.80± 7.02  180.40± 7.55  
Body weight [kg] 78.90± 15.25 78.51± 16.13 85.80± 10.90 84.79± 11.19 85.50± 14.80 84.53± 14.51 94.80± 13.20 94.06± 13.80 
Body mass index 
[kg/m²] 24.20± 4.15 
c
 24.13± 4.50 25.90± 2.83 25.67± 2.78 25.40± 2.91 25.14± 2.86 29.00± 2.98 c 28.82± 3.25 
TC [mg/dl] 184.10± 13.3 c 195.60± 26.10 194.00± 22.2 d 188.90± 21.50 261.00± 48.1 d 257.50± 60.30 262.20± 61.9 c 264.40± 49.20 
TG [mg/dl] 82.40± 35.3 c 66.20± 16.7 A 155.60± 53.80 87.40± 14.8 A 175.00± 56.20 186.90± 49.60 322.40± 258.9 c 230.80± 147.0 §_T 
HDL-C [mg/dl] 59.00± 10.4 c 65.20± 14.4 §_T 52.70± 12.70 52.60± 11.60 47.90± 10.02 47.40± 8.21 B 45.20± 6.50 c 50.80±  9.43 §B 
LDL-C [mg/dl] 108.70± 12.8 c_T 117.20± 22.10 118.10± 25.1 d 118.60± 28.20 178.10± 45.4 d 172.60±  54.4 B_T 146.10± 5.31 c_T 167.40±  23.6 §_T B_T 
LDL-C/HDL-C 
quotient 1.89± 0.4 
c
 1.88± 0.54 2.41± 0.89 d 2.41± 0.98 3.74± 0.68 d 3.60± 0.73 3.20± 0.58 c 3.24± 0.73 
LA (18:2n-6)[%]* 0.25± 0.03 0.19± 0.03 § 0.23± 0.03 0.20± 0.05 0.22± 0.03 0.18± 0.05 0.23± 0.03 0.17± 0.03 § 
AA (20:4n-6)[%]* 15.95± 0.81 c 13.00± 0.65 §a 15.74± 1.48 15.99± 1.74 a 14.94± 1.47 14.88± 1.22 b 12.82± 2.19 c 11.98± 1.61 b 
EPA (22:5n-3) 
[%]* 2.31± 0.41 3.74± 0.51 
§a
 2.31± 0.22 2.44± 0.18 a 2.09± 0.41 2.39± 0.35 §b 2.00± 0.43 3.31±  0.26 §b 
DHA (22:6n-3) 
[%]* 4.39± 0.68 6.87± 0.78 
§a
 4.16± 1.14 4.09± 0.94 a 4.28± 1.27 4.57± 1.10 b 3.90± 1.42 6.59± 0.75 §b 
Omega-3-index 
[%]* 5.24± 0.70 10.70± 1.06
 §aA
 5.08± 1.41 4.78± 1.16 aA 5.27± 1.69 5.50± 1.57 bB 4.90± 1.80 9.84± 1.26 §bB 
*  percentage of total fatty acids  
§
 p < 0.05 (Changes between baseline and month three were evaluated within groups by Student’s t test for dependent samples) 
a
 p < 0.05 (Changes of means were evaluated between FO-N and CO-N by Student’s t test)  
b
 p < 0.05 (Changes of means were evaluated between FO-D and CO-D by Student’s t test)  
c
 p < 0.05 (Changes of means were evaluated between FO-N and FO-D by Student’s t test)  
d
 p < 0.05 (Changes of means were evaluated between CO-N and CO-D by Student’s t test)  
A
 p < 0.05 (Changes of means were evaluated between FO-N and CO-N group by ANCOVA using baseline as covariate)  
B
 p < 0.05 (Changes of means were evaluated between FO-D and CO-D group by ANCOVA using baseline as covariate)  
_T
 trend of significance (p < 0.1) 
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2.3.3.2 Pathway analyses 
Pathway analysis of the regulated genes were performed for each group and time point. All 
pathways with regulated genes were attributed to processes according to the KEGG 
database (metabolism; genetic information processing, environmental information 
processing, cellular processes, organismal systems and human diseases) 
(http://www.genome.jp/kegg/pathway.html) to analyse the influence of the supplemented oil 
type on gene expression changes in different processes. Furthermore, the number of 
regulated genes in pathways belonging to different processes was determined for each 
group and compared as a percentage of total regulated genes between groups. Thus, the 
influence of the supplemented oil type on different processes could be investigated.  
Table 2.2 shows processes where a higher number of genes in both FO groups were 
regulated at the different time points compared to the corresponding CO groups. It was 
noticeable that the lipid metabolism was regulated at all time points after FO 
supplementation. A greater number of processes were regulated in both FO groups after 
twelve weeks (t12), including, for example, lipid metabolism, the immune system and CVD.  
Further analyses concentrated on the long-term effects after twelve weeks of FO 
supplementation (t12). Therefore, corresponding pathways and regulated genes from three 
exemplary processes that were dominantly regulated in both FO groups after twelve weeks 
(lipid metabolism, the immune system, CVD) were selected and listed for the FO-D group in 
Table 2.3. In some pathways of the lipid metabolism, genes were mainly down-regulated (FA 
synthesis,-metabolism and elongation, AA-, LA- and alpha linolenic acid metabolism), 
whereas in others pathways, genes were mainly up-regulated (glycerolipid and 
glycerophospholipid metabolism). The immune system-related pathway of complement and 
coagulation cascade, as well as the two pathways related to CVD, showed mainly down-
regulated genes. 
Generally, the majority of regulated genes in all groups were detected in pathways related to 
the immune system. It is known that FO supplementation provokes immune-modulatory and 
anti-inflammatory effects. Therefore, regulated genes related to inflammation and immune 
response, were individually selected for the FO-D group to show the direction of regulation 
(Table 2.4). This examination showed that a greater number of pro-inflammatory genes were 
down-regulated after twelve weeks of supplementation, while a higher number of immune 
response related genes were up-regulated. However, roughly the same number of anti-
inflammatory genes was up- and down-regulated.  
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Table 2.2: Selected processes dominantly regulated in dys- and normolipidemic subjects in 
response to fish oil supplementation for four hours (t4h), one week (t1) and twelve weeks (t12) 
compared to corn oil supplementation. The selection was performed as follows: The number 
of regulated genes within pathways was counted for each group. Pathways were assigned to 
corresponding processes and the number of regulated genes in these pathways was 
summed up. The resulting data represent the number of regulated genes in different 
processes for each group. These numbers were compared between groups and those 
processes were selected where both fish oil treatment groups (FO-D, FO-N) showed more 
regulated genes compared with the corn oil treatment groups (CO-D, CO-N). 
t4h t1 t12 
Cell Communication 
Cell Growth and Death 
Circulatory System 
Digestive System 
Endocrine System 
Excretory System 
Folding, Sorting and 
Degradation 
Immune System 
Lipid Metabolism 
Nervous System 
Signalling Molecules 
and Interaction 
Carbohydrate Metabolism 
Cardiovascular Diseases 
Circulatory System 
Digestive System 
Energy Metabolism 
Folding, Sorting and 
Degradation 
Lipid Metabolism 
Signal Transduction 
Signalling Molecules and 
Interaction 
Xenobiotics 
Biodegradation and 
Metabolism 
Amino Acid Metabolism 
Biosynthesis of Other 
Secondary Metabolites 
Cardiovascular Diseases 
Cell Growth and Death 
Endocrine System 
Energy Metabolism 
Excretory System 
Immune System 
Immune System Diseases 
Lipid Metabolism 
Metabolic Diseases 
Metabolism of Cofactors and 
Vitamins 
Metabolism of Other Amino 
Acids 
Nervous System 
Nucleotide Metabolism 
Sensory System 
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Table 2.3: Selected pathways and genes dominantly regulated in dyslipidemic subjects (FO-
D) in response to fish oil supplementation for twelve weeks. 
 Pathway Gene name Gene symbol Entrez_ID Ratio t12 : t0 
Fatty acid biosynthesis acetyl-CoA carboxylase beta ACACB 32 -4.67 
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA 
thiolase/enoyl-CoA hydratase (trifunctional 
protein), alpha subunit 
HADHA 3030 -3.70 Fatty acid elongation in 
mitochondria 
hydroxyacyl-CoA dehydrogenase HADH 3033 -2.34 
enoyl-CoA delta isomerase 2 ECI2 10455 -4.54 
enoyl-CoA delta isomerase 1 ECI1 1632 6.02 
hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA 
thiolase/enoyl-CoA hydratase (trifunctional 
protein), alpha subunit 
HADHA 3030 -3.70 
hydroxyacyl-CoA dehydrogenase HADH 3033 -2.34 
acyl-CoA dehydrogenase, short/branched chain ACADSB 36 -13.69 
Fatty acid metabolism 
aldehyde dehydrogenase 2 family (mitochondrial) ALDH2 217 3.26 
1-acylglycerol-3-phosphate O-acyltransferase 6 AGPAT6 137964 2.67 
diacylglycerol kinase, alpha 80kDa DGKA 1606 2.47 
diacylglycerol kinase, eta DGKH 160851 -3.05 
diacylglycerol kinase, theta 110kDa DGKQ 1609 3.40 
aldehyde dehydrogenase 2 family (mitochondrial) ALDH2 217 3.26 
Glycerolipid metabolism 
monoacylglycerol O-acyltransferase 3  MOGAT3 346606 -3.48 
1-acylglycerol-3-phosphate O-acyltransferase 6 AGPAT6 137964 2.67 
phospholipase B1 PLB1 151056 11.68 
diacylglycerol kinase, alpha 80kDa DGKA 1606 2.47 
diacylglycerol kinase, eta DGKH 160851 -3.05 
diacylglycerol kinase, theta 110kDa DGKQ 1609 3.40 
phospholipase A2, group IIE PLA2G2E 30814 2.51 
Glycerophospholipid 
metabolism 
phosphatidylserine synthase 1 PTDSS1 9791 -2.84 
phospholipase B1 PLB1 151056 11.68 
gamma-glutamyltransferase 5 GGT5 2687 7.98 
glutathione peroxidase 3 (plasma) GPX3 2878 -2.15 
glutathione peroxidase 5 GPX5 2880 -2.41 
Arachidonic acid metabolism 
phospholipase A2, group IIE PLA2G2E 30814 2.51 
phospholipase B1 PLB1 151056 11.68 Linoleic acid metabolism 
phospholipase A2, group IIE PLA2G2E 30814 2.51 
phospholipase B1 PLB1 151056 11.68 
Li
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Alpha-linolenic acid 
metabolism 
phospholipase A2, group IIE PLA2G2E 30814 2.51 
complement component (3b/4b) receptor 1 CR1 1378 -3.37 
coagulation factor III (thromboplastin, tissue 
factor) 
F3 2152 -4.23 
fibrinogen gamma chain FGG 2266 -12.30 
Im
m
u
n
e 
 
sy
s
te
m
 Complement and coagulation 
cascades 
serpin peptidase inhibitor, clade C (antithrombin), 
member 1 
SERPINC1 462 3.23 
desmocollin 2 DSC2 1824 -2.50 
calcium channel, voltage-dependent, gamma 
subunit 5 
CACNG5 27091 -9.92 
integrin, alpha 3 ITGA3 3675 -4.32 
Arrhythmogenic right 
ventricular cardiomyopathy 
(ARVC) 
transcription factor 7-like 1 TCF7L1 83439 -4.93 
adenylate cyclase 7 ADCY7 113 -2.13 
calcium channel, voltage-dependent, gamma 
subunit 5 
CACNG5 27091 -9.92 
integrin, alpha 3 ITGA3 3675 -4.32 C
ar
di
o
v
as
cu
la
r 
di
se
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es
 
Dilated cardiomyopathy 
myosin, light chain 2, regulatory, cardiac, slow MYL2 4633 2.68 
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Table 2.4: Selection of inflammation and immune response related genes regulated in 
dyslipidemic subjects after supplementation with fish oil for twelve weeks.  
Gene name Gene symbol Entrez_ID Ratio t12 : t0 
Pro-inflammatory genes 
Nitric oxide synthase, inducible NOS2 4843 -4.77 
C-C chemokine receptor type 3 CCR3 1232 -4.49 
Tumour necrosis factor receptor superfamily member 18 Precursor TNFRSF18 8784 -2.07 
Interleukin-31 receptor A Precursor  IL31RA 133396 -4.74 
72 kDa type IV collagenase Precursor MMP2 4313 -6.16 
Interleukin-8 Precursor  IL8 3576 -5.67 
Tumour necrosis factor receptor superfamily member 5 Precursor  CD40 958 -4.72 
Interleukin-2 receptor subunit beta Precursor  IL2RB 3560 -3.22 
Interleukin-3 receptor subunit alpha Precursor  IL3RA 3563 -2.22 
Stromelysin-1 Precursor  MMP3 4314 -2.17 
C-C motif chemokine 5 Precursor CCL5 6352 2.24 
CD97 antigen Precursor  CD97 976 2.26 
Prostaglandin D2 receptor  PTGDR 5729 4.47 
Integrin alpha-L Precursor  ITGAL 3683 5.07 
Arachidonate 5-lipoxygenase-activating protein (FLAP) ALOX5AP 241 6.97 
Anti-inflammatory genes 
C-X-C motif chemokine 11 Precursor CXCL11 6373 -2.98 
NF-kappa-B-repressing factor  NKRF 55922 -82.11 
NF-kappa-B inhibitor-like protein 2 NFKBIL2 4796 -3.30 
Cytokine receptor-like factor 1 Precursor  CRLF1 9244 -3.07 
Lipopolysaccharide-induced tumour necrosis factor-alpha factor LITAF 9516 3.06 
Interferon regulatory factor 1 IRF1 3659 3.16 
Interferon-alpha/beta receptor alpha chain Precursor IFNAR1 3454 5.13 
Suppressor of cytokine signalling 6 SOCS6 9306 6.01 
Immune response related genes 
Suppressor of cytokine signalling 2  SOCS2 8835 -6.05 
Disintegrin and metalloproteinase domain-containing protein 10 Precursor  ADAM10 102 -5.23 
A disintegrin and metalloproteinase with thrombospondin motifs 10 Precursor ADAMTS10 81794 -3.14 
Nitric oxide synthase, endothelial  NOS3 4846 -2.55 
SL cytokine Precursor  FLT3LG 2323 -2.46 
Prostaglandin E2 receptor EP3 subtype PTGER3 5733 -2.21 
CD99 antigen-like protein 2 Precursor CD99L2 83692 2.18 
Cytokine receptor common gamma chain Precursor  IL2RG 3561 2.85 
Monocyte differentiation antigen CD14 Precursor  CD14 929 2.88 
Chemokine-like factor (C32) CKLF 51192 11.73 
T-cell surface glycoprotein CD3 delta chain Precursor  CD3D 915 7.65 
Tumour necrosis factor receptor superfamily member 1B Precursor  TNFRSF1B 7133 2.51 
B-lymphocyte antigen CD20 MS4A1 931 2.12 
Interleukin-31 receptor A Precursor IL31RA 133396 5.72 
Intercellular adhesion molecule 3 Precursor  ICAM3 3385 5.85 
CD320 antigen Precursor  CD320 51293 8.17 
CD2 antigen cytoplasmic tail-binding protein 2  CD2BP2 10421 8.77 
T-cell antigen CD7 Precursor  CD7 924 2.30 
C-C chemokine receptor-like 2 (Putative MCP-1 chemokine receptor) CCRL2 9034 17.55 
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2.4 Discussion 
It is known from numerous in vitro and in vivo studies that FO and its general n-3 PUFAs, 
EPA and DHA, regulate the expression of genes, but human intervention studies 
investigating the effect of FO on whole genome gene expression are lacking. Our study 
aimed to investigate two main objectives: The first intention was to investigate the effects of 
FO supplementation on gene expression changes in dyslipidemic subjects in comparison to 
normolipidemic subjects. The second objective was to compare the effects of FO with CO, 
which is used as placebo in many intervention studies, investigating the physiological effects 
of FO. To the best of our knowledge, this is the first randomized intervention study disclosing 
gene expression profiles on the whole genome level under these specific conditions. In 
general, we anticipated regulative effects of FO on the expression of genes associated with 
the immune system and the lipid metabolism, especially in dyslipidemic subjects. 
2.4.1 Serum lipid and omega-3 index levels 
As expected, the FO supplementation of dyslipidemic subjects was followed by an increase 
in HDL-C levels and a decrease in TG levels after twelve weeks, although not significant due 
to the low group size. There was little or no effect on the lipid levels in normolipidemic 
subjects after FO or CO supplementation. The omega-3 index increased significantly in both 
FO treatment groups from levels ~ 5% to levels of ~10% after twelve weeks of 
supplementation, which is a shift from an unfavourable area in view of the cardiovascular risk 
to optimal levels of 8% or greater (Harris 2010). Moreover, the omega-3 index increased in 
all subjects of the two FO groups, indicating an efficient uptake and subsequent incorporation 
of EPA and DHA in tissue membranes. It can, therefore, be assumed that changes observed 
in gene expression in the FO supplementation groups are the result of the treatment. 
2.4.2 Normolipidemic vs. dyslipidemic subjects 
Gene expression profiles of normo- and dyslipidemic subjects differed substantially after FO 
supplementation. In the dyslipidemic study group, considerably more genes were regulated 
after FO supplementation, whereas genes were mainly down-regulated. Although the reason 
for this finding cannot be clarified here, it might be partly explained by the interrelation 
between inflammation and dyslipidemia (Esteve et al. 2005). Several studies have 
demonstrated that a dyslipidemic – in particular hypertriglyceridemic – state is accompanied 
by an induction of pro-inflammatory pathways (Jonkers et al. 2002; Lundman et al. 2003), 
while n-3 PUFAs are known to suppress these pathways (Adkins and Kelley 2010). Indeed, a 
number of pro-inflammatory genes were down-regulated in dyslipidemic subjects after FO 
supplementation, including members of the TNFα pathway. However, besides the regulated 
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genes involved in inflammatory pathways, it is apparent that a large number of other genes 
were regulated in dyslipidemic subjects in response to FO treatment, suggesting a strong 
regulative effect of FO in people with dyslipidemia. It needs to be clarified in future studies if 
some of these genes are associated with the known beneficial effects FO or n-3 PUFAs in 
dyslipidemia.  
In contrast to dyslipidemic subjects, a higher number of genes were up-regulated in 
normolipidemic subjects in response to FO supplementation. This finding corresponds with 
the outcomes of two intervention studies investigating the effect of FO supplementation on 
whole genome expression in healthy subjects (Bouwens et al. 2009; Gorjão et al. 2006). The 
study of Gorjão and co-workers was conducted with ten men aged between 25 and 45 years 
supplemented with 1.62 g DHA and 0.78 g EPA per day over a period of eight weeks. The 
design of this study is comparable with our study, except for the sample material used for 
RNA isolation (fractionated lymphocytes vs. whole blood). Different RNA sources could yield 
different expression patterns, and cell fractioning itself could alter the gene expression 
pattern (Vartanian et al. 2009). Nevertheless, both studies provided similar results. Gorjão 
and co-workers discovered 71 up- and 6 down-regulated genes by macroarray analysis. Our 
normolipidemic FO group showed 627 total regulated genes, 383 of which were up-regulated 
and 244 down-regulated. Therefore, both studies indicate that genes in normolipidemic 
subjects are mainly up-regulated after FO supplementation. In the study by Bouwens and 
colleagues, a total of 111 men and woman aged between 66 and 80 years were 
supplemented with 1.09 g EPA and 0.85 g DHA per day over 26 weeks. There were great 
differences in the study design compared to our study with regard to gender (men and 
woman vs. men), subject age (older vs. middle aged), daily n-3 PUFAs intake (1.94 g vs. 2.7 
g/d EPA+DHA), and sample material used for RNA isolation (PBMCs vs. whole blood), which 
makes it difficult to compare the results. However, the number of total regulated genes in 
both studies was in the same order of magnitude. Bouwens and co-workers identified a total 
of 1040 regulated genes, with 537 up-regulated and 503 down-regulated genes.  
2.4.3 Fish oil vs. corn oil  
CO serves as placebo in many FO supplementation studies based on the assumption that 
CO is inert without biological effects. However, CO is rich in the n-6 PUFA LA, a precursor 
for AA. Thus, CO similarly contains FAs, capable of directly regulating gene expression or 
serving as precursors for other bioactive lipid mediators which regulate gene expression. It 
was, therefore, our intention to enlighten the possible regulative effects of CO on gene 
expression. The administration of six CO capsules provided three grams of LA per day, 
which is less than a quarter of the usual dietary intake of LA, and considerably less than a 
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high consumption of vegetable oil. In view of this small amount and the low conversion rate 
of LA to AA, we assumed that the effect of LA on gene expression would be infinitesimal. 
Surprisingly, our data revealed that the administration of even small amounts of LA caused 
changes in gene expression patterns. However, during the evaluation of the study data, we 
focussed on the specific effects of FO on gene expression. 
Our data demonstrated substantial differences in gene expression regulation between FO 
and CO supplementation. Pathway analysis showed that considerably more pathways were 
dominantly regulated in the FO groups compared to the CO groups (in both normolipidemic 
and dyslipidemic subjects). Additionally, significantly more genes in these pathways and 
metabolisms were shown to be regulated in dyslipidemic subjects after FO supplementation 
compared to normolipidemic subjects, suggesting a more pronounced regulative potential of 
FO in dyslipidemic subjects. Metabolisms that were dominantly affected by FO include, for 
example, the immune system, lipid metabolism and CVD. 
2.4.3.1 Immune system metabolism 
Both FO and CO administration resulted in the regulation of genes associated with the 
immune system and infectious diseases, which is expected in view of the RNA source used. 
RNA was isolated from whole blood, including leukocytes, which are mainly involved in the 
immune system and pathogen defence. Therefore, it is not surprising that a great number of 
regulated genes are involved in immune system related pathways. However, comparing the 
effect of FO and CO supplementation on the expression of immune system related genes, it 
appears that FO regulates significantly more genes in specific pathways compared to CO, 
indicating the immune-modulatory capability of FO and its bioactive FAs, EPA and DHA. 
Generally, EPA and DHA have anti-inflammatory properties by increasing the production of 
potent bioactive lipid mediators (protectins and resolvins), and inhibiting the formation of n-6 
FA-derived pro-inflammatory eicosanoids (i.e. PGE2 and LTB4) (Kang and Weylandt 2008). 
Together, these effects directly or indirectly suppress the activity of nuclear transcription 
factors, such as NFκB, which controls the expression of a variety of pro-inflammatory and 
pro-atherogenic genes, including those encoding for IL-1, IL-6, IL-8, tumour necrosis factor 
alpha (TNFα), E-selectin, VCAM-1, and COX-2 (Kang and Weylandt 2008; Massaro et al. 
2008).  
With a few exceptions, our data revealed that none of the key regulators mentioned above 
were regulated after FO supplementation, either in dyslipidemic or in normolipidemic subjects 
(IL-8 was down-regulated after one week and twelve weeks in dyslipidemic FO-
supplemented subjects, as well as IL-1 receptor, type II after one week). However, a number 
of inflammation and immune response related genes were regulated after twelve weeks of 
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FO supplementation, especially in dyslipidemic subjects. The ratios demonstrate that more 
pro-inflammatory genes were down-regulated than up-regulated, whereas the rate of up- and 
down-regulation was balanced for anti-inflammatory genes. Moreover, pathway analyses 
showed that genes of the complement and coagulation cascades (complement component 
[3b/4b] receptor 1, coagulation factor III [thromboplastin, tissue factor], fibrinogen gamma 
chain) were mainly down-regulated in dyslipidemic subjects supplemented with FO. Since 
the blood coagulation cascade is evolutionarily closely related to the innate immune 
response, its pathways are assigned to the immune system. The coagulation pathway is 
essential for clot formation and the prevention of excessive bleeding. A dysregulation of the 
cascade activities can result in clinical manifestations of several diseases with critical 
thrombotic and/or inflammatory complications (Oikonomopoulou et al. 2012). Our results 
underline the well-known effect of FO to diminish the coagulant activity by the lowering of 
several coagulation factors and by reducing the capability of plasma to support thrombin 
generation, especially in patients with hyperlipidemia (Vanschoonbeek et al. 2004). 
2.4.3.2 Lipid metabolism  
As expected, pathway analyses revealed that the effect of FO supplementation on the 
expression of genes involved in lipid metabolism was more pronounced compared to CO. 
Similarly, the regulatory effect of FO supplementation was markedly stronger among 
dyslipidemic subjects compared to normolipidemic subjects relating to the number of 
regulated genes. The liver plays a central role in lipid metabolism and n-3 PUFAs have been 
shown to regulate hepatic gene expression by targeting several transcriptional regulatory 
networks (Adkins and Kelley 2010): For example, n-3 PUFAs regulate several inflammation 
molecules, including serum amyloid A, TNFα and IL-6 (Tai and Ding 2010). These 
inflammation mediators modulate the expression of many lipid metabolism-related genes, for 
example, by suppressing the expression of perilipin, SREBP-1 and LPL. Together, these 
regulatory pathways result in induced lipolysis and reduced lipogenesis (Tai and Ding 2010). 
Besides the down-regulation of FA synthesis gene expression, n-3 PUFAs up-regulate gene 
expression involved in FA oxidation, which is triggered by an activation of the transcription 
factor PPARα (Adkins and Kelley 2010). 
Again, none of the lipid metabolism-related genes mentioned above were regulated in the 
present study after 12 weeks of supplementation, probably because the compartment 
examined (whole blood) is inappropriate to reflect the transcriptional profile of the liver. 
However, FO supplementation provoked a regulation of several lipid metabolism-associated 
pathways in dyslipidemic subjects in contrast to normolipidemic subjects, where only a few 
genes were regulated. This finding emphasises the regulating effect of n-3 PUFAs on the 
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lipid metabolism in dyslipidemic conditions. Genes, for example, in pathways related to FA 
metabolism and FA elongation in mitochondria, including genes coding several enzymes, 
were mainly down-regulated in FO supplemented dyslipidemic subjects. These enzymes 
(several dehydrogenases and an isomerase) are mainly promoters of mitochondrial FA 
oxidation. This down-regulation is in contrast to studies, which showed an increased 
peroxisomal FA oxidation in rats in response to FO administration, while the effect of FO on 
mitochondrial ß-oxidation was inconsistent (Ide et al. 2000). The observed reduced FA 
oxidation after 12 weeks of FO treatment in this study may be the result of increasing levels 
of oxidised n-3 PUFAs, which are prone to oxidation. Subsequently, the resulting oxidative 
stress may lead to an induction of antioxidative mechanisms, which in turn reduce oxidation. 
The finding that PPARα was up-regulated one week after FO capsule ingestion in 
dyslipidemic subjects (data not shown) support this hypothesis. 
We observed a down-regulation of the gene coding for acetyl-CoA carboxylase beta, which is 
one of the key enzymes in FA biosynthesis, indicating a reduced lipogenesis. This finding 
may partly explain the reduced TG levels observed in this study. In the same group, several 
genes in pathways involved in FA metabolism were regulated. Interestingly, genes coding for 
phospholipase A2, group IIE (PLA2G2E), a member of the secreted phospholipase A2 
[sPLA2] family) and phospholipase B1 (PLB1) were up-regulated. The regulatory functions of 
PLA2G2E have not been completely uncovered. It is known that PLA2G2E catalyzes the 
hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides in membranes and could promote 
inflammation, since the release of AA is the first step in the AA breakdown pathway, which 
can be metabolized to several inflammatory and thrombogenic eicosanoids (PGs and LTs) 
by the activity of COX and LOX (Murakami et al. 2002). The up-regulation of PLA2G2E 
observed could also point to an intensified exchange of membrane bound AA in favour of 
EPA and DHA, which is indeed reflected in the decrease in AA levels and concomitant 
increase in EPA and DHA levels in RBC membranes observed. 
In addition, an up-regulation of several genes related to glycerolipid metabolism was 
observed in FO supplemented dyslipidemic subjects. Glycerolipids are essential components 
of membranes and an up-regulation of the glycerolipid metabolism indicates remodelling 
activities of the membrane. Finally, several genes of the glycerophospholipid metabolism 
were up-regulated in FO supplemented dyslipidemic subjects. Glycerophospholipids, also 
referred to as PLs, are key components of the lipid bilayer of biological membranes and 
constitute the binding site for EPA and DHA, which are integrated in the membrane. An up-
regulation of the glycerophospholipid metabolism results in an increased de novo PL 
biosynthesis, enabling the incorporation of EPA and DHA into the membrane (Wilkinson et 
al. 1996). 
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2.4.3.3 CVD metabolism 
Pathway analysis showed that FO supplementation induced the regulation of pathways 
involved in specific CVD related metabolisms, especially among dyslipidemic subjects. 
Several genes from pathways involved in arrhythmogenic right ventricular cardiomyopathy 
(ARVC) and dilated cardiomyopathy (DCM) were mainly down-regulated. ARVC and DCM 
belong to cardiomyopathies, a group of diseases that primarily affect the myocardium. While 
ARVC is characterized by a fibro-fatty replacement of right ventricle myocardium, DCM is a 
myocardial disease with dilated left ventricle myocardium impairing the systolic pump 
function of the heart. ARVC and DCM may cause ventricular tachyarrhythmias, blood clots or 
sudden death. Although the aetiopathogenesis, including the role of dyslipidemia in ARVC 
and DCM, is largely unknown (Skwarek et al. 2008), inflammatory processes are likely to be 
involved (Campian et al. 2010; Cihakova and Rose 2008). The down-regulating effect of FO 
on genes involved in ARVC and DCM pathways observed may be the result of diverse 
regulatory effects on lipid metabolism and anti-inflammatory processes. However, the effect 
of n-3 PUFA supplementation on the pathogenesis of ARVC and DCM in humans is 
unknown. An animal study showed that FO supplementation reduces arrhythmia in boxers 
(Canis lupus) with ARVC (Smith et al. 2007). In a recent intervention study with non-ischemic 
DCM patients, it was shown that n-3 PUFA treatment increased left ventricle systolic function 
and functional capacity (Nodari et al. 2011). 
2.4.4 Strengths and Limitations 
Strengths: The methodological approach of this study was carefully elaborated. The use of 
whole blood for RNA isolation is advantageous in view of the easy sample collection and the 
prevention of altered gene expression patterns which emerge during cell fractionation steps 
(Vartanian et al. 2009). In addition, the pooling of RNA samples reduces inter-individual 
variation, enabling one to focus on the characteristics of a population in contrast to an 
individual level (Kendziorski et al. 2005). Moreover, only men were enrolled in the study 
population. Women are subjected to several hormonal changes which involve individual gene 
expression changes and hamper the attribution of observed effects to treatment.  
Limitations: The study has a number of potential limitations, for example, the small sample 
size. Moreover, nine subject samples had to be excluded from microarray analysis. To 
minimize the already high effort for the participants, it was desisted from obtaining multiple 
baseline samples, which is recommended due to heavy fluctuations in lipid – especially TG – 
levels. The effect of FO on gene expression was compared to CO, which is often used in n-3 
PUFA supplementation studies as a placebo control. It would have been instructive to 
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examine the gene expression of a third untreated study group. However, this additional 
expenditure would have gone beyond the scope of our study. 
2.4.5 Conclusion 
This is the first study showing significant differences in gene expression profiles between 
normo- and dyslipidemic subjects after FO supplementation. Dyslipidemic subjects presented 
substantially more regulated genes and pathways, which were mainly down-regulated. 
Several of the pathways that were especially regulated in dyslipidemic subjects in response 
to FO supplementation are related to the immune system, inflammation, lipid metabolism, 
and CVD. In particular, several genes involved in FA metabolism were down-regulated, 
emphasising the regulating effect of n-3 PUFA on the lipid metabolism in dyslipidemic 
conditions. Further studies combining genetic with physiological endpoints need to clarify the 
mechanisms by which n-3 PUFAs trigger gene regulation and affect various regulatory 
networks. The disentanglement of such interferences may also explain the beneficial effects 
of n-3 PUFAs on dyslipidemia, atherosclerosis and CVD in many experimental models and 
clinical conditions. 
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3. Transcriptome-based identification of antioxidative gene expression 
after fish oil supplementation in normo- and dyslipidemic men 
3.1 Introduction 
CVD is the leading cause of morbidity and mortality in Europe, and frequently appears in 
subjects with disorders of lipid metabolism. Evidence of an association between dyslipidemia 
and increased oxidative stress (Ohara et al. 1993; Rocha-Pereira et al. 2001), as well as 
between increased oxidative stress and the pathogenesis of CVD, are given by many studies 
(Jung et al. 2004; Knight 1995; Landmesser et al. 2000; Madamanchi et al. 2005; Wang et al. 
1998). These associations indicate that dyslipidemia increases oxidative stress, and thus 
promotes the pathogenesis of CVD.  
Enhanced oxidative stress results from either an overproduction of ROS or a decreased 
antioxidative defence system. The most important ROS producers are nicotinamide adenine 
dinucleotide phosphate oxidase (Griendling et al. 2000), xanthine oxidase (Spiekermann et 
al. 2003), uncoupled endothelial nitric oxide synthase (Alp and Channon 2004), and enzymes 
of the AA metabolism and the mitochondria (Mueller et al. 2005). The consequences of an 
increased ROS production in CVD are vascular cell dysfunction (Kondo et al. 2009), 
increased growth of the myocard, apoptosis (Tsutsui et al. 2011), and cardiac remodelling via 
activation of MMPs (Kameda et al. 2003).  
The human body possess enzymatic and non-enzymatic strategies to compensate oxidative 
damage and protect itself against such cytotoxic effects. Important antioxidative enzymes 
include catalase (CAT), superoxide dismutase (SOD), heme oxygenase (HMOX), and 
glutathione peroxidase (GPX). Non-enzymatic antioxidants, such as glutathione, ascorbate 
and α-tocopherol, are also important regulators of the oxidative status.  
In the last few decades, numerous observational and intervention studies have shown the 
beneficial effects of FO and its principal n-3 PUFAs, EPA and DHA, in the prevention of 
atherosclerosis and CVD (Amano et al. 2011; Sekikawa et al. 2008; Sudheendran et al. 
2010). Beyond the beneficial effects of n-3 PUFAs on the lipid profile (Harris 1996, 1997; 
Musa-Veloso et al. 2010), especially in subjects with HTG (Balk et al. 2006; Skulas-Ray et al. 
2008; Tremoli et al.1994), n-3 PUFAs appear to increase antioxidative capacity and thus 
reduce oxidative stress (Bouzidi et al. 2010; Richard et al. 2008). However, the effects of n-3 
PUFAs on oxidative stress have not been studied in detail and some existing results are 
inconsistent. Investigations in patients with chronic renal failure showed reduced oxidative 
stress after n-3 PUFA supplementation (Bouzidi et al. 2010). Furthermore, in vitro studies 
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with human aortic endothelial and human hepatocellular carcinoma (HepG2) cells also 
determined reduced oxidative stress after n-3 PUFA treatment (Richard et al. 2008). 
However, an indication of increased oxidative stress in healthy judo athletes after n-3 PUFA 
supplementation was observed (Filaire et al. 2010). 
The underlying molecular mechanisms by which EPA and DHA influence oxidative stress are 
not completely understood. Changes in expression levels of antioxidative genes in response 
to FO supplementation have not been investigated in dyslipidemic subjects so far. In regard 
to the fact that dyslipidemia increases oxidative stress and that dyslipidemic subjects 
possess a pro-oxidant status (Araujo et al. 1995; Hiramatsu and Arimori 1988), we 
hypothesised that n-3 PUFAs show their potential antioxidative effects especially in 
dyslipidemic subjects. Therefore, this intervention trial aimed to investigate the expression 
changes of oxidative stress-related genes in normo- and dyslipidemic subjects after FO 
supplementation to gain information about the potential antioxidant effects of n-3 PUFAs. 
3.2 Material and Methods 
This study focused on changes in oxidative stress-related genes as part of a trial 
investigating the effects of FO supplementation on whole-genome gene expression profiles 
in normo- and dyslipidemic men. The randomized, controlled, parallel intervention study was 
conducted at the Institute of Food Science and Human Nutrition at the Leibniz University of 
Hannover in Germany, and was designed and performed according to the principles of the 
GCP Guidelines laid down in the Declaration of Helsinki. It was approved by the Freiburg 
International Ethical Commission and registered at ClinicalTrials.gov (ID: NCT01089231).  
3.2.1 Subjects 
Normo- and dyslipidemic men were recruited by several advertisements and study placards 
in Hannover. The suitability of volunteers was checked in telephone interviews and by diet, 
lifestyle and disease questionnaires. Exclusion criteria comprised smoking; body mass 
index > 35; intake of any corticosteroids, lipid-lowering or anti-inflammatory drugs; diagnosed 
chronically cardiovascular or liver diseases; gastrointestinal disorders; blood coagulation 
disorders and intake of coagulation-inhibiting drugs; renal failure; periodic intake of laxatives; 
ingestion of supplements enriched with n-3 PUFAs, phytosterols, polyglucosamines, other 
lipid-binding ingredients or daily eating of fatty fish; allergy to fish or FO; and participation in 
another clinical study < 30 days before the start of the study or at the same time. Selected 
subjects were invited for a screening examination to collect fasting blood and determine 
serum lipid levels. Among these subjects, ten normolipidemic (TC < 200 mg/dl; LDL-
C < 130 mg/dl; TG < 150 mg/dl) and ten dyslipidemic (TC > 200 mg/dl; LDL-C > 130 mg/dl; 
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TG > 150 mg/ml) men, aged between 29 and 51 years, were enrolled in the study population. 
All participants included gave their written informed consent to take part in the study. The 
study protocol was approved by the Freiburger ethics committee. 
3.2.2 Study design 
The normo- and dyslipidemic subjects each ingested six FO capsules per day for a period of 
twelve weeks. The daily n-3 PUFA intake for each subject via FO capsules was 2.7 g (1.14 g 
DHA and 1.56 g EPA). The subjects were instructed to take the capsules together with food, 
three in the morning and three in the evening, and to maintain their usual exercise and 
dietary habits throughout the intervention time. As an exception, on the first intervention day, 
all six capsules were ingested at the same time in the morning after a standardised 
breakfast. Additionally, participants completed a questionnaire to obtain information about 
changes in medication, diet (i.e. changes in weekly fish intake, preferred fish dishes or 
species, respectively) and lifestyle habits (i.e. physical activity), as well as the tolerability of 
the capsules. 
3.2.3 Determination of red blood cell membrane fatty acid composition 
Fasting venous blood samples were collected into BD Vacutainer® Blood Collection Tubes 
(Becton Dickinson, Heidelberg, Germany). RBC membrane FA composition, including the 
omega-3 index (EPA+DHA levels in RBC membranes), was analysed at baseline (t0) and 
after twelve weeks of supplementation with FO (t12), according to the omega-3 index 
methodology (Harris and Schacky von 2004). Accordingly, RBCs were first transesterificated, 
resulting in a generation of FA methyl esters, followed by gas chromatography analysis using 
a GC2010 Gas Chromatograph (Shimadzu, Freising, Germany) equipped with a SP2560, 
100-m column (Supelco, Bellefonte, PA) using hydrogen as carrier gas. Identification of FAs 
was enabled by comparison with a standard mixture of FAs characteristic for RBCs. The 
results are presented as a percentage of the total identified FAs after response factor 
correction. The coefficient of variation for EPA and DHA was 5%. Quality was assured 
according to DIN ISO 15189.  
3.2.4 Gene expression analyses 
3.2.4.1 Sample collection 
Fasting venous blood samples were collected in PAXgene Blood RNA Tubes (PreAnalytiX, 
Hombrechtikon, Switzerland) at baseline (t0), after one week (t1) and after twelve weeks (t12) 
of supplementation to analyse medium- and long-term effects of the FO supplementation on 
gene expression regulation. For short-term effects, venous blood samples were collected 
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four hours (t4h) after the first intake of the capsules. The whole blood samples were collected 
and incubated for 24 hours in the PAXgene Blood RNA Tubes at room temperature. Whole 
blood samples were used for RNA isolation and examination of gene expression, because 
cell fractioning steps such as lymphocyte isolation could alter the gene expression pattern 
(Vartanian et al. 2009). 
3.2.4.2 Total RNA isolation from human whole blood, RNA purification and 
sample pooling 
The total RNA was isolated with the PAXgene Blood RNA Kit (PreAnalytiX, Hombrechtikon, 
Switzerland), according to the manufacturer’s recommended procedures. The RNA yield was 
quantified by Nanodrop ND-1000 spectrophotometer (peQLab Biotechnologie GmbH, 
Erlangen, Germany) measurement. The total RNA was purified with the Globin Clear Kit 
(Ambion, Applied Biosystems, Darmstadt, Germany), according to the manufacturer’s 
instructions. The reduction of highly abundant globin mRNA transcripts in whole blood 
samples is necessary to enable the detection of low-abundance transcripts (Debey et al. 
2006). The purified RNA was quantified again, and the quality was measured with an Agilent 
2100 Bioanalyzer using RNA 6000 Nano Chips and a RNA 6000 Nano Kit (Agilent 
Technologies, Böblingen, Germany).  
Equal amounts of purified RNA samples from each member of the respective group were 
pooled together. This was done for all different time points (t0, t4h, t1, and t12). Therefore, four 
pool samples were generated by this process for each group. The approach of sample 
pooling was chosen to reduce biological inter-individual variability, which is frequent due to 
variations in the relative proportions of specific blood cell subsets, gender, age, and disease 
state (Whitney et al. 2003). 
3.2.4.3 Microarray analysis (cDNA synthesis, hybridisation and data 
analysis) 
First-strand cDNA synthesis and TSA was performed using the Micromax TSA Labelling and 
Detection Kit (Perkin Elmer Life Sciences, Rodgau, Germany) with several protocol 
modifications. A total amount of 6 µg from every RNA pool, as well as random hexamer 
primer (Fermentas, St. Leon-Rot, Germany) and oligo(dT) primer (Roth, Karlsruhe, 
Germany), were used for the cDNA synthesis, which was facilitated by using Superskript III 
reverse transcriptase (Invitrogen, Karlsruhe, Germany). The incubation time of two hours 
was split into two one-hour incubations and additional Superskript III was added after the first 
hour. Each RNA pool was synthesized into two differently labelled cDNAs, fluorescein-
labelled and biotin-labelled cDNA.  
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After labelling, the cDNA samples were purified with the QIAquick PCR Purification Kit 
(Qiagen, Hilden, Germany), according to the manufacturer’s instructions. Furthermore, the 
cDNA samples were first vacuum-dried and then resolved in hybridization buffer (4 x SSPE; 
2.5 x Denhardt’s reagent; 30% formamid). After a final degradation step (3 minutes, 95°C), 
one-tenth of top-block (Sigma-Aldrich, Steinheim, Germany) was added. Equal amounts of 
biotin-labelled and fluorescein-labelled cDNA were hybridized simultaneously in one 
experiment to human whole genome OneArray™ Microarrays (Phalanx Biotech Group; 
Belmont, CA, USA). Hybridizations were carried out overnight at 42°C in hybridization 
chambers (Eppendorf AG, Hamburg, Germany). After hybridization, unbound and non-
specific fixed cDNA was removed by stringent washing from the array. Specifically bound 
fluorescein- and biotin-labelled cDNA were sequentially detected with a series of conjugate 
reporter molecules according to the TSA process, ultimately with tyramide-Cy3 and tyramide-
Cy5. Microarray experiments were performed for each study group in a loop design to 
prevent dye-dependent variety effects (Kerr and Churchill 2001).  
The array data were submitted to GEO (Barrett et al. 2011), which supports MIAME (Brazma 
et al. 2001). The accession number of the submitted dataset is GSE34898. Genes that were 
detected as differentially expressed between baseline and time point t4h, t1 or t12 were 
subjected to pathway analysis using the KEGG database and GenMAPP (Dahlquist et al. 
2002).  
3.2.4.4 Quantitative real-time polymerase chain reaction and data analysis 
In order to quantify the expression levels of selected genes, equal amounts of cDNA were 
synthesized using 2 µg of purified RNA and M-MLV reverse transcriptase (Promega, 
Mannheim, Germany), as well as random hexamer (Fermentas, St. Leon-Rot, Germany) and 
oligo(dT) primers (Carl Roth; Karlsruhe, Germany). Synthesized cDNA was diluted 1:20 with 
nuclease-free water and used for the qRT-PCR together with iQ SYBR Green Supermix (Bio-
Rad Laboratories, Hercules, Ca, USA) and 5 pmol of both forward and reverse primers. The 
sequences for target and reference genes were retrieved from GenBank and applied primers 
were manually designed with the Primer-Basic Local Alignment Search Tool (BLAST) of the 
National Centre for Biotechnology Information, which is based on the program Primer3 
(Rozen and Skaletsky 2000). The primer sequences used are listed in Table 3.1. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and ribosomal protein S2 (RPS2) 
were identified as the most stable reference genes by the freely available algorithm geNorm 
version 3.5. 
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Table 3.1: Sequences of primer pairs of catalase (CAT), heme oxygenase 2 (HMOX2), 
cytochrome P450 enzyme 1A2 (CYP1A2), glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) and ribosomal protein S2 (RPS2) for quantitative real-time polymerase chain 
reaction 
  
Gene symbol RefSeq_ID Sequences (5´-> 3´) 
forward CTGACACTCACCGCCATCGCC CAT NM_001752.2 
reverse TGTCCTGCATGCACATCGGGC 
forward GCAGCAAGAACCACACCCAGCA 
HMOX2 
NM_001127204.1 
NM_001127205.1 
NM_001127206.1 
NM_002134.3 reverse TGGGTGTTTTCTGCCCGGTCG 
forward AGCGCCGGTGTATCGGGGAAG 
Target 
genes 
CYP1A2 NM_000761.3 
reverse TCAGTTGATGGAGAAGCGCAGCCG 
forward AAGGTGGTGAAGCAGGCGTCG GAPDH NM_002046.3 
reverse AATGCCAGCCCCAGCGTCAAAG 
forward GCAACTTCGCCAAGGCCACCTT 
Reference 
genes RPS2 NM_002952.3 
reverse TGGGTCTTGACGAGGTGGTCAGT 
3.2.5 Statistics 
Statistical analysis of blood lipids and RBC membrane FAs were processed with SPSS 
software version 17 (SPSS Inc., Chicago, IL, USA). The results are based on per protocol 
population, defined as subjects completing all visits not infringing the study protocol, and are 
presented as mean ± SD. Differences between baseline blood lipid values of both groups 
were tested by t-test. Differences of FAs in RBC membranes between t0 and t12 were tested 
within groups by t-test for dependent samples. Statistical significance was accepted 
generally at p < 0.05. 
For statistical analysis of the microarray data, arrays were scanned with a 4000 B scanner 
(Axon Instruments, Union City, CA, USA) and images were quantified using GenePixPro 6.0 
software. The average pixel intensity within each spot was determined and a local 
background was computed for each spot. The net signal was determined by subtracting local 
background from the average intensity. Signals not consistently detectable (background 
corrected signal lower than two times background standard deviation) were excluded from 
further analysis. Following the primary analysis, data from different scans had to be 
summarized. The scans first had to be normalized by the sum of all corresponding spot-
intensities due to different laser power and photomultiplier-tube settings. Afterwards, data 
from different scans for each individual spot could be averaged by the mean. The mean of 
the data for differently labelled targets for each gene on two microarrays was taken. It was 
assumed that the distribution of the preprocessed data was normal, and hence, a standard 
two-state pooled-variance t-test (1% and 5% probability of error) was applied in order to 
detect differentially expressed genes. 
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Statistical analysis of expression ratios of genes, which were quantified by qRT-PCR were 
calculated with the Gene Expression Macro tool (Bio-Rad), which is based on the algorithm 
of geNorm (Vandesompele et al. 2002). First, normalization factors were calculated from the 
geometric mean of the reference genes GAPDH and RPS2. Furthermore, the baseline 
values of the normolipidemic group were defined as control values so that relative expression 
values could be calculated. Therefore, the baseline samples of the normolipidemic group are 
given a value of 1. By the reason that the Gene Expression Macro tool offers no statistics, 
differences between baseline and endpoint (t12) Ct values were tested by a paired t-test using 
the statistical package R version 2.15.0. 
3.3 Results 
3.3.1 Subject characteristics 
All 20 subjects (ten normolipidemic and ten dyslipidemic men) completed the study. No 
significant differences of the mean age and mean weight were observed between both study 
groups at baseline. The dyslipidemic subjects presented a 4.47 kg/m² higher BMI, higher TC 
and TG level as well as a higher LDL-C/HDL-C quotient than the normolipidemic subjects 
(Table 3.2). Subjects of the dyslipidemic group can be chracterised as pre-obese (BMI25-
30), which is, among others, an underlying cause for dyslipidemia. The BMI was not changed 
by dietary intervention in either study groups (data not shown). 
Table 3.2: Subjects characteristics of normo- and dyslipidemic men at baseline (t0).  
Parameters Normolipidemic (n=9) Dyslipidemic (n=7) 
Age [years] 36.56 ± 8.00 41.43 ± 6.63 
Height [cm] 180.61 ± 6.56 180.28 ± 8.62 
Weight [kg] 77.41 ± 15.44 91.84 ± 12.83 
Body mass index (kg/m²] 23.66 ± 3.97 a 28.13 ± 1.99 a 
Total cholesterol [mg/dl] 183.33 ± 13.88 a 272.86 ± 67.1 a 
Triacylglycerol [mg/dl] 82.22 ± 37.42 a 362.00 ± 284.62 a 
High density lipoprotein [mg/dl] 58.67 ± 10.92 45.86 ± 6.15 
Low density lipoprotein cholesterol [mg/dl] 108.33 ± 13.54 146.60 ± 6.43 
LDL-C/HDL-C quotient 1.90 ± 0.37 a 3.10 ± 0.47 a 
a
 t0 values of normolipidemic subjects vs. t0 values of dyslipidemic subjects were tested by 
student’s t-test; p < 0.05  
3.3.2 Fatty acid composition of red blood cell membranes and omega-3 index 
No significant differences of EPA or DHA levels in RBC membranes or in the omega-3 index 
were observed between the study groups at baseline (Table 3.3). However, dyslipidemic 
subjects presented lower AA levels in RBC membranes than normolipidemic subjects at 
baseline. The percentage of EPA and DHA, and the omega-3 index in RBC membranes 
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significantly increased within both study groups after twelve weeks of supplementation. 
Additionally, the normolipidemic group showed a significant decrease of the percentage of 
AA in RBC membranes. 
Table 3.3: Red blood cell membrane fatty acid composition of normo- and dyslipidemic men 
at baseline (t0) and after supplementation with fish oil over twelve weeks (t12). 
Normolipidemic (n = 9) Dyslipidemic (n = 7) 
Fatty acid [%]* t0 t12 t0 t12 
C20:4n-6 (AA) 16.04 ± 0.80 a 13.09 ± 0.63 # 12.71 ± 2.52 a 11.56 ± 1.58 
C20:5n-3 (EPA) 0.85 ± 0.20 3.85 ± 0.64 # 1.02 ± 0.43 3.46 ± 0.68 # 
C22:6n-3 (DHA) 4.47 ± 0.67 6.92 ± 0.81 # 3.85 ± 1.45 6.46 ± 0.77 # 
SFA 36.42 ± 1.46 39.24 ± 1.25 # 36.74 ± 1.78 39.24 ± 1.74  
MUFA 17.98 ± 1.64 a 17.20 ± 1.02 b 22.15 ± 3.44 a 19.03 ± 1.18 b# 
PUFA 44.59 ± 2.37 a 42.98 ± 1.16 # 40.13 ± 2.90 a 41.11 ± 1.71 
n-3 PUFA 7.90 ± 0.94 14.71 ± 1.45 # 7.33 ± 2.04 13.53 ± 1.49 # 
n-6 PUFA 36.68 ± 2.09 a 28.27 ± 1.39 # 32.80 ± 2.04 a 27.58 ± 1.86 # 
Omega-3 index 5.32 ± 0.74 10.77 ± 1.10 # 4.87 ± 1.83 9.92 ± 1.34 # 
*  percentage of total fatty acids 
a
 t0 values of normolipidemic subjects vs. t0 values of dyslipidemic subjects were  tested by 
student’s t-test; p < 0.05 
b
 t12 values of normolipidemic subjects vs. t12 values of dyslipidemic subjects were tested by 
student’s t-test; p < 0.05 
#
 t0 values vs. t12 values were tested by student’s t-test for dependent samples; p < 0.05 
 
3.3.3 Regulation of gene expression by n-3 PUFA supplementation 
It was necessary to exclude the RNA samples of one normo- and three dyslipidemic subjects 
from the microarray experiments and following data analysis due to several reasons: Low 
RNA yield (three subjects) and consumption of medication that led to exclusion (one subject). 
Therefore, RNA pools were generated and data was analysed from nine normolipidemic and 
seven dyslipidemic subjects for each investigation time point. 
Microarray experiments showed that several genes related to different oxidative processes 
were regulated. These genes are listed with the respective regulation ratio for each time 
point in Table 3.4. Several enzymes of the glutathione metabolism are regulated after FO 
supplementation, particularly in dyslipidemic subjects. While genes related to the glutathione 
synthesis were similarly up- and down-regulated during the first two time points (t4h and t1), 
these genes were mainly up-regulated after twelve weeks of FO supplementation. Two 
different glutathione transferases (GST) and glutathione reductase (GR) were up-regulated, 
whereas glutathione peroxidases were down-regulated in both normo- and dyslipidemic 
subjects. MMPs were down-regulated in both normolipidemic (MMP25) and dyslipidemic 
subjects (MMP2, MMP3) after twelve weeks of supplementation. Furthermore, CYP enzymes 
were mainly down-regulated after twelve weeks of supplementation, especially in 
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dyslipidemic subjects. Additionally, some antioxidative enzymes, such SOD3, CAT and 
HMOX2, were up-regulated after twelve weeks of supplementation in dyslipidemic subjects. 
Moreover, pathway analysis discovered several regulated genes within stress-activated 
signalling pathways such as MAPK signalling pathway, NFκB pathway and oxidative stress 
pathway (see appendix 7.1).  
Several genes were selected for analyses of gene expression ratios by qRT-PCR, including 
the two antioxidative enzymes, CAT and HMOX2, and CYP1A2 (Figure 3.1), a member of 
the CYP family known to be involved in epoxidation of EPA and DHA (Fer et al. 2008). The 
expression of HMOX2 was significantly up-regulated after FO supplementation over a period 
of twelve weeks in both normo- and dyslipidemic subjects (p = 0.02 and p = 0.04). The 
expression of CAT was also up-regulated, but reached significance only in normolipidemic 
subjects (p = 0.002). The expression of CYP1A2 was significantly up-regulated only in 
dyslipidemic subjects (p = 0.04). The qRT-PCR results mainly confirm the microarray results 
observed, whereupon differences in the strength of expression occur. 
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    Table 3.4: Ratios of differentially expressed genes related to oxidative processes  
Dyslipidemic Normolipidemic Regulated genes Gene symbol Entrez_ID RefSeq_ID Ratio t4h : t0 Ratio t1 : t0 Ratio t12 : t0 Ratio t4h : t0 Ratio t1 : t0 Ratio t12 : t0 
Gluthatione metabolism 
Glutathione peroxidase 1 GPX1 2876 NM_000581.2 NM_201397.1 - - - - - -2.48 
3
 
Glutathione S-transferase Mu 3 GSTM3 2947 NM_000849.4 -2.30 1 4.12 2 2.47 2 - - - 
Glutathione synthetase GSS 2937 NM_000178.2 -7.97 1 - - - - - 
Phospholipid hydroperoxide glutathione 
peroxidase, mitochondrial GPX4 2879 
NM_001039848.1 
NM_001039847.1 
NM_002085.3 
- -3.74 1 - - - - 
Glutathione S-transferase P GSTP1 2950 NM_000852.3 - -2.00 2 - - - - 
Gamma-glutamyltransferase 5 GGTLA1 2687 
NM_001099782.1 
NM_001099781.1 
NM_004121.2 
3.44 1 14.90 1 7.98 1 - - - 
Glutathione peroxidase 3 (plasma) GPX3 2878 NM_002084.3 - - -2.15 1 - - - 
Glutathione reductase GSR 2936 NM_000637.2 - - 2.38 3 - - - 
Matrix metalloproteinases 
Matrix metalloproteinase-25 MMP25 64386 NM_022468.4 - - - 2.14 2 - -2.30 1 
Metalloproteinase inhibitor 2 TIMP2 7077 NM_003255.4 - -4.18 1 -2.29 1 - - - 
stromelysin-1 MMP3 4314 NM_002422.3 - - -2.17 1 - - - 
72 kDa type IV collagenase MMP2 4313 NM_001127891.1 NM_004530.4 - -3.91 
1
 -6.16 1 - - - 
Cytochrom P450 enzymes 
Cytochrome P450 1A2 CYP1A2 1544 NM_000761.3 - - - - - -7.74 2 
Cytochrome P450 2A7 CYP2A7 1548 NM_000762.5 - -2.46 1 -  2.42 1 2.70 1 
Cytochrome P450 4X1 CYP4X1 260293 NM_178033.1 - -5.66 1 -11.35 1 - - - 
Cytochrome P450 26A1 CYP26A1 1592 NM_057157.2 NM_000783.3 2.87 
1
 - - - - - 
Cytochrome P450 2B6 CYP2B6 1555 NM_000767.4 2.60 1 - - - - - 
Cytochrome P450 4F12 CYP4F12 66002 NM_023944.3 2.46 1 - - - - - 
Cholesterol side-chain cleavage enzyme, 
mitochondrial CYP11A1 1583 
NM_001099773.1 
NM_000781.2 -2.30 
1
 -2.78 1 -2.79 1 - - - 
Cytochrome P450 26B1 CYP26B1 56603 NM_019885.2 -3.11 1 - - - - - 
Cytochrome P450 2C19 CYP2C19 1557 NM_000769.1 -7.48 1 - - - - - 
Steroid 17-alpha-hydroxylase/17,20 lyase CYP17A1 1586 NM_000102.3 -7.96 1 - -4.19 1 - - - 
Cytochrome P450 2J2 CYP2J2 1573 NM_000775.2 - 3.54 1 - - - - 
Cytochrome P450 27C1 CYP27C1 339761 NM_001001665.3 - -4.46 1 -3.41 1 - - - 
Cytochrome P450 2A13 CYP2A13 1553 NM_000766.3 - -4.49 1 -8.90 1 - - - 
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Dyslipidemic Normolipidemic Regulated genes Gene symbol Entrez_ID RefSeq_ID Ratio t4h : t0 Ratio t1 : t0 Ratio t12 : t0 Ratio t4h : t0 Ratio t1 : t0 Ratio t12 : t0 
Cytochrom P450 enzymes (continued) 
Cytochrome P450 2J2 CYP2J2 1573 NM_000775.2 - 3.54 1 - - - - 
Cytochrome P450 27C1 CYP27C1 339761 NM_001001665.3 - -4.46 1 -3.41 1 - - - 
Cytochrome P450 2A13 CYP2A13 1553 NM_000766.3 - -4.49 1 -8.90 1 - - - 
Others 
Extracellular superoxide dismutase [Cu-Zn] SOD3 6649 NM_003102.2 - - 4.70 3 - - 2.91 3 
Catalase CAT 847 NM_001752.2 - 13.15 1 8.90 1 - - - 
Heme oxygenase 1 HMOX1 3162 NM_002133.1 - -8.57 1 -17.52 1 - - - 
Heme oxygenase 2 HMOX2 3163 
NM_001127204.1 
NM_001127205.1 
NM_001127206.1 
NM_002134.3 
- 11.44 1 7.84 1 - - - 
Epoxide hydrolase 1 EPHX1 2052 NM_000120.3 NM_001136018.2 - - 3.14 
2
 -2.24 2 - 2.22 2 
Arachidonate 5-lipoxygenase-activating 
protein ALOX5AP 241 NM_001629.2 - - 6.97 
1
 - - - 
Nitric oxide synthase, endothelial NOS3 4846 NM_000603.4 - -4.22 1 -2.55 1 - - - 
Nitric oxide synthase, inducible  NOS2 4843 NM_000625.4 - -8.11 1 -4.77 1 - - - 
Nitric oxide synthase-interacting protein NOSIP 51070 NM_015953.3 - - - - - 3.64 1 
NADPH oxidase 1 NOX1 27035 NM_013955.2 NM_007052.4 - - 2.06 
1
 - - - 
 Expression ratios were displayed for genes which were differentially expressed after four hours (t4h), one week (t1) and twelve weeks (t12) of fish oil    
 supplementation in normolipidemic and dyslipidemic men.  
 - no regulation 
 1
 slightly significant regulation; p = 0.05 
 2
 significant regulation regulation; p < 0.05 
 3
 highly significant regulation; p < 0.01 
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Figure 3.1: Transcript levels of catalase (CAT), heme oxygenase 2 (HMOX2) and 
dytochrome P450 enzyme 1A2 (CYP1A2) in normo- and dyslipidemic men. Transcript levels 
of CAT, HMOX2 and CYP1A2 were determined by qRT-PCR in normo- and dyslipidemic 
men before (t0) and after twelve weeks (t12) of fish oil supplementation. Pooled group 
samples were used in triplicates. Triplicates were averaged and corrected by two reference 
genes, GAPDH and RPS2. Corrected expressions were compared with baseline gene 
expression of normolipidemic and relative expression changes are displayed. Differences 
between baseline and endpoint (t12) Ct values were tested by a paired t-test and differences 
between groups at each time point were tested by unpaired t-test.  
* p < 0.05 
3.4 Discussion 
To the best of our knowledge, this is the first intervention study disclosing gene expression 
changes in normo- and dyslipidemic subjects after FO supplementation. We identified 
several genes involved in oxidative processes, which were regulated by FO. The expression 
of antioxidative enzymes was up-regulated particularly in dyslipidemic subjects, while the 
expression of pro-oxidative or tissue damage-related enzymes was down-regulated. We 
suggest that n-3 PUFAs may have an antioxidative potential. 
Antioxidative effects could be facilitated by either a reduced production of ROS or an 
increased production of antioxidative enzymes. Several human studies and in vitro 
experiments showed reduced superoxide or ROS production by monocytes and neutrophils 
after n-3 PUFA administration (Hill et al. 2007; Luostarinen and Saldeen 1996; Zhang et al. 
2002). Additionally, negative correlations between ROS production and n-3 PUFA membrane 
content in healthy (Hill et al. 2007) and dyslipidemic subjects (Luostarinen and Saldeen 
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1996) were observed. On the other hand, positive correlations between the n-3 PUFA 
membrane content and the activity of antioxidative enzymes could be investigated in 
fibroblasts cell cultures (Benito et al. 1997) and in type 2 diabetes patients (Smaoui et al. 
2006). In the present study, the supplementation of normo- and dyslipidemic subjects with 
FO resulted in decreasing AA levels in RBC membranes in favour of EPA and DHA, whose 
levels increased considerably. Accordingly, the increase of EPA and DHA levels observed in 
RBC membranes together with an increased expression ratio of the antioxidative enzymes 
CAT and HMOX2 are in agreement with the findings of Benito (Benito et al. 1997) and 
Smaoui (Smaoui et al. 2006). Moreover, the replacement of AA, which is an important ROS 
producer, in biological membranes may partly explain the antioxidative properties of n-3 
PUFAs. On the other hand, the incorporation of EPA and DHA in RBC membranes in 
response to long-term administration results in increased induced lipid peroxidation (Palozza 
et al. 1996). In this context, an activation of antioxidative gene expression in response to n-3 
PUFA supplementation might be a reaction of the defence system to lower lipid peroxidation. 
Complementary analysis such oxidative damage assay or the determination of oxidative 
stress markers combined with expression changes of anti- and pro-oxidant genes should be 
used to indentify global antioxidative effects.  
Nevertheless, an increased expression of HMOX2 and CAT in normo- and dyslipidemic 
subjects may indicate some antioxidative effects of n-3 PUFAs. To our knowledge, this is the 
first study at all showing a regulation of HMOX2 expression after n-3 PUFA supplementation 
in humans. HMOXs are antioxidative enzymes which catabolise heme to biliverdin and 
carbon monoxide. The two existing HMOXs 1 and 2 differ in their activity. HMOX2 is 
constitutively expressed, whereas HMOX1 is inducible, i.e. by cellular stress (Abraham and 
Kappas 2008). HMOX2 was identified as part of the large-conductance calcium and voltage-
activated potassium (BK(Ca)) channel complex and could enhance its activity, while 
knockdown of HMOX2 expression reduced channel activity (Williams et al. 2004). BK(Ca) 
channels could influence the cell membrane potential and, therefore, play an important role 
in many physiological functions, including oxygen-sensing, neuronal excitability, vascular 
tone regulation, and neurotransmitter release (Hou et al. 2009; Salkoff et al. 2006). However, 
a possible clinical relevance of an increased HMOX2 expression after FO supplementation 
has to be clarified in further studies.  
CAT is an effective antioxidative enzyme (Goyal and Basak 2010) known to compensate 
hydrogenperoxide (H2O2) (Gaetani et al. 1996; Mueller et al. 1997), i.e. in the centre of 
inflammation (Agar et al. 1986; Halliwell and Gutteridge 1984). In this study, expression 
ratios of the microarray experiments showed an increased expression of CAT in dyslipidemic 
subjects, whereas qRT-PCR showed an increased expression in both study groups, reaching 
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statistical significance only in normolipidemic subjects. These differences are also known 
from several other gene expression studies and are mainly explained by the greater 
sensitivity of the qRT-PCR (Rajeevan et al. 2001; Toft et al. 2008). The increased expression 
of CAT in normolipidemic subjects is in contrast to studies with healthy volunteers, which 
mostly showed no effects on CAT activity after FO supplementation (Jenkinson et al. 1999; 
Poprzecki et al. 2009). Results from animal studies, however, indicated an increased CAT 
activity after treatment with n-3 PUFA (Iraz et al. 2005; Venkatraman et al. 1998). Human 
studies analysing the effects of n-3 PUFAs on the activity or expression of CAT in 
dyslipidemic subjects are very limited. In accordance with our results, Bouzidi and coworkers 
(Bouzidi et al. 2010) reported an increased CAT activity in patients with dyslipidemia and 
chronic renal failure after n-3 PUFA supplementation, assuming a greater protection against 
oxidative stress and prevention of vascular complications. Similarly, an animal study with 
hypercholesterolemic rats also observed increased CAT activity after DHA feeding. Taken 
together, these findings suggest that long-term supplementation with n-3 PUFAs results in an 
enhanced capacity to detoxify H2O2 and might induce adaptive changes in the antioxidative 
defence system (Hossain et al. 1999).  
Glutathione is an important antioxidant which could be readily oxidized non-enzymatically to 
glutathione disulfide (Wu et al. 2004). Most studies analysing the effects of n-3 PUFA 
supplementation on the activity of glutathione metabolism related enzymes, such as GPX, 
gamma-glutamylcysteine synthetase (gamma-GCL), GST, and GR, in healthy and 
dyslipidemic subjects showed increased activities of these enzymes (Arab et al. 2006; 
Bellisola et al. 1992; Olivieri et al. 1988). In our study, the expression of GST and GR was 
increased in dyslipidemic subjects, while the expression of GPX was decreased in both 
normo- and dyslipidemic subjects. The increased expression of GST and GR is an indication 
of an increased glutathione synthesis and, therefore, an increased antioxidative defence 
status. GPX is recognized as an antioxidative enzyme which oxidizes glutathione to reduce 
and detoxify H2O2. Consequently, this enzyme is required when H2O2 levels rise in phases of 
oxidative stress (Felice et al. 2010; Matsunami et al. 2009). Therefore, a decreased 
expression of GPX – observed in this study – could be an indicator of decreased oxidative 
stress. However, the results in the literature are inconsistent. Mabile and co-workers could 
not observe a change in the GPX activity in healthy and hypertriglyceridemic subjects 
(Mabile et al. 2001), while other studies reported a stimulated GPX activity after n-3 PUFA 
supplementation in healthy (Bellisola et al.1992) and hyperlipidemic subjects (Olivieri et al. 
1988). Furthermore, it was shown that DHA increased the activity of GST, gammaGCL and 
GR, as well as the mRNA expression of gamma-GCL and GR (Arab et al. 2006), in human 
fibroblasts, which is in agreement with our results.  
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CYP enzymes catalyze the oxidation of xenobiotic substances, such as pharmaceuticals, but 
also metabolize many endogenous substances, such as lipids and steroidal hormones. 
Besides COX and LOX, CYPs are also involved in the metabolism of PUFAs to form 
numerous different oxidized FA metabolites, also named oxylipines. The CYP isoforms of 
families 1 to 3 are mainly epoxygenases, and CYP isoforms from family 4 are mainly ω-
hydroxylases (Lucas et al. 2010). In this study, several CYPs, mostly isoforms of family 2, 
were regulated after FO supplementation. The oxidation of EPA and DHA by epoxygenases 
could produce epoxy-derivates (Fer et al. 2006) and highly anti-inflammatory resolvins and 
protectins (Stables and Gilroy 2011). Generated EPA and DHA epoxides are effective 
dilators of coronary arterioles, facilitated by the activation of calcium-activated potassium 
channels (Lauterbach et al. 2002; Ye et al. 2002). The qRT-PCR showed that CYP1A2, 
which is one of the most efficient CYPs for the epoxidation of EPA and DHA in human liver 
microsomes (Fer et al. 2008), was up-regulated in dyslipidemic subjects after FO 
supplementation, suggesting the formation of specific EPA and DHA epoxides. Expression 
ratios of the microarray experiments showed decreased expression of CYP1A2 in 
normolipidemic subjects, which was, however, not confirmed by qRT-PCR. According to 
qRT-PCR experiments, the expression of CYP1A2 in normolipidemic subjects was not 
affected by FO treatment. Both results are in contrast to microarray experiments, where 
CYP1A2 was unregulated in dyslipidemic subjects and down-regulated in normolipidemic 
subjects. In view of the higher accurancy of qRT-PCR, it is suggested that the microarray 
results fpr CYP1A2 was false positive for normolipidemic subjects, while the microarray 
technique was insensitive to analyse the up-regulation of CYP1A2 in dyslipidemic subjects, 
which was generally much weaker. Interestingly, human liver microsomes, which were 
incubated with EPA and DHA (200 µM) showed a decreased CYP1A2 activity (Yao et al. 
2006). Although the results are contradictory, it has been repeatedly shown that n-3 PUFAs 
could induce the expression or activity of CYP enzymes, resulting in the formation of EPA 
and DHA metabolites (Arnold et al. 2010; Fer et al. 2006, 2008; Lucas et al. 2010; Yao et al. 
2006). The complex formation of n-3 PUFA metabolites by CYPs has not been investigated 
systematically so far; however, it is likely that the formation of these metabolites may explain 
numerous of the anti-inflammatory and cardioprotective effects of n-3 PUFAs (Calder 2009).  
MMPs are zinc-based proteases and could cleave macromolecules of the extracellular 
matrix, i.e. collagens, as well as non-ECM molecules, such as growth factors, cytokines and 
their receptors (Shiomi et al. 2010). ROS could induce the activity of MMPs (Lim et al. 2010), 
which could result in tissue remodelling processes (Clee 2010) and promote the 
pathogenesis of several CVDs (Spinale et al. 2000; Tyagi et al. 1996). In this study, MMP2 
and MMP3 in dyslipidemic subjects and MMP25 in normolipidemic subjects were down-
regulated after FO supplementation. In accordance with our results, several other authors 
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have shown decreased MMP2 and/or MMP9 expression or activity by n-3 PUFA in 
dyslipidemic subjects (Derosa et al. 2009) and human cell cultures (Delbosc et al. 2008; Kim 
et al. 2008b). However, no changes in MMP9 activity were detected after FO 
supplementation in patients with CHD (Furenes et al. 2008). Similarly, another study 
observed a slight increase of the MMP2 activity in hypertriglyceridemic men after FO 
supplementation (Kelley et al. 2009). Further studies are needed to clarify these 
discrepancies and the function of n-3 PUFAs in the regulation of MMPs with regard to 
potential cardioprotective effects.  
3.4.1 Strengths and Limitations 
The methodological approach of this study was carefully elaborated. The use of whole blood 
for RNA isolation is advantageous in view of the easy sample collection and the prevention of 
altered gene expression patterns which emerge during cell fractionation steps (Vartanian et 
al. 2009). In addition, the pooling of RNA samples reduces inter-individual variation, enabling 
one to focus on the characteristics of a population in contrast to an individual level 
(Kendziorski et al. 2005). However, the approach of sample pooling also provide several 
limitations, primarily the reduction of statistical power. Finally, oxidative damage and 
oxidative stress markers were not analysed in this study, which complicates the evaluation of 
the antioxidative effects.  
3.4.2 Conclusions 
In conclusion, this study showed indications of the antioxidative potential of n-3 PUFAs, 
especially in dyslipidemic subjects. FO supplementation resulted in an increased expression 
of glutathione synthesis-related genes, an up-regulation of antioxidative enzymes, such as 
CAT and HMOX2, and a reduced expression of MMPs and several CYPs. Interestingly, 
CYP1A2 was up-regulated in dyslipidemic subjects, suggesting an increased formation of n-3 
epoxides. Taken together, these results indicate that n-3 PUFAs may have numerous 
different possibilities to reduce oxidative stress. It appears that n-3 PUFAs not only up-
regulates antioxidative enzymes, but rather induces a specific interplay of differential 
regulations to generate an optimal balance of the oxidative status. Although the molecular 
mechanisms by which n-3 PUFAs mediate potential antioxidative effects could not clarified 
here, we hypothesise an involvement of PPARs. In vitro studies with human hepatocytes and 
pancreatic ß-cells have demonstrated an activation of PPARα or -γ by n-3 PUFAs, which 
resulted in an increased expression of CAT, as well as antioxidative effects (Chung et al. 
2011; Li et al. 2012). Beside CAT, HMOX-1 has also been demonstrated as a target gene of 
PPAR (Krönke et al. 2007). Moreover, an increased expression of antioxidative genes could 
result in reduced oxidative stress, which further influences stress-activated pathways (MAPK 
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and NFκB pathway) as well as other stress-related genes such as MMPs. However, studies 
analysing the expression of antioxidative enzymes, oxidative signalling processes and 
metabolic outcomes are needed to clarify the exact role of n-3 PUFAs within the antioxidative 
defence system. 
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4. Lipid-related gene expression in normo- and dyslipidemic men after fish 
oil supplementation 
4.1 Introduction 
FO and its principal n-3 PUFAs, EPA and DHA have shown beneficial effects on the lipid 
profile in numerous interventional studies (Harris 1996, 1997; Musa-Veloso et al. 2010). 
Primarily, n-3 PUFAs lower TG levels, especially in subjects with HTG (Balk et al. 2006; 
Skulas-Ray et al. 2008; Tremoli et al. 1994). The TG-lowering effect of n-3 PUFAs is more 
pronounced at higher baseline TG levels (Musa-Veloso et al. 2010) and appears to be dose-
dependent (Harris 1996; Musa-Veloso et al. 2010). The recommended daily intake of n-3 
PUFAs for TG lowering in hypertriglyceridemic subjects ranges from 2 to 5 g/d; amounts 
which could only be reached by supplementation (Kris-Etherton et al. 2002; Park and Harris 
2003). However, moderate n-3 PUFA doses (1.68 mg/d) are similarly efficient at reducing 
elevated TG levels in subjects with mild HTG (Schuchardt et al. 2011).  
Numerous mechanisms have been proposed as contributors to the TG-lowering effect of n-3 
PUFAs, for example, by reducing very VLDL-TG synthesis and secretion from the liver, or by 
enhancing the TG clearance of circulating VLDL and chylomicron particles (Shearer et al. 
2012). Beyond TG lowering, n-3 PUFAs additionally affect the HDL-C metabolism by 
elevating the cholesterol-rich HDL2 subtype and reducing the TG-rich HDL3 subtype (Mori et 
al. 1999, 2000). Beside these beneficial effects, studies have repeatedly shown that n-3 
PUFAs increase LDL-C levels, which may result from the conversion of VLDL to LDL-C (Lu 
et al. 1999).  
The molecular mechanisms by which n-3 PUFAs modify the lipid metabolism are not 
completely clarified. The regulation of gene expression is believed to be a key mechanism of 
how n-3 PUFAs mediate their functions. Specifically, n-3 PUFAs can modulate the activity of 
several transcription factors, such as SREBP1 (Caputo et al. 2011), HNF4α (López-Soldado 
et al. 2009), LXRs (Howell et al. 2009), RXR (Urquiza et al. 2000), FXR (Zhao et al. 2004), 
and PPARs (Oyekan 2011), resulting in an altered expression of corresponding target genes 
(Clarke et al. 2002; Davidson 2006; Jump et al. 1999; Price et al. 2000; Vanden Heuvel 
2009). Although it is known that these genes, or rather their products, play eminent roles in 
the regulation of the lipid metabolism, the influence of n-3 PUFAs on a number of additional 
lipid metabolism-related genes and involved pathways remain to be discovered. Unravelling 
these connections may contribute to the understanding of the molecular mechanisms 
explaining the physiological functions of n-3 PUFAs. 
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The approach of this interventional trial was to monitor gene expression changes in normo- 
and dyslipidemic male subjects after n-3 PUFA supplementation using whole blood samples. 
With a focus on lipid metabolism-related genes, we aimed to not only identify genes and 
associated pathways that confirm already known mechanisms, but also to point out 
alternative mechanisms of how n-3 PUFAs affect lipid metabolism.  
4.2 Material and methods 
This controlled, parallel group intervention study was conducted at the Institute of Food 
Science and Human Nutrition, Leibniz University of Hannover, Germany, and performed with 
respect to GCP Guidelines. The approval of the Freiburg Ethics Commission International 
was received. The clinical investigation was registered at ClinicalTrials.gov with the 
identification number NCT01089231.  
4.2.1 Subjects 
Normo- and dyslipidemic men were recruited by several advertisements and study placards 
in the area of Hannover. The suitability of volunteers was checked in telephone interviews 
and by an admission questionnaire on diet, lifestyle and diseases. Exclusion criteria were 
defined as: Smoking; BMI> 35 kg/m²; intake of any corticosteroids, lipid-lowering or anti-
inflammatory drugs; chronic cardiovascular or liver diseases; gastrointestinal disorders; blood 
coagulation disorders and intake of coagulation-inhibiting drugs; renal failure; periodic intake 
of laxatives; regular use of dietary supplements containing n-3 PUFAs, phytosterols, 
polyglucosamines, and other lipid-binding ingredients or daily eating of fatty fish; allergy to 
fish or FO; and participation in another clinical study < 30 days before the study start or at the 
same time. Selected subjects were invited to a screening examination where serum lipid 
levels were determined. Among these subjects, ten normolipidemic (TC < 200 mg/dl; LDL-
C < 130 mg/dl; TG < 150 mg/dl) and ten dyslipidemic (TC > 200 mg/dl; LDL-C > 130 mg/dl; 
TG > 150 mg/ml) men, aged between 29 and 51 years, were enrolled in the study population. 
Written informed consent was obtained from all participants. 
4.2.2 Study design 
Subjects ingested six FO capsules per day for a period of twelve weeks. The daily n-3 PUFA 
intake was 2.7 g (1.14 g DHA and 1.56 g EPA). The subjects were instructed to take three in 
the morning and three in the evening together with food. Usual exercise and dietary habits 
should be maintained throughout the intervention time. As an exception, all six capsules 
were ingested at the same time in the morning after a standardised breakfast on the first 
intervention day. Additionally, participants completed a questionnaire to obtain information 
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about changes in medication, diet (i.e. changes in weekly fish intake, preferred fish dishes or 
species, respectively) and lifestyle habits (i.e. physical activity), as well as the tolerability of 
the capsules. 
4.2.3 Determination of fasting serum lipids and statistics 
Fasting venous blood samples were collected into BD Vacutainer® Blood Collection Tubes 
(Becton Dickinson, Heidelberg, Germany) at baseline (t0) and after twelve weeks (t12) of 
supplementation. The plasma lipid levels were determined by specific enzymatic colour 
reactions from an external contract laboratory (LADR, Hannover, Germany). Statistical 
analysis was processed with SPSS software version 17.0 (SPSS Inc., Chicago, IL, USA). 
Statistical analyses were based on per protocol population, defined as subjects completing 
all visits not infringing the study protocol. The results are presented as mean ± SD (Table 
4.2). Differences between t0 and t12 were tested within groups by paired t-test and differences 
between groups were examined by t-test. P-values < 0.05 were interpreted as statistically 
significant. 
4.2.4 Gene expression analyses 
4.2.4.1 Sample collection 
Fasting venous blood samples were collected in PAXgene Blood RNA Tubes (PreAnalytiX, 
Hombrechtikon, Switzerland) at baseline (t0), after one week (t1) and after twelve weeks (t12) 
of supplementation to analyse the medium- and long-term effects of the FO supplementation 
on gene expression regulation. Venous blood samples were collected four hours (t4h) after 
the first intake of the capsules for the short-term effects. The whole blood samples collected 
were incubated for 24 hours in the PAXgene Blood RNA Tubes at room temperature. 
4.2.4.2 Total RNA isolation from human whole blood, RNA purification and 
sample pooling and microarray analysis (cDNA synthesis, 
hybridisation and data analysis) 
Detailed description of RNA isolation, RNA purification, sample pooling and microarray 
experiment procedures such cDNA synthesis, hybridisation and data analysis have been 
already published by Schmidt et al. (2012). 
4.2.4.3 Quantitative real-time polymerase chain reaction and data analysis 
In order to quantify the expression levels of selected genes, equal amounts of cDNA were 
synthesized using 2.0 µg of purified RNA and M-MLV reverse transcriptase (Promega, 
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Mannheim, Germany), as well as random hexamer (Fermentas, St. Leon-Rot, Germany) and 
oligo(dT) primers (Carl Roth, Karlsruhe, Germany). Synthesized cDNA was diluted 1:20 with 
nuclease-free water and used for the qRT-PCR together with iQ SYBR Green Supermix (Bio-
Rad Laboratories, Hercules, Ca, USA) and 5 pmol of both forward and reverse primers. The 
sequences for target and reference genes were retrieved from GenBank and the primers 
applied were manually designed with the Primer-BLAST of the National Centre for 
Biotechnology Information, which is based on the program Primer3 (Rozen and Skaletsky 
2000). The primer sequences used are listed in Table 4.1. GAPDH and RPS2 were identified 
as the most stable reference genes by the freely available algorithm geNorm version 3.5. 
The Gene Expression Macro tool (Bio-Rad), which is based on the algorithm of geNorm 
(Vandesompele et al. 2002), was used to calculate relative expression values. Normalization 
factors for this are calculated from the geometric mean of the reference genes GAPDH and 
RPS2. Furthermore, the baseline values of the normolipidemic group were defined as control 
values so that relative expression values could be calculated. Therefore, the baseline 
samples of the normolipidemic group are given a value of 1. Because the Gene Expression 
Macro tool offers no statistics, differences between baseline and endpoint (t12) Ct values 
were tested by a paired t-test, and differences between groups at each time point were 
tested by unpaired t-test using the statistical package R version 2.15.0 
Table 4.1: Sequences of primer pairs of apolipoproetin CII (Apo CII), low-density lipoprotein 
receptor (LDLR), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and ribosomal 
protein S2 (RPS2) for quantitative real-time polymerase chain reaction  
  
Gene 
symbol RefSeq_ID Sequences (5´-> 3´) 
forward GCTCCCCCTTCCCAGTAGCTCT Apo C II NM_000483.3 
reverse TTCACTGCTTTATTCCCATGGACCC 
forward GGGGCCCTGTGTAGGGGGTT 
Target 
genes LDLR NM_000527.3 
reverse AAAGTGACACCCATCTCCCAGAAGC 
forward AAGGTGGTGAAGCAGGCGTCG GAPDH NM_002046.3 
reverse AATGCCAGCCCCAGCGTCAAAG 
forward GCAACTTCGCCAAGGCCACCTT 
Reference 
genes RPS2 NM_002952.3 
reverse TGGGTCTTGACGAGGTGGTCAGT 
4.3 Results 
4.3.1 Subject characteristics 
All subjects completed the study. One normo- and three dyslipidemic subjects had to be 
excluded from the analyses because of low RNA yield (n = 3) and consumption of medication 
that led to exclusion (n = 1). Thus, data were available from nine normolipidemic and seven 
dyslipidemic subjects for each investigation time point. 
Chapter 4  Results 
60 
 Age and mean weight at baseline did not show any differences between either group. 
However, the dyslipidemic subjects had a significantly higher BMI than the normolipidemic 
subjects (28.13 kg/m² vs. 23.66 kg/m², respectively). Subjects of the dyslipidemic group can 
be characterised as pre-obese (BMI 25-30), which is, among others, an underlying cause for 
dyslipidemia. Nevertheless, the BMI was not changed by dietary intervention in either of the 
study groups. 
4.3.2 Changes of blood lipids 
According to the inclusion criteria, dyslipidemic subjects had significantly higher TC and TG 
levels as well as a higher LDL-C/HDL-C ratio at baseline (Table 4.2). After twelve weeks of 
supplementation with FO, the group differences in TC and TG levels and the LDL-C/HDL-C 
ratio remained unaffected and similar to differences observed at baseline. TG levels 
decreased both in normolipidemic (-19.2 mg/dl; -23.34%) and dyslipidemic subjects (-99.86 
mg/dl, -27.59%). The difference between both groups was not statistically significant. The 
LDL-C level increased significantly after FO supplementation in dyslipidemic subjects (29.6 
mg/dl; 20.19%), whereas the effect in normolipidemic subjects was marginal (4.0 mg/dl; 
3.69%). Furthermore, FO supplementation resulted in a significant increase in the HDL-C 
levels in dyslipidemic subjects (6.28 mg/dl; 13.69%), whereas the HDL-C increase in 
normolipidemic subjects (7.0 mg/dl; 11.93%) showed a tendency towards statistical 
significance.  
Table 4.2: Serum lipid levels of the normo- and dyslipidemic men at baseline (t0) and after 
supplementation with fish oil over twelve weeks (t12)  
Normolipidemic (n = 9) Dyslipidemic (n = 7) 
Parameters 
t0 t12 t0 t12 
TC [mg/dl] 183.33 ± 13.88 a 190.56 ± 21.88 b 272.86 ± 67.17 a 278.40 ± 45.21 b 
TG [mg/dl] 82.22 ± 37.42 a 63.00 ± 14.09 b 362.00 ± 284.62a 262.14 ± 153.52 b 
HDL-C [mg/dl] 58.67 ± 10.92 65.67 ± 15.23 c_T 45.86 ± 6.15 52.14 ± 9.84 c 
LDL-C [mg/dl] 108.33 ± 13.54 112.33 ± 16.88 b 146.60 ± 6.43 176.20 ± 20.56 b c 
LDL-C/HDL-C 
quotient 1.90 ± 0.37 
a
 1.80 ± 0.51 b 3.10 ± 0.47 a 3.28 ± 0.89 b 
a
 p < 0.05 (Changes of means at baseline were evaluated between normolipidemic and 
dyslipidemic subjects by Student’s t-test)  
b
 p < 0.05 (Changes of means after twelve weeks of supplementation were evaluated between 
normolipidemic and dyslipidemic subjects by Student’s t-test) 
c
 p < 0.05 (Changes between t0 and t12 were evaluated within groups by Student’s t-test for 
dependent samples) 
_T
 p < 0.1 (trend of significance) 
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4.3.3 Gene expression changes of lipid-related genes after n-3 PUFA 
supplementation  
Microarray experiments revealed a transcriptional regulation of several transcription factors 
after FO supplementation, including PPAR alpha (PPARα), RXR alpha (RXRα), RXR gamma 
(RXRγ), HNF6, and HNF1ß (Table 4.3). While some transcription factors were similarly 
regulated in normolipidemic men, the expression was distinctly more strongly regulated in 
dyslipidemic men. Additionally, several genes related to TG synthesis and HDL-C and 
cholesterol metabolism were regulated in dyslipidemic men (Table 3). More precisely, the 
PPAR target gene phospholipid transfer protein (PLTP), as well as the ATP-binding cassette 
sub-family G member 5 (ABCG5) were up-regulated, while 2-acylglycerol O-acyltransferase 
3 (MOGAT3), MOGAT2, diacylglycerol O-acyltransferase 1 (DGAT1), and sterol O-
acyltransferase 1 (SOAT1) were down-regulated after FO supplementation in dyslipidemic 
men. 
Gene expression changes of Apo CII and LDLR were quantified by qRT-PCR (Figure 4.1). 
The expression of Apo CII in dyslipidemic subjects at baseline was three times higher 
compared to normolipidemic subjects (p = 0.05). After twelve weeks of FO supplementation, 
the expression of Apo CII was slightly up-regulated in normolipidemic subjects, and 
significantly down-regulated in dyslipidemic subjects (-57.2%; p = 0.04). The expression of 
LDLR in normolipidemic subjects at baseline was twice as high compared to dyslipidemic 
subjects (p = 0.008). After twelve weeks of FO supplementation, no changes in LDLR 
expression were observed in normolipidemic subjects, while dyslipidemic subjects showed a 
significant down-regulation in LDLR expression (p = 0.02). 
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Figure 4.1: Transcript levels of apolipoprotein CII (Apo CII) and low-density lipoprotein 
receptor (LDLR) in normolipidemic and dyslipidemic men. Transcript levels of Apo CII 
and LDLR was determined by qRT-PCR in normo- and dyslipidemic men before (t0) and after 
twelve weeks (t12) of fish oil supplementation. Pooled group samples were used in triplicates. 
Triplicates were averaged and corrected by two reference genes, glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and ribosomal proteine S2 (RPS2). Corrected 
expressions were compared with baseline gene expression of normolipidemic subjects and 
relative expression changes are displayed.  
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Table 4.3: Expression ratios of lipid metabolism-related genes. Expression ratios were displayed for genes which were differentially  
expressed after four hours (t4h), one week (t1) and twelve weeks (t12) of fish oil supplementation in normolipidemic and dyslipidemic men. 
dyslipidemic normolipidemic 
Gene Gene 
symbol Entrez_ID RefSeq_ID Ratio 
t4h:t0 
Ratio 
t1:t0 
Ratio 
t12:t0 
Ratio 
t4h:t0 
Ratio 
t1:t0 
Ratio 
t12:t0 
Function 
Transcription factors 
Peroxisome proliferator-
activated receptor alpha PPARA 5465 
NM_001001928.2 
NM_005036.4 -8.19
1
 2.722 - - - - 
Retinoic X receptor RXR-
alpha RXRA 6256 NM_002957.4 - -4.50
1
 - 3.141 3.791  
Retinoic acid receptor 
RXR-gamma RXRG 6258 NM_006917.3 3.16
3
 4.793 4.113 -3.192 - -2.032 
Hepatocyte nuclear factor 
6 HNF6 3175 NM_004498.1 -2.27
1
 -4.891 -3.431 - - - 
Hepatocyte nuclear factor 
1-beta HNF1B 6928 NM_000458.2 - -3.64
1
 -2.561 - - - 
Regulation of the lipid 
metabolism 
Triacylglycerol synthesis 
2-acylglycerol O-
acyltransferase 3 MOGAT3 346606 NM_178176.2 - -27.07
1
 -3.481 - - - 
2-acylglycerol O-
acyltransferase 2 MOGAT2 80168 NM_025098.2 -3.08
1
 - - - - - 
Diacylglycerol O-
acyltransferase 1 DGAT1 8694 NM_012079.4 - -2.67
1
 - - - - 
TG synthesis 
HDL-C metabolism 
Phospholipid transfer 
protein PLTP 5360 
NM_006227.2 
NM_182676.1 - 3.30
1
 4.151 - - - Modify HDL-C particles 
size 
Cholesterol metabolism 
ATP-binding cassette sub-
family G member 5 ABCG5 64240 NM_022436.2 - 4.06
1
 5.341 - - - Cholesterol efflux 
sterol O-acyltransferase 1 SOAT1 6646 NM_003101.4 - -2.451 -2.372 - - - Cholesterol synthesis 
- no regulation 
1
 p = 0.05 
2
 p < 0.05 
3
 p < 0.01  
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4.4 Discussion 
The effects of n-3 PUFAs on lipid levels in dyslipidemic conditions are well-known, however, 
only a few human studies investigated the underlying molecular mechanisms of gene 
expression levels in humans. Therefore, we performed a twelve-week long n-3 PUFA 
supplementation trial with normo- and dyslipidemic male subjects aiming to identify possible 
molecular pathways by which n-3 PUFAs influence lipid metabolism. Although the lipid 
metabolism is mainly located in the liver, several key regulators of the TG, HDL-C and LDL-C 
metabolism were found to be regulated on a transcriptional level in whole blood cells.  
4.4.1 TG metabolism 
Supplementation of normo- and dyslipidemic subjects with n-3 PUFAs resulted in a decrease 
of TG levels by 23 and 28%, which is comparable to other studies (Shearer et al. 2012). 
Several genes which are likely to be involved in TG lowering were observed to be regulated 
(Figure 4.2). While PPARα was up-regulated in dyslipidemic men after one week of n-3 
PUFA supplementation, the expressional regulation of PPAR heterodimer partner RXRα and 
RXRγ was different between the two receptors as well as between dys- and normolipidemic 
subjects. The fact that the exact roles of RXR isotypes are not clearly defined further 
hampers the interpretation of our findings. However, linkage analysis unveiled an association 
of RXRγ with TG and cholesterol levels (Knoblauch et al. 1999; Pei et al. 2000). The 
continuous up-regulation of RXRγ in dyslipidemic subjects might suggest a role of RXRγ 
together with PPARα in the lipid metabolism. Consistent with our findings, it is also known 
from other studies that EPA, DHA and/or their oxidized metabolites transactivate PPARs and 
RXRs (Forman et al. 1997; Kliewer et al. 1997; Lengqvist et al. 2004; Urquiza et al. 2000), 
resulting in a repression of Apo CIII and Apo B, which, in turn, results in an enhanced LPL-
mediated catabolism of VLDL and reduced VLDL production (Staels et al. 1998). Currently, 
this metabolic pathway is believed to be the main mechanism by which n-3 PUFAs reduce 
TG levels (Shearer et al. 2012). Expression changes of genes coding for Apo CIII and Apo B 
were not observed in this study, possibly because these factors are not expressed in blood 
cells but in other organs and tissues (Jong et al. 1999; Knott et al. 1985; Wang and Eckel 
2009). In vivo studies are required to evaluate this hypothetical molecular pathway. 
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Figure 4.2: Regulatory effects of eicosapentaenoic acid and docosahexaenoic acid on lipid 
metabolism related genes. The Figure presented is based on the analysis of gene 
expression changes after fish oil supplementation in dyslipidemic male subjects. While bold 
text and black and grey arrows present findings discovered in this thesis, grey arrows 
symbolize that until now it has not been clarified if genes are target genes of PPARα. In 
addition, broken arrows symbolize further possible mechanisms of action based on findings 
from the literature. 
Two other transcription factors besides PPARα were regulated after n-3 PUFA 
supplementation. HNF6 and HNF1ß were down-regulated in dyslipidemic subjects at nearly 
all time-points. HNF6 is associated with several regulatory pathways influencing glucose 
metabolism, cholesterol metabolism, bile acid biosynthesis, as well as the synthesis and 
transport of serum carrier proteins (Wang and Holterman 2012). Synergisms between HNF6 
and HNF1α or between HNF1β and GATA6 could increase the activity of the HNF4α 
promoter (Hatzis and Talianidis 2001), which, in turn, increases VLDL secretion. Since Apo 
CIII and Apo B are target genes of HNF4α (Ladias et al. 1992), a reduced HNF4α 
expression, mediated by a down-regulation of HNF6 and HNF1ß, may reduce the VLDL 
secretion; the main TG-lowering effect of n-3 PUFAs. However, expression changes of 
HNF4α were not observed after FO supplementation in our experiments, most likely because 
HNF4α is expressed in liver, kidney, intestine, and pancreas (Sladek 1994). Nevertheless, a 
robust suppression of the transcriptional HNF4α activity by n-3 PUFAs has been shown in 
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vitro (Hertz et al. 1998). Furthermore, it was found that n-3 PUFAs reduce the expression of 
HNF4α in rat hepatocytes resulting in a decreased expression of Apo B and microsomal TG 
transfer protein, which suggests a reduced VLDL secretion (López-Soldado et al. 2009). 
Taken together, these findings suggest that this molecular pathway is a possible mechanism 
explaining the TG-lowering effect of n-3 PUFAs. Moreover, it is believed that PPARα and 
HNF4α compete for the binding site of the Apo CIII promoter (Hertz et al. 1995). While 
PPARα binding reduces Apo CIII expression, HNF4α binding increases Apo CIII expression. 
Further studies should investigate the potential of n-3 PUFAs to activate PPARα and inhibit 
HNF4α.  
In addition to transcription factors, the expression of several other TG metabolism-associated 
genes was regulated after n-3 PUFA supplementation. Apo CII acts as a cofactor for LPL, 
which hydrolyses TGs in chylomicrons and VLDL particles to glycerine and free FAs. 
Therefore, constant Apo CII levels are crucial for LPL activation (Kei et al. 2012), ensuring 
efficient lipolysis of TG-rich lipoproteins. Studies have shown that dyslipidemic subjects 
without genetic disorders present higher Apo CII levels (7.0 mg/dl) than normolipidemic 
subjects (3.0 mg/dl) (Liu et al. 2009; Sakurabayashi et al. 2001), which results in a 
disturbance of the Apo CII/LPL balance. Dyslipidemic subjects of our study consistently 
exhibited higher Apo CII mRNA expression levels than normolipidemic subjects at baseline. 
After FO treatment, Apo CII expression was down-regulated in dyslipidemic men suggesting 
a re-establishment of the Apo CII/LPL balance and an increased LPL-mediated TG 
clearance. In agreement, Zhang et al. (2012) observed reduced plasma Apo CII levels in 
Chinese woman after increased fish intake (80 g fatty fish five times per week) over eight 
weeks. 
Finally, the mRNA expression of three genes involved in TG synthesis, MOGAT3, MOGAT2 
and DGAT1, were down-regulated in dyslipidemic men after n-3 PUFA supplementation. 
MOGATs and DGATs are key enzymes of the monoacylglycerol (MAG) pathway (Hall et al. 
2012), which is primarily responsible for the re-synthesis of TGs from FAs and 2-MAG in 
enterocytes (Cheng et al. 2003; Hiramine and Tanabe 2011; Yen and Farese 2003). Besides 
the intestine, MOGAT2 and MOGAT3 are similarly expressed in the liver (Hall et al. 2012; 
Yen and Farese 2003), whereas DGAT1 is expressed ubiquitously (Cases et al. 1998). To 
the best of our knowledge, an effect of n-3 PUFAs on the expression of MOGAT2 and 
MOGAT3 has not yet been described. Knockdown of MOGAT3 by siRNA in liver-derived 
cells was followed by a reduced enzyme activity (Hall et al. 2012). A reduced enzyme activity 
was accompanied by reduced intestinal dietary fat absorption in mice (Yen et al. 2009). It is 
believed that MOGAT3 might be a potential therapeutic drug target for treating metabolic 
abnormalities, such as dyslipidemia (Hall et al. 2012). Similarly, MOGAT2 knockout mice 
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were also protected against diet-induced obesity and hypercholesterolemia (Yen et al. 2009), 
indicating that MOGAT2 might be a potential drug target too. Similarly, the existing data 
describing an effect of n-3 PUFAs on DGAT1 are rare. Two studies reported a reduced 
DGAT activity in cultured rat hepatocytes in response to EPA treatment, resulting in reduced 
TG synthesis and secretion (Berge et al. 1999; Rustan et al. 1988), whereas an activation of 
PPARα was suggested as the initial regulator (Berge et al. 1999). Similarly to MOGAT2, 
DGAT1 deficient mice are also resistant to diet-induced obesity and show reduced TG levels 
in the liver (Smith et al. 2000; Buhman et al. 2002). It was also shown that DGAT1 knockout 
mice accumulated lipid droplets in the cytoplasm of enterocytes when fed a chronically high-
fat diet. We assume that the down-regulation of MOGAT2, MOGAT3 and DGAT1, observed 
in whole blood cells after FO supplementation, will similarly take place in enterocytes or 
hepatocytes, resulting in a reduced re-synthesis of TG and thus TG levels in circulation. 
4.4.2 HDL cholesterol metabolism 
As expected, FO supplementation increased HDL-C levels in both normo- and dyslipidemic 
subjects. The underlying HDL-C level raising mechanisms are not completely understood. 
Another target gene of PPARα that might be involved in raising HDL-C levels is PLTP (Bouly 
et al. 2001; Lemay and Hwang 2006; Tu and Albers 1999), which was up-regulated in 
dyslipidemic subjects (Figure 4.2). PLTP can modulate HDL-C size and composition 
(Jauhiainen et al. 1993; Settasatian et al. 2001) by the transfer of PLs from TG-rich 
lipoproteins to HDL-C particles (Tall et al. 1985). However, in contrast to our results, 
incubation of Hep G2 cells with EPA, DHA or AA resulted in a decreased expression of PLTP 
(Kuang et al. 2012). In the same way, results from animal trials were inconsistent. Both PLTP 
deficiency and PLTP overexpression resulted in a significant reduction of HDL-C levels in the 
circulation (Yazdanyar et al. 2011). Further studies need to clarify the influence of n-3 PUFAs 
on the expression of PLTP and the resulting HDL-C levels.  
4.4.3 Total cholesterol and LDL cholesterol metabolism 
A well-known effect of FO supplementation is a slight increase of LDL-C levels after n-3 
PUFA supplementation (Balk et al. 2006), which is most likely the result of an increased 
conversion of VLDL-C to LDL-C (Lu et al. 1999). Although we observed a considerable 
increase in LDL-C levels in dyslipidemic subjects, the expression of several regulated genes 
in the same subjects indicate not only cholesterol-lowering, but also an enhancing effect 
(Figure 4.2). LDLR, which is expressed in nearly all cells, but predominantly in liver cells, 
transports cholesterol-rich lipoprotein particles, preferably LDL-C, via endocytosis into the 
cell, resulting in LDL-C clearance (Brown and Goldstein 1986). Even though high cholesterol 
concentrations inhibit the LDLR expression (Goldstein and Brown 2001), LDLR expression 
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values in dyslipidemic subjects were two times higher compared to normolipidemic subjects. 
After FO supplementation, the LDLR expression was down-regulated in dyslipidemic 
subjects, which is in agreement with other studies (Dawson et al. 2011). The reduced LDLR 
expression suggests a diminished LDL-C clearance and could be another mechanism 
explaining the n-3 PUFA-induced rise in LDL-C levels.  
In contrast, the regulation of two other factors points to a cholesterol-lowering effect. The 
half-transporters ABCG5 and ABCG8 play a pivotal role in the regulation of dietary 
cholesterol transport into the intestinal and biliary lumen for faecal excretion (Yu et al. 2002). 
Consequently, these transporters are strongly expressed in the liver, while lower levels are 
found in the small intestine and colon (Kidambi and Patel 2008). The up-regulation of ABCG5 
in dyslipidemic subjects might induce a pathway that results in increased cholesterol efflux. 
In agreement with our results, two animal studies revealed an increased hepatic ABCG5 and 
ABCG8 expression in mice after FO feeding (Kamisako et al. 2012; Nishimoto et al. 2009). 
The regulation might be triggered by PPARα, since PPARα agonists caused an up-regulation 
of ABCG5 expression in hypercholesterolemic subjects (Roglans et al. 2004). 
SOAT1, also referred to as acyl-Coenzyme A cholesterol acyltransferase 1 (ACAT), is a 
membrane-bound protein that utilizes long-chain fatty acyl-CoA and cholesterol as substrates 
to form cholesteryl esters (Chang et al. 2009). SOATs play important roles in cellular 
cholesterol homeostasis in various tissues, and SOAT inhibitors have been focused as drug 
targets for atherosclerosis and for Alzheimer’s disease (Chang et al. 2009). The down-
regulation of SOAT1 observed in dyslipidemic subjects after FO supplementation similarly 
suggests a cholesterol-lowering effect. Accordingly, a down-regulation of SOAT1 expression 
after n-3 PUFA treatment has been observed in human breast cancer cells (Hammamieh et 
al. 2007). Further studies need to clarify the exact role of n-3 PUFAs in the regulation of 
these factors and the resulting effects on cholesterol metabolism. 
4.4.4 Limitations 
The study has a number of potential limitations. As has already been pointed out, it is critical 
to investigate the regulative effect of n-3 PUFAs on the expression of lipid metabolism-
associated genes in whole blood cells instead of liver cells. However, the taking of biopsy 
samples from the liver in this study was precluded for ethical and medical reasons. We 
similarly abstained from isolating lymphocytes or PBMCs, an approach which was chosen by 
two other groups investigating a similar question (Bouwens et al. 2009; Gorjão et al. 2006), 
since cell fractioning steps involve stress-induced alterations in gene expression profiles 
(Vartanian et al. 2009). However, many lipid metabolism-associated genes are also 
expressed in nucleated blood cells: For example, PPARα is expressed in monocytes, 
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macrophages and lymphocytes (Chinetti et al. 1998; Mandard et al. 2004), while HNF6 and 
DGAT were found to be expressed in PBMCs (Cases et al. 1998; Zhao et al. 2007).  
4.4.5 Conclusion 
This pilot study suggests molecular pathways on how n-3 PUFAs affect lipid metabolism. 
Although the study is limited by the usage of whole blood cells obviating strong conclusions 
about lipid metabolism, several lipid metabolism-associated genes were shown to be 
regulated on a transcriptional level in dyslipidemic subjects, including transcription factors 
PPARα, RXRα, RXRγ, HNF6, and HNF1ß, as well as other lipid regulators, MOGAT2, 
MOGAT3, DGAT1, Apo CII, PLTP, LDLR, ABCG5, and SOAT1. We assume that this 
transcriptional regulation will equally take place in cells of the liver or other tissues. Given this 
assumption, n-3 PUFAs activate several transcription factors resulting in the regulation of 
numerous target genes which, in turn, affect multiple lipid regulators. Accordingly, the results 
give indications for (1) decreased TG levels as a result of an enhanced VLDL catabolism and 
reduced VLDL production, as well as a decreased TG re-synthesis in enterocytes and 
hepatocytes, while (2) increased HDL-C levels may be the result of an increased transfer of 
PLs from TG-rich lipoproteins to HDL-C particles. Finally, (3) LDL-C levels may be influenced 
in both directions: A decreased LDL-C clearance may result in rising LDL-C levels, on the 
one hand, while an increased cholesterol efflux and a reduced cholesteryl ester synthesis 
result in decreasing LDL-C levels, on the other hand. Future studies combining gene 
expression, metabolic markers and clinical end points need to clarify the significance of the 
hypothesized molecular mechanisms. 
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5. General discussion 
The work presented here was aimed at investigating the effect of FO or CO supplementation 
on gene expression changes in whole blood samples from normo- and dyslipidemic male 
subjects to find possible indications for the molecular mechanism of action described. In 
addition, the suitability of whole blood samples for investigating gene expression changes 
after supplementation was tested to clarify if supplemental effects of n-3 PUFAs on 
inflammatory and lipid-related genes could be observed in this kind of sample material. For 
these purposes, a double-blind, placebo-controlled, monocentric human interventional trial of 
twelve weeks duration was undertaken with normo- and dyslipidemic men. The subjects of 
this study ingested either CO or FO capsules and gene expression changes were 
determined by microarray experiments and qRT-PCR. The results of the interventional trial 
conducted were divided into three parts with different main focuses and are presented within 
this thesis (chapters 2, 3 and 4). Each chapter contains an individual discussion related to its 
main content. In this section, the results are discussed in the context of the suitability of the 
methods applied, as well as of the effects of n-3 PUFAs on gene expression changes 
detected in humans. In addition, future perspectives for further research topics based on the 
results from this thesis are given.  
5.1 Methodological aspects 
5.1.1 Suitability of transcriptomics  
Transcriptomics – the study of transcribed sequences – enable the measurement of the 
expression level of messenger ribonucleic acids (mRNAs) in a given cell population. The 
usage of high-throughput techniques such as DNA microarrays, permit the analysis of 
expression changes of thousands of genes simultaneously. Determination of whole genome 
gene expression changes by microarray experiments in this proof of concept study facilitated 
it becoming an overview of complex regulatory networks and revealed several already known 
gene expression changes after FO supplementation, but also showed many regulated genes 
which might be part of potential new regulatory networks of n-3 PUFAs (see 5.2). The result 
of a microarray experiment is a large list of differentially expressed genes. These gene lists 
are hard to interpret in a biological context (Morine et al. 2011) and bioinformatics tools are 
indispensable for analyzing and interpreting such large amounts of data (Goodman 2002). 
Pathway analyses are the most applied tool for the interpretation of differentially expressed 
gene lists. Although this tool is easy to execute, technical limitations, such as inherent 
redundancy among pathways and interconnectedness between one pathway and the next, 
are the reason for the limited biological interpretation of high-throughput datasets (Morine et 
al. 2011). However, the results of microarray experiments could give an initial indication and 
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thus afford a good opportunity to investigate the effects of nutrition components on human 
health. In addition, qRT-PCR analysis was performed in this study to validate microarray 
results and to quantificate the transcript levels of target genes sensitively. In conclusion, the 
combination of both of these transcriptomic tools, microarray and qRT-PCR, is very suitable 
for producing high quality data and to investigate nutrient-induced gene expression changes 
in humans.  
5.1.2 Suitability of blood samples for gene expression analysis 
Analyzing gene expression changes in humans presents some difficulties due to methodical 
limitations. Firstly, human nutrition studies are mostly influenced by side-effects, unless 
volunteers were admitted to a hospital or casern and physical activity and food intake is 
constantly controlled. The second limitation is the availability of sample material. Most 
nutritional studies use blood samples, because blood can be easily collected by minimal 
invasiveness under low pain conditions. Some studies also use samples which were 
collected during surgery, and others take cell biopsies and cultivated these cells. However, 
both of these methods do not reflect a normal physiological state and, in both cases, tissue 
and cells are under the influence of anesthesia or narcotic drugs, as well as damaging 
procedures, which may alter gene expression patterns. Isolated and cultured cells 
additionally present only one small unit of the whole body, which limits the observations to 
this small unit without knowing if this reaction would also occur in the complex body. Due to 
ethical reasons, blood samples were used in this study for analyzing whole genome 
expression changes after supplementation with FO or CO in normo- and dyslipidemic male 
subjects. 
Whole blood cells could be divided into three main cell subtypes: erythrocytes, thrombocytes 
and leucocytes (monocytes, lymphocytes and granulocytes). Leucocytes are a main 
component of the cellular immune system, facilitating complex processes of the immune 
defense against pathogens and toxins, such as recognition of pathogen structures, 
production of antibodies and destruction of pathogens by phagocytosis. Therefore, whole 
blood – containing immune cells – is a good choice to analyze the immune-modulatory 
effects of n-3 PUFAs. As has already been mentioned in chapter 4, it is critical to investigate 
the regulative effect of n-3 PUFAs on the expression of lipid metabolism-associated genes in 
whole blood cells instead of liver cells. However, many lipid metabolism-associated genes 
are also expressed in nucleated blood cells, such as PPARα (Chinetti et al. 1998; Mandard 
et al. 2004), HNF6 and DGAT (Cases et al. 1998; Zhao et al. 2007). The results of this study 
indicate that whole blood cells have the potential to reflect the regulatory effects of n-3 
Chapter 5  General Discussion 
72 
PUFAs in other body compartments and thus provide a good opportunity to analyze the 
effects of n-3 PUFAs by a minimum invasive method. 
5.2 Effects of n-3 PUFAs on gene expression 
N-3 PUFAs can modify gene expression through several mechanisms (see 1.2.4), of which 
the modification of transcription factors plays a major part in this regulation. Gene expression 
changes of specific transcription factors and corresponding target genes, and expression 
changes of genes related to the lipid metabolism, inflammation and oxidative metabolism are 
observed by this study. In the following section, firstly, the main study findings are 
summarized. Afterwards, the role of n-3 PUFAs in the regulation of gene expression within 
the lipid metabolism, inflammation and oxidative metabolism are described in detail.  
5.2.1 Summarized evaluation of main study findings 
The objective of this thesis was to analyze the influence of an FO or CO supplementation on 
whole genome gene expression patterns of whole blood samples derived from normo- and 
dyslipidemic male subjects and to propose possible molecular mechanism of action. This 
study approach permits, on the one hand, a comparison of gene expression changes 
between dyslipidemic and normolipidemic male subjects and, on the other hand, the 
comparison between the effects of FO and CO. Regarding the second, comparison between 
FO and CO supplementation, pathway analyses showed a higher number of influenced 
pathways after FO than after CO supplementation, including pathways of the immune 
system, inflammation and lipid metabolism. In the following sections, firstly, differences in 
gene expression changes after supplementation with FO or CO in normo- and dyslipidemic 
male subjects were discussed. Afterwards, all gene expression changes observed of 
transcription factors and genes after FO supplementation were taken together to discover the 
role of n-3 PUFAs in the transcriptional regulation of the lipid metabolism, inflammation and 
oxidative metabolism, as well as other potential cardioprotective effects. 
5.2.1.1 Normo- vs. dyslipidemic male subjects 
The analysis of whole genome microarray data (chapter 2) revealed that normo- and 
dyslipidemic male subjects feature different expression profiles after supplementation, which 
is characterized by the direction of gene regulation (normolipidemic male subjects showed 
more up-regulated genes and dyslipidemic male subjects showed more down-regulated 
genes) and by the extent of gene regulatory effect of n-3 PUFAs (higher number of regulated 
genes and thus more pronounced effects in dyslipidemic male subjects). In this connection, 
the more pronounced gene regulatory effect of n-3 PUFAs in dyslipidemic male subjects 
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might be in response to dyslipidemia, a metabolic state, which is often associated with a low 
grade of inflammation, being present (Esteve et al. 2005). It is believed that subjects with 
inflammatory conditions are more sensitive to the immune-modulatory effects of n-3 PUFAs 
than healthy subjects, because they have a disease-dependent higher turnover rate of 
immune cells (Sjiben and Calder 2007). A higher number of immune cells possess a higher 
capacity to produce eicosanoids and other metabolites, which could influence inflammation 
and serve as ligands for transcription factors (Sjiben and Calder 2007). In addition, n-3 PUFA 
supplementation might influence the count of immune cells, especially granulocytes and, 
therefore, leucocyte numbers, resulting in anti-inflammatory effects by reduced inflammatory 
cell numbers and responses (Kelley et al. 1998, Kelley et al. 1999). Furthermore, subjects 
with inflammatory conditions feature a lower buffering capacity than healthy subjects (Sjiben 
and Calder 2007) and inflammation could result in an increased production of oxidized 
metabolites of n-3 PUFAs (see 1.2.3.3). This suggests that local anti-inflammatory effects are 
perhaps greater than systemic effects in healthy subjects, which might explain why n-3 PUFA 
supplementation in healthy subjects mostly showed no immune-modulatory effects. 
5.2.1.2 Effects of n-3 PUFA supplementation on the lipid metabolism 
Interventional studies have shown that n-3 PUFAs lower TG levels and elevate HDL-C levels 
(Harris 1996, 1997; Musa-Veloso et al. 2010). In this study, FO supplementation resulted in a 
TG decrease by ~25% as well as an HDL-C increase by ~12% in both normo- and 
dyslipidemic male subjects. It is believed that the TG-lowering effect of n-3 PUFAs results 
from reduced VLDL-TG synthesis and secretion from the liver, and enhanced TG clearance 
(Shearer et al. 2012). The HDL-C increase might be the cause of the modification of HDL-C 
subtypes (Mori et al. 1999, 2000). However, molecular mechanisms by which n-3 PUFAs 
modify the lipid metabolism are not completely clarified. The results of this study showed that 
EPA and DHA may exert their effects on lipid metabolism-related genes via direct effects on 
the transcription factors, such as PPARα, RXRs and HNFs (Figure 5.1). The down-
regulation of HNF1ß and HNF6, which could both activate HNF4α together with HNF1α or 
GATA6 (Hatzis and Talianidis 2001), might reduce the promotor activity of HNF4α, resulting 
in repressed expression of Apo CIII and Apo B which, in turn, reduces the VLDL secretion 
and TG level in the circulation (Ladias et al. 1992). In addition, the activation of PPARα 
causes several downstream processes, resulting in modified cholesterol and TG metabolism. 
PPARα activation could increase the expression of ABCG5 (Roglans et al. 2004), leading to 
increased cholesterol efflux (Yu et al. 2002) and may reduce the expression of SOAT1, 
resulting in decreased cholesterol synthesis (Chang et al. 2009). Regarding the influence of 
HNF4α on Apo CIII and Apo B expression described above, PPARα compete for binding 
sites for these target genes and this resulted in an inverse regulation (Hertz et al. 1995). 
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Therefore, activation of PPARα could result in a repression of the expression of Apo CIII, 
leading to a decreased VLDL secretion and TG level. Furthermore, PLTP is a target gene of 
PPARα, which could modify the HDL particle size and might be a reason for the HDL 
increase observed. Besides these named transcription factors, several genes which are 
related to the TG metabolism were regulated after FO supplementation. While genes of the 
TG re-synthesis were down-regulated (MOGAT2, MOGAT3, DGAT1), the level of Apo CII 
was modified, suggesting the generation of an optimal balance to LPL. Apo CII could be 
increased by the transcription factor FXR, which was regulated by n-3 PUFAs in liver cells 
(Adkins and Kelley 2010). In addition, the down-regulation of RXRα could be an indication for 
a reduced formation of the RXRα/LXRα and, in turn, reduced activity of SREBP-1c (Adkins 
and Kelley 2010), which leads to a decreased expression of FAS and acetyl CoA 
carboxylase ß (ACACB). These named factors are indications of a reduced lipogenesis, TG 
synthesis and increased TG clearance. Taken together, the results of this study with the use 
of whole blood samples indicate that effects of EPA and DHA on the lipid metabolism in 
humans are mainly exerted via activation of PPARα.  
 
 
 
 
 
 
 
 
 
Figure 5.1: Summarized regulatory effects of eicosapentaenoic acid and docosahexaenoic 
acid on lipid metabolism. The Figure presented is based on the analysis of gene expression 
changes after fish oil supplementation in dyslipidemic male subjects. While bold text and 
black and grey arrows present findings discovered in this thesis, grey arrows symbolize that 
until now it has not been clarified if genes are target genes of PPARα. In addition, broken 
arrows symbolize further possible mechanisms of action based on findings from the 
literature.  
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5.2.1.3 Effects of n-3 PUFA supplementation on inflammation and 
oxidative metabolism 
In addition to the lipid profile improving effects, n-3 PUFAs have shown anti-inflammatory 
properties in vitro and partly in vivo (Calder 2003, 2006). All observations within this study, 
which are related to the anti-inflammatory as well as to antioxidative effects of EPA and DHA, 
are displayed in Figure 5.2. Similar to the regulatory effects within the lipid metabolism, 
PPARα activation also plays an important role in the effects on inflammation and oxidative 
processes. It is known that PPARα activation induces the expression of genes related to FA 
oxidation (Mozaffarian and Wu 2011; Shearer et al. 2012). Although this could not be 
observed in this study, indication for an increased production of oxidized metabolites of EPA 
and DHA was detected (CYP1A2 was up-regulated in dyslipidemic male subjects). An 
increased FA oxidation could increase oxidative stress (Harats et al. 1991; Meydani et al. 
1991) and may induce the body’s defense system to generate antioxidative enzymes for the 
prevention of cellular damage. In this case, the up-regulation of CAT and HMOX2 discovered 
gives a hint of such antioxidative induced processes. In addition, PPARα could activate CAT 
directly, which is an additional indication that PPARα activation results simultaneously in 
increased FA oxidation and increased antioxidative gene expression. The increased 
expression of CAT and HMOX2, as well as the down-regulation of FA oxidation-related 
genes (HADHA, HADH; ECI2) after FO supplementation, suggests that oxidative stress and 
ROS production might be reduced. Regarding the fact that ROS induce MMP expression, 
reduced ROS concentration may lead to decreased MMP expression, which could be 
observed in this study and may prevent plaque rupture during atherosclerosis. Furthermore, 
reduced oxidative stress could influence stress-activated pathways, such as NFκB, and the 
MAPK pathway, which was also influenced by FO supplementation in this study. These 
pathways regulate several inflammatory genes, of which, for example, IL-8 was seen to be 
down-regulated in this study. This last connection could also be induced by reduced AA 
concentration in membranes, because AA is an important ROS producer. The membrane 
content of AA decreased, while the content of EPA and DHA increased after FO 
supplementation. In addition, the up-regulation of PLA2GE2 and PLB1, as well as several 
up-regulated genes within the glycerolipid- and glycerophospholipid metabolism, indicates an 
exchange of membrane bound AA and membrane remodeling processes. In conclusion, this 
study shows several indications that the anti-inflammatory effects of EPA and DHA might be 
exerted via antioxidative effects by PPARα activation.  
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Figure 5.2: Summarized regulatory effects of eicosapentaenoic acid and docosahexaenoic 
acid on inflammation and oxidative processes. The Figure presented is based on the 
analysis of gene expression changes after fish oil supplementation in dyslipidemic male 
subjects. While bold text and black arrows present findings discovered in this thesis, broken 
arrows symbolize further possible mechanisms of action based on findings from the 
literature. 
5.2.1.4 Effects of n-3 PUFA supplementation on other potential 
cardioprotective effects 
Beside regulated genes, which are related to the lipid metabolism, inflammation and 
oxidative metabolism, numerous other genes which might be associated with the 
cardioprotective effects of n-3 PUFAs were seen to be regulated after FO supplementation. 
Several cardioprotective effects of EPA and DHA are described in the literature, such as 
inhibition of inflammation, monocyte infiltration, NFκB activation, platelet aggregation, 
vasoconstriction, and arrhythmia, as well as stimulation of pro-resolving mediators, 
stabilization of atherosclerotic plaques, TG lowering, and changes in membrane lipid 
composition (Adkins and Kelley 2010). Some indications for these named cardioprotective 
effects could also be observed in this study. These include the improvement of the inhibition 
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of platelet aggregation, the modulation of ion channels, the stabilization of potential 
atherosclerotic plaque, and anti-inflammatory properties. 
• Indications for the inhibition of platelet aggregation by EPA and DHA were discovered 
by pathway analyses of differential regulated genes of dyslipidemic male subjects. 
While blood coagulation supporting genes such as complement component (3b/4b) 
receptor 1, coagulation factor III (thromboplastin, tissue factor) and fibrinogen gamma 
chain were down-regulated, and anti-thrombin (serpin peptidase inhibitor, clade C 
member 1) was up-regulated. N-3 PUFAs could reduce platelet aggregation (Harris et 
al. 2008), which prevents critical thrombotic and/or inflammatory complications during 
several diseases (Oikonomopoulou et al. 2012; Vanschoonbeek et al. 2004), 
indicating that n-3 PUFAs posses anti-thrombotic properties.  
• Modulation of ion channels is an important approach by which n-3 PUFAs may exert 
their anti-arrhythmic effects. In this study, HMOX2 was up-regulated after FO 
supplementation in both normo- and dyslipidemic male subjects. The fact that 
HMOX2 was identified as part of the BK(Ca) channel complex (Williams et al. 2004) 
suggests that n-3 PUFAs may influence cell membrane potential, resulting, for 
example, in oxygen-sensing, neuronal excitability, vascular tone regulation, and 
neurotransmitter release (Hou et al. 2009; Salkoff et al. 2006). 
• The ability to stabilize atherosclerotic plaque is another aspect by which n-3 PUFAs 
may prevent CVD. Increased expression of MMPs could result in tissue remodeling 
processes (Clee 2010) and promote the pathogenesis of several CVDs (Spinale et al. 
2000; Tyagi et al. 1996). In this study, different MMPs were down-regulated after FO 
supplementation in normo- and dyslipidemic male subjects, indicating the potential 
cardioprotective effects of n-3 PUFAs by the prevention of plaque rupture.  
• Moreover, several genes of the ARVC and dilated DCM pathways were down-
regulated in dyslipidemic men after FO supplementation. This might be the result of 
diverse regulatory effects on lipid metabolism and anti-inflammatory processes. 
However, the effect of n-3 PUFA supplementation on the pathogenesis of ARVC and 
DCM in humans is unknown and further studies are needed to analyze the protective 
function of n-3 PUFAs in this group of patients. 
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5.3 Conclusion 
In conclusion, this proof of concept study showed significant differences in gene expression 
profiles between normo- and dyslipidemic men after FO supplementation. Dyslipidemic men 
presented substantially more regulated genes and pathways, of which several are related to 
the immune system, inflammation, lipid metabolism, and CVD. Several lipid metabolism-
associated transcription factors and genes were shown to be regulated on a transcriptional 
level in the blood samples analyzed, and it is assumed that this transcriptional regulation will 
equally take place in the cells of the liver or other tissues. Additionally, the study showed that 
n-3 PUFAs activate and repress several transcription factors resulting in the regulation of 
numerous target genes. In this case, lipid metabolism-related transcription factors, such as 
the hepatic nuclear factor (HNF) 6 and HNF1ß, which could affect HNF4α, an additional 
important regulator of the lipid metabolism, were repressed by n-3 PUFA supplementation. 
Otherwise, peroxisome proliferator-activated receptor (PPAR) α was activated by n-3 PUFA 
supplementation. The regulation of named transcription factors may induce expression 
changes of target genes resulting in TG lowering, which could be observed in normo- and 
dyslipidemic male subjects. Moreover, the activation of PPARα appears to play a significant 
role in various other cardioprotective effects of n-3 PUFAs. In this case, antioxidative genes 
were up-regulated and pro-inflammatory genes were down-regulated after n-3 PUFA 
supplementation, suggesting that n-3 PUFA may induce anti-inflammatory and antioxidative 
effects via PPARα activation.  
Although this study revealed several indications of possible molecular mechanisms of action 
in what extent n-3 PUFAs mediate their cardioprotective effects, further studies analyzing a 
combination of gene expression, metabolic markers and clinical end-points are needed to 
clarify the mechanisms by which n-3 PUFAs trigger gene regulation and affect various 
regulatory networks.  
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5.4 Perspectives 
With regard to lipid metabolism-related effects, several open questions arose from this study. 
Firstly, the role of PLTP in the regulation of the HDL level is not clarified and inconsistent 
results were observed in literature and this study. While the incubation of Hep G2 cells with 
EPA, DHA or AA resulted in a decreased expression of PLTP (Kuang et al. 2012), this study 
showed an up-regulation of PLTP after FO supplementation in dyslipidemic men. However, 
both PLTP deficiency and PLTP over-expression resulted in a significant reduction of HDL-C 
levels in the circulation (Yazdanyar et al. 2011). Therefore, the influence of n-3 PUFAs on the 
expression of PLTP and the resulting HDL-C levels has to be analyzed and the importance of 
protein concentration of PLTP for the modification of HDL particles has to be investigated. In 
addition, the relevance of the up-regulation observed of the half-transporter ABCG5, which 
plays a pivotal role in the regulation of dietary cholesterol transport into the intestinal and 
biliary lumen for fecal excretion (Yu et al. 2002), for increased cholesterol efflux should be 
determined. Moreover, the potential involvement of PPARα in the regulation of ABCG5 
should be investigated in more intensity. Furthermore, in vitro studies enlightened that 
PPARα compete for binding sites of target genes with HNF4α, but until now, this has not 
been shown in vivo and might be a further study approach for analyzing the TG-lowering 
effects of n-3 PUFAs. Last but not least, existing literature as well as this study showed that 
an optimal balance of Apo CII and LPL might be essential for efficient TG clearance. 
Unfortunately, only a limited number of cross-section studies showing Apo CII and LPL levels 
in different populations or subjects with different diseases have been undertaken so far. The 
determination of Apo CII, LPL and their relationship to each other may reveal essential 
knowledge about the modification of TG clearance by n-3 PUFAs.  
In addition, an important question, which arises from this and also from other studies is, why 
anti-inflammatory effects could be observed in vitro, but rarely in vivo (Calder 2003, 2006). In 
vitro studies showed a down-regulation of IL-1, IL-6, TNFα, COX-2, and several CAMs by n-3 
PUFAs (Calder 2003), but these genes were not seen to be regulated in this study. One 
possibility for this phenomenon could be differences in the concentration of free n-3 PUFAs: 
While the concentration of n-3 PUFAs in cultured cells was ≥ 50 µM (Galli and Calder 2009), 
intracellular concentrations of free n-3 PUFAs in vivo is less than 10 µM (Jump 2002). In 
addition, it might be possible that the decreased expression of these genes is linked to areas 
of high inflammation (see 1.2.3.3) and that, in turn, anti-inflammatory effects could be 
observed mainly locally instead in a systemic reaction in the whole body. Therefore, an 
intervention study with n-3 PUFAs analyzing gene expression changes in centers of 
inflammation compared with changes within the peripheries would be interesting to clarify 
this hypothesis.  
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Following studies investigating the initial cause of the antioxidative properties of n-3 PUFAs 
would help us to understand possible complex regulator networks induced by n-3 PUFAs. It 
has to be clarified if the antioxidative potential of n-3 PUFAs is caused only by n-3 PUFA-
mediated increased oxidative stress with initiated body defense reaction to reduce oxidative 
damage, or is it also caused by the direct increased expression of antioxidative enzymes, 
such as the regulation of CAT via PPARα activation. Hence, studies analyzing the 
expression of antioxidative enzymes, oxidative signaling processes and metabolic outcomes 
should be undertaken to investigate this question. Furthermore, it would be interesting to 
know if other antioxidative genes, such as GPX, GR, GST, and HMOX2, are also target 
genes of PPARα, which may reveal that n-3 PUFAs induce both antioxidative genes 
expression directly and indirectly via an increase of the body’s defense system induced by 
elevated PUFA-mediated FA oxidation. Moreover, analyzing further influences on stress-
activated pathways (MAPK and NFκB pathways), as well as other stress-related genes such 
as MMPs, may reveal additional properties of n-3 PUFAs. 
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7. Appendix 
7.1 Regulated genes within stress-activated pathways 
Genes, which were regulated after four hours (t4h), one week (t1) and twelve weeks (t12) of fish oil supplementation in normolipidemic and 
dyslipidemic men were submitted to pathway analyses according to the KEGG database as well as performed with GenMAPP. Expression  
ratios of regulated genes within mitogen-activated protein kinase (MAPK) signalling pathway, nuclear factor kappa b (NFκB) pathway and  
oxidative stress pathway were displayed. 
Dyslipidemic Normolipidemic Gene name Gene symbol Entrez_ID RefSeq_ID 
Ratio t4h : t0 Ratio t1 : t0 Ratio t12 : t0 Ratio t4h : t0 Ratio t1 : t0 Ratio t12 : t0 
Mitogen-activated protein kinase (MAPK) signaling pathway 
Arrestin beta-1 ARRB1 408 NM_004041.3 NM_020251.2 - - 8.60
1
 - - -2.122 
Arrestin beta-2 ARRB2 409 NM_199004.1 NM_004313.3 2.13
2
 3.863 2.582 - -2.372 - 
V-raf murine sarcoma viral oncogene 
homolog B1 BRAF 673 NM_004333.4 -2.16
1
 -2.931 -3.431 - - - 
Monocyte differentiation antigen CD14 
Precursor CD14 929 
NM_000591.2 
NM_001040021.1 4.82
3
 - 2.882 - - - 
Dual specificity phosphatase Cdc25B CDC25B 994 
NM_021873.2 
NM_021872.2 
NM_004358.3 
-2.071 -2.661 - - - 2.831 
Cell division cycle 42 CDC42 998 NM_001791.3 NM_001039802.1 - - - - - 14.42
1
 
Dual specificity protein phosphatase 1 DUSP1 1843 NM_004417.2 -2.071 -9.671 - -2.392 -2.531 - 
Dual specificity protein phosphatase 8 DUSP8 1850 NM_004420.2 - -4.371 -3.091 - - - 
ETS domain-containing protein Elk-4 ELK4 2005 NM_021795.2 NM_001973.2 - - 2.38
2
 - - - 
Fibroblast growth factor 3 FGF3 2248 NM_005247.2 - -4.421 -16.681 - - - 
Fibroblast growth factor receptor 4 
Precursor FGFR4 2264 
NM_022963.2 
NM_213647.1 
NM_002011.3 
- - 2.081 - - - 
MAP kinase-interacting serine/threonine-
protein kinase 2 MKNK2 2872 
NM_017572.3 
NM_199054.2 - - 2.25
2
 - - -2.041 
Growth factor receptor-bound protein 2 GRB2 2885 NM_203506.2 NM_002086.4 - -2.94
2
 - - 2.363 - 
Heat shock 70 kDa protein 6 HSPA6 3310 NM_002155.3 - - - 2.411 - - 
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Mitogen-activated protein kinase (MAPK) signaling pathway [continuation] 
Heat shock 70kDa protein 8 HSPA8 3312 NM_153201.1 NM_006597.3 - -3.04
1
 - - 2.631 4.801 
Heat shock protein beta-1 HSPB1 3315 NM_001540.3 - -2.291 2.292 - - - 
Transcription factor jun-D JUND 3727 NM_005354.4 - 2.141 8.661 - - - 
GTPase KRas Precursor KRAS 3845 NM_033360.2 NM_004985.3 - -2.86
1
 -3.971 - - - 
Protein max MAX 4149 
NM_145113.1 
NM_145112.1 
NM_002382.3 
5.491 - 5.051 - -2.621 - 
Mitogen-activated protein kinase kinase 
kinase 3 MAP3K3 4215 
NM_203351.1 
NM_002401.3 - -3.53
1
 -5.151 - - - 
Mitogen-activated protein kinase kinase 
kinase 5 MAP3K5 4217 NM_005923.3 - - -3.65
1
 - - - 
Mitogen-activated protein kinase kinase 
kinase 11 MAP3K11 4296 NM_002419.3 - 2.71
1
 - - - - 
High affinity nerve growth factor receptor 
Precursor NTRK1 4914 
NM_001012331.1 
NM_002529.3 
NM_001007792.1 
4.931 - - - - - 
cAMP-dependent protein kinase catalytic 
subunit alpha PRKACA 5566 
NM_207518.1 
NM_002730.3 - -5.55
1
 - - - - 
Protein kinase C alpha type PRKCA 5578 NM_002737.2 -4.941 - -2.601 - - - 
Protein kinase C beta type PRKCB 5579 NM_002738.6 - 12.471 23.651 - - - 
Mitogen-activated protein kinase 8 MAPK8 5599 
NM_139049.1 
NM_139047.1 
NM_139046.1 
NM_002750.2 
- -2.901 -2.521 - - - 
Dual specificity mitogen-activated 
protein kinase kinase 3 MAP2K3 5606 
NM_002756.3 
NM_145109.2 - -6.68
1
 - -2.342 - - 
Tyrosine-protein phosphatase non-
receptor type 7 PTPN7 5778 
NM_080588.1 
NM_002832.2 3.51
1
 - - - - - 
Ras-related C3 botulinum toxin substrate 
2  RAC2 5880 NM_002872.3 2.01
1
 - - -2.582 -2.761 - 
Mitogen-activated protein kinase kinase 
kinase kinase 2 MAP4K2 5871 NM_004579.2 - -8.82
1
 - - - 2.781 
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Mitogen-activated protein kinase (MAPK) signaling pathway [continuation] 
Ras GTPase-activating protein 1 RASA1 5921 NM_002890.1 NM_022650.1 - 14.46
1
 16.671 - - - 
Ribosomal protein S6 kinase alpha-1  RPS6KA1 6195 NM_002953.3 NM_001006665.1 - -5.52
1
 2.992 - - 2.323 
Dual specificity mitogen-activated 
protein kinase kinase 4 MAP2K4 6416 NM_003010.2 -2.35
1
 - -2.721 - - - 
TGF-beta receptor type-2 Precursor  TGFBR2 7048 NM_003242.5 NM_001024847.2 8.64
1
 - 5.951 -3.101 -2.361 - 
Interleukin-1 receptor type II IL1R2 7850 NM_173343.1 NM_004633.3 - -5.50
1
 - - - - 
MAP kinase-activated protein kinase 5 MAPKAPK5 8550 NM_139078.1 NM_003668.2 - -9.40
1
 -6.521 - - - 
Tumor necrosis factor receptor 
superfamily member 1A TNFRSF1A 7132 NM_001065.2 - -10.73
1
 - -2.742 -3.621 - 
Ribosomal protein S6 kinase alpha-4 RPS6KA4 8986 NM_003942.2 NM_001006944.1 -4.00
1
 -4.651 -3.421 - - - 
Mitogen-activated protein kinase kinase 
kinase 6 MAP3K6 9064 NM_004672.3 - - - - - 2.34
1
 
Serine/threonine-protein kinase TAO2 TAOK2 9344 NM_016151.2 - - 3.041 - 2.161 - 
Mitogen-activated protein kinase kinase 
kinase kinase 4 MAP4K4 9448 
NM_145687.2 
NM_004834.3 
NM_145686.2 
- - -6.732 - - - 
Rap guanine nucleotide exchange factor 
2 RAPGEF2 9693 NM_014247.2 - -2.73
1
 - - - - 
Mitogen-activated protein kinase kinase 
kinase 7-interacting protein 1 TAB1 10454 NM_006116.2 4.41
1
 16.231 6.791 - - - 
Calcium-binding protein p22 CHP 11261 NM_007236.4 5.033 - -2.581 - - - 
Mitogen-activated protein kinase kinase 
kinase 7-interacting protein 2  TAB2 23118 NM_015093.3 - -3.91
1
 -9.241 - - - 
Voltage-dependent calcium channel 
gamma-5 subunit CACNG5 27091 NM_014404.1 - -5.04
1
 -9.921 - - - 
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Mitogen-activated protein kinase (MAPK) signaling pathway [continuation] 
Group IIE secretory phospholipase A2 PLA2G2E 30814 NM_014589.1 - - 2.511 -2.011 - - 
Voltage-dependent calcium channel 
gamma-6 subunit CACNG6 59285 
NM_031897.2 
NM_145815.1 
NM_145814.1 
- - - - 2.921 5.891 
Calcineurin B homologous protein 2 CHP2 63928 NM_022097.2 - -5.751 -5.311 - - - 
Protein kinase C eta type PRKCH 5583 NM_006255.3 - -2.911 -2.361 - - - 
Mitogen-activated protein kinase 4 MAPK4 5596 NM_002747.3 - -13.561 -2.921 - - - 
Member of RAS oncogene family RAPIB 5908 
NM_001010942.2 
NM_001251917.1  
NM_001251918.1 
NM_001251921.1 
NM_001251922.1 
NM_015646.5 
- 4.151 2.051 - - - 
Dual specificity mitogen-activated 
protein kinase kinase 6 MAP2K6 5608 NM_002758.3 - -3.25
1
 -2.891 - - - 
Protein kinase C zeta type PRKCZ 5590 
NM_001033581.1 
NM_001033582.1 
NM_001242874.1 
NM_002744.4 
-2.651 - - - - - 
Caspase-9 CASP9 842 NM_032996.1 NM_001229.2 3.69
1
 - - - - - 
Caspase-1 CASP1 834 
NM_033293.2 
NM_033292.2 
NM_001223.3 
2.121 - - - - - 
ECSIT homolog (Drosophila) ECSIT 51295 
NM_001142464.2 
NM_001142465.2 
NM_001243204.1 
NM_016581.4 
- 8.231 8.721 - - - 
Receptor-interacting serine/threonine-
protein kinase 1 RIPK1 8737 NM_003804.3 - 3.45
1
 2.202 - - - 
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Nuclear factor kappa b pathway 
Alkaline phosphatase, tissue-nonspecific 
isozyme ALPL 249 
NM_000478.4 
NM_001127501.2 
NM_001177520.1 
- -3.471 2.032 - 2.421 2.811 
Tumor necrosis factor receptor 
superfamily member 8 TNFRSF8 943 
NM_152942.2 
NM_001243.3 7.79
1
 - - - - - 
Tumor necrosis factor receptor 
superfamily member 1A TNFRSF1A 7132 NM_001065.2 - -10.73
1
 - -2.742 -3.621 - 
Protein kinase C zeta type PRKCZ 5590 
NM_001033581.1 
NM_001033582.1 
NM_001242874.1 
NM_002744.4 
-2.651 - - - - - 
cAMP-dependent protein kinase catalytic 
subunit alpha PRKACA 5566 
NM_207518.1 
NM_002730.3 - -5.55
1
 - - - - 
Tumor necrosis factor receptor 
superfamily member 1B TNFRSF1B 7133 NM_001066.2 - - 2.51
2
 -2.662 - - 
Receptor-interacting serine/threonine-
protein kinase 1 RIPK1 8737 NM_003804.3 - 3.45
1
 2.202 - - - 
Kinectin KTN1 3895 NM_182926.2 -5.371 - - - - - 
DNA replication licensing factor MCM5 MCM5 4174 NM_006739.3 -4.071 - - - - - 
Guanine nucleotide-binding protein 
subunit beta-2-like 1 GNB2L1 10399 NM_006098.4 9.05
3
 6.063 14.733 - -2.762 - 
BAG family molecular chaperone 
regulator 4 BAG4 9530 NM_004874.2 - 6.19
1
 4.971 - - - 
Ribosomal protein L4 RPL4 6124 NM_000968.2 - -3.851 2.912 - -2.592 - 
Ribosomal protein S11 RPS11 6205 NM_001015.3 - -4.942 2.102 - - 2.203 
Ribosomal protein L30 RPL30 6156 NM_000989.2 - - 3.341 - - 2.732 
Mitogen-activated protein kinase kinase 
kinase 3 MAP3K3 4215 
NM_203351.1 
NM_002401.3 - -3.53
1
 -5.151 - - - 
Ras GTPase-activating protein-binding 
protein 2 G3BP2 9908 
NM_012297.4 
NM_203505.2 
NM_203504.2 
-2.931 -3.231 -5.211 - - - 
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Nuclear factor kappa b pathway [continuation] 
14-3-3 protein eta YWHAH 7533 NM_003405.3 - -9.331 - - - - 
Heat shock protein beta-1 HSPB1 3315 NM_001540.3 - -2.291 2.292 - - - 
Mitogen-activated protein kinase kinase 
kinase 7-interacting protein 1 MAP3K7IP1 10454 NM_006116.2 4.41
1
 16.231 6.791 - - - 
Mitogen-activated protein kinase kinase 
kinase 7-interacting protein 1 MAP3K71P2 23118 NM_015093.3 - -3.91
1
 -9.241 - - - 
Casein kinase 2, beta polypeptide CSNK2B 1460 NM_001320.5 - - 2.812 -2.112 - - 
14-3-3 protein gamma YWHAG 7532 NM_012479.3 - -3.291 -2.411 - - - 
Histone deacetylase 6 HDAC6 10013 NM_006044.2 - 5.463 6.893 - - - 
SWI/SNF complex subunit SMARCC2 SMARCC2 6601 
NM_001130420.1 
NM_003075.3 
NM_139067.2 
- -7.441 -2.602 - - 2.541 
DNA-directed RNA polymerases I and III 
subunit RPAC1 POLR1C 9533 
NM_004875.2 
NM_203290.1 - -14.84
1
 -5.721 - - - 
5-azacytidine-induced protein 2  AZI2 64343 NM_022461.3 - -2.151 -5.291 - - - 
Mitogen-activated protein kinase kinase 
kinase 7-interacting protein 2 TXLNA 200081 NM_175852.3 - 5.06
1
 3.451 - - - 
oxidative stress pathway 
Glutathione peroxidase 1 GPX1 2876 NM_000581.2 NM_201397.1 - - - - - -2.48
3
 
Extracellular superoxide dismutase [Cu-
Zn] SOD3 6649 NM_003102.2 - - 4.07
3
 - - 2.913 
Nuclear factor 1 X-type NFIX 4784 NM_002501.2 - -3.501 3.042 -2.571 - - 
Superoxide dismutase 2, mitochondrial SOD2 6648 NM_000636.2 - - - 2.681 - - 
Glutathione reductase GSR 2936 NM_000637.2 - - 2.383 - - -2.542 
Transcription factor Sp1 SP1 6667 
NM_001251825.1 
NM_003109.1 
NM_138473.2 
3.911 - - - - - 
Cytochrome b-245 light chain CYBA 1535 NM_000101.2 - -3.771 2.612 - - - 
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oxidative stress pathway [continuation] 
Heme oxygenase 1 HMOX1 3162 NM_002133.1 - -8.571 -17.521 - - - 
Glutathione peroxidase 3  GPX3 2878 NM_002084.3 - - -2.151 - - - 
NAD(P)H dehydrogenase [quinone] 1  NQO1 1728 
NM_001025434.1 
NM_001025433.1 
NM_000903.2 
- 4.661 - - - - 
Catalase CAT 847 NM_001752.2 - 13.151 8.901 - - - 
 -  no regulation 
 1
  slightly significant regulation; p = 0.05 
 2
  significant regulation; p < 0.05 
 3
  highly significant regulation; p < 0.01 
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